



(51) International Patent Classification:

A61K 38/27 (2006.01) C07K 14/615 (2006.01)
A61K 38/16 (2006.01)

(21) International Application Number:

PCT/US2015/068328

(22) International Filing Date:

31 December 2015 (31.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/099,431 2 January 2015 (02.01.2015) US

(71) Applicant: AMUNIX OPERATION INC. [US/US]; 500
Ellis Street, Mountain View, CA 94043 (US).

(72) Inventor: CLELAND, Jeffrey, L.; 225 Aberdeen Drive,
San Carlos, CA 94070 (US).

(74) Agents: DASGUPTA, Indrani et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA
94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANA-
LOGUES

FIG. 1

AEPAGSPTSTEEGTPGSGTASSPGSSSTPSGATGSPGASPGTSTGSPGPAGSPTSTEEGTSESATPESGPPT
STEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPA
TSGETPGSPAGSPTSTEEGTSESATPESGPPTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSE
GSAPGTSTEPSEGSAPGTSESATPESGPPTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTPSTEPSEGS
APGTSTEPSEGSAPGTSESATPESGPPTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETP
GTSESATPESGPPTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGT
STEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPA
SGSETPGTSESATPESGPPTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPT
TEEGTSESATPESGPPTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETP
GTSESATPESGPPTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSP
AGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPPTSESATPESGPPTSESATPESGPGSEPA
TSGETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATP
ESGPPTSTEPSEGSAPGFPFTIPLSRILFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLS
CFSESIPTPSNREETQOKSNLELLRISLLLIQSWLEPVQFLRSVFANSVYVGASDSNVYDILLKDLLEGI
QTLMGRLDGSPTGQIFKQIYKFDNTSHNDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEG
SCGEGGTSESATPESGPPTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPPTSTEPSEGSAPGTSTEPSE
SAPGTSESATPESGPPTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP
G (SEQ ID NO:1)

(57) Abstract: The present disclosure provides a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. In some embodiments, the therapy comprises administering to the pediatric patient with PGHD a human growth hormone -XTEN (hGH-XTEN) fusion protein in therapeutically effective doses once a month, two-times a month, three-times a month, or four-times a month, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In some embodiments, methods disclosed herein achieve results that are not statistically inferior compared to the height velocity achieved with daily injections of hGH alone over the same period.

TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES

BACKGROUND OF THE INVENTION

Human growth hormone (hGH) is naturally secreted from the human anterior pituitary as intermittent pulses lasting from minutes to hours typically occurring during sleep. The rate and extent of hGH secretion decreases with aging and is maximal in puberty in normal healthy well-nourished children. hGH binds to the hGH receptor initiating signaling processes involving the STAT (signal transducer and activator of transcription), the MAPK (mitogen-activated protein kinase) and the PI3K (phosphoinositide-3 kinase) pathways.

Insulin-like growth factor-I (IGF-I) gene expression is activated from hGH receptor signaling resulting in secretion of IGF-I into the circulation. IGF-I forms a complex with insulin-like growth factor binding protein-3 (IGFBP-3) and the acid labile subunit (ALS). Both IGFBP-3 and ALS expression are also regulated by hGH receptor activation.

In children with growth hormone deficiency (GHD) resulting from lack of expression or secretion of hGH and not caused by a defect in the hGH receptor, replacement therapy with daily injections of recombinant human growth hormone (rhGH) is often prescribed to facilitate near normal growth and development. New bone is formed at the epiphyses in response to hGH and IGF-I resulting in linear growth until the growth plates fuse after puberty. Daily rhGH administration does not mimic the normal endogenous pulses of hGH in non-GHD children, but does result in significant increases in growth with a typical first year growth rate on treatment of 11 cm/yr. Clinical studies of continuous infusion of rhGH with a pump demonstrated comparable growth velocity and IGF-I levels (e.g., standard deviation scores) to those achieved with daily rhGH injections (Jørgensen et al. J. Clin Endocrinol Metab. 70(6), 1616-23 (1990); Laursen, T. et al. J Clin Endocrinol Metab. 80(8), 2410-8 (1995); Tauber, M. et al. J Clin Endocrinol Metab. 76(5), 1135-9 (1993)). Therefore, continuous, as well as pulsatile, administration of rhGH is efficacious.

The safety of daily rhGH therapy has been studied in both GHD children and adults. In some overweight or obese patients, a trend toward increasing fasting and post-prandial insulin levels has been observed. Although generally well tolerated, daily rhGH therapy may cause mild to moderate headache, arthralgia, nausea, vomiting and injection reactions.

Others have reported on various sustained release GH preparations (Cook DM, et al. 2002. J Clin Endocrinol Metab 87(10):4508-4514; Biller BM, et al. 2011. J Clin Endocrinol Metab 96(6):1718-1726; Peter F. et al., 2012. J Clin Endocrinol Metab 97(2):400-407; Fares F. et al, 2010. Endocrinology 151(9):4410-4417; Sondergaard E, et al. 2011. J Clin

Endocrinol Metab 96(3):681-688; de Schepper J et al. 2011. European Journal of Endocrinology 165(3):401-409; Bidlingmaier M, et al. 2006. J Clin Endocrinol Metab 91(8):2926-2930). However, there remains a need for alternative GH therapeutics, dosages, and treatment regimens.

Currently approved growth hormone drugs comprising recombinant human growth hormone (rhGH) require daily injections and consequently pose considerable challenges to patients with GHD. In addition, analysis of clinical trial data on daily rhGH indicates that daily rhGH results in rapid initial growth that wanes over the first year (as well as subsequent years). VRS-317 (SEQ ID NO:1, FIG. 1) is a novel fusion protein (M.W. 119 kDa) designed to improve upon currently approved growth hormone drugs and consists of rhGH with amino acid sequences (XTEN) attached at the N- and C-termini. Compositions and methods related to VRS-317 are described in, for example, U.S. Patent No. 8,703,717, U.S. Patent Publication No. 2014-0162949, and WO/2014/164568 (U.S. Patent Application No. 14/771,445), which are incorporated herein by reference in their entirety. In some embodiments, the novel fusion protein designed to improve upon currently approved growth hormone drugs retains the biological activity of VRS-317 and comprises an amino acid sequence having at least about 80%, or alternatively, at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:1.

SUMMARY OF THE INVENTION

The present disclosure provides, in various embodiments, an improved therapeutic regimen for pediatric growth hormone deficiency (“PGHD”) therapy in children. In particular, the disclosure provides methods for bolus dose administration of compositions of fusion proteins comprising human growth hormone fused to one or more extended recombinant polypeptides (XTEN) (the fusion protein hereinafter referred to as “hGH-XTEN”). Accordingly, in one aspect, the present disclosure provides a method of treating pediatric patients having human PGHD with an hGH-XTEN fusion protein.

In one aspect, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient by administering to the patient with PGHD a dose of human growth hormone-XTEN (hGH-XTEN) fusion protein. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:1 when optimally aligned. In

another embodiment, the hGH-XTEN fusion protein comprises SEQ ID NO:1. In one other embodiment, the dose is a bolus dose. In one embodiment, the bolus dose of hGH-XTEN is a bodyweight adjusted bolus dose effective to increase the height of said pediatric patient. In another embodiment, the bolus dose of hGH-XTEN is between about 0.80 mg/kg and about 6.3 mg/kg. In another embodiment, the bolus dose of hGH-XTEN is between about 0.80 mg/kg and about 7.0 mg/kg. In one embodiment, the treatment with the bolus dose of hGH-XTEN continues for at least about 3 months from first administration of the bolus dose. In a preferred embodiment, the pediatric patient's height velocity does not decline during the treatment.

In one embodiment, the treatment with the bolus dose of hGH-XTEN continues for at least about 6 months from first administration. In another embodiment, the treatment with the bolus dose of hGH-XTEN continues for at least about 12 months from first administration. In another embodiment, the treatment with the bolus dose of hGH-XTEN continues for at least about 18 months from first administration.

In other embodiments, the bolus dose of the hGH-XTEN fusion protein is administered once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is administered once a month. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is administered three-times a month. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is administered four-times a month. In a preferred embodiment, the bolus dose of the hGH-XTEN fusion protein is administered every two weeks or semimonthly (two-times a month). In additional embodiments, the bolus dose of hGH-XTEN is administered subcutaneously.

In one embodiment, the treatment with the bolus dose of hGH-XTEN is effective to maintain the pediatric patient's height velocity within at least about 10%, at least about 20%, or at least about 30% of that compared to the height velocity achieved in pediatric patients administered daily injections of human growth hormone (hGH) alone of an equivalent amount, on a molar basis, over a comparable dose period.

In one embodiment, the treatment with the bolus dose of hGH-XTEN is effective to achieve a height velocity equivalent to at least about 7 cm/yr to 12 cm/yr in a pediatric patient. In another embodiment, the treatment with the bolus dose of hGH-XTEN is effective to achieve a height velocity equivalent to at least about 8 cm/yr to 11 cm/yr in a pediatric patient. In another embodiment, the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing with

hGH-XTEN fusion protein in the pediatric patient. In another embodiment, the height velocity achieved in the pediatric patient is a first year height velocity. In a preferred embodiment, the treatment with hGH-XTEN fusion protein is effective to achieve at least the same height velocity as that achieved by administering daily injections of hGH alone (i.e., hGH not linked to XTEN or any other protein) over the same time period.

In one embodiment, the amount of hGH-XTEN fusion protein administered is comparable, on a molar basis, to an equivalent amount of an hGH alone and administered to a pediatric patient. In other embodiments, the bolus dose of the hGH-XTEN fusion protein is selected from about 0.8 mg/kg to about 1.5 mg/kg, about 1.8 mg/kg to about 3.2 mg/kg, or about 3.5 mg/kg to about 6.3 mg/kg.

In an additional embodiment, the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration of the hGH-XTEN fusion protein. In another embodiment, the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein. In another embodiment, the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

In one embodiment, the pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the hGH-XTEN fusion protein bolus dose. In another embodiment, the pediatric patient has a serum IGF-I SDS that is selected from the group consisting of greater than about -1.5 to about 2.0, greater than about -1.0 to about 2.0, greater than about -0.5 to about 2.0, greater than about 0 to about 2.0, greater than about 0.5 to about 2.0, greater than about 1.0 to about 2.0, and greater than about 1.5 to about 2.0. In another embodiment, the pediatric patient has a serum IGF-I SDS that is selected from the group consisting of greater than about -1.0 to about 2.0, greater than about 0 to about 2.0, and greater than about 1.0 to about 2.0. In another embodiment, the pediatric

patient exhibits said serum IGF-I SDS following administration of the bolus dose, wherein the administration of the hGH-XTEN fusion protein is once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, wherein the pediatric patient exhibits said serum IGF-I SDS following administration of the bolus dose, wherein the administration of the hGH-XTEN fusion protein is two-times a month, or once a month. In another embodiment, the pediatric patient exhibits said serum IGF-I SDS following administration of at least a second, or a third, or a fourth bolus dose of the hGH-XTEN fusion protein. In another embodiment, the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration of the hGH-XTEN fusion protein. In another embodiment, the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein. In another embodiment, the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein. In another embodiment, the serum IGF-I SDS is maintained between about -2.0 and about 2.0 following administration of a first, or a second, or a third, or a fourth bolus dose of the hGH-XTEN fusion protein.

In one embodiment, the bolus dose of the hGH-XTEN fusion protein is selected from the group consisting of about 0.8 mg/kg, about 1.0 mg/kg, about 1.2 mg/kg, about 1.4 mg/kg, about 1.6 mg/kg, about 1.8 mg/kg, about 2.0 mg/kg, about 2.2 mg/kg, about 2.4 mg/kg, about 2.6 mg/kg, about 2.7 mg/kg, about 2.8 mg/kg, about 3 mg/kg, about 3.2 mg/kg, about 3.4 mg/kg, about 3.6 mg/kg, about 3.8 mg/kg, about 4.0 mg/kg, about 4.2 mg/kg, about 4.4 mg/kg, about 4.6 mg/kg, about 4.8 mg/kg, about 5.0 mg/kg, about 5.2 mg/kg, about 5.4 mg/kg, about 5.6 mg/kg, about 5.8 mg/kg, about 6.0 mg/kg, and about 6.3 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 0.8 mg/kg to about 2.0 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 2.0 mg/kg to about 4.0 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion

protein is about 4.0 mg/kg to about 6.0 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 0.8 mg/kg to about 1.5 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 6.0 mg/kg to about 7.0 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 0.8 mg/kg to about 1.5 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 1.8 mg/kg to about 3.2 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is about 3.5 mg/kg to about 6.3 mg/kg.

In one embodiment, the hGH-XTEN fusion protein has at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In a preferred embodiment, the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1.

In another aspect, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient by administering to the patient with PGHD a dose of human growth hormone-XTEN (hGH-XTEN) fusion protein that is effective to maintain the patient's serum IGF-I standard deviation score (SDS) at a certain level. In one embodiment, the method comprises administering an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In one embodiment, the method comprises administering an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In one embodiment, the method comprises administering an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In one embodiment, the dose is a therapeutically effective bodyweight adjusted bolus dose. In another embodiment, the bolus dose is effective to maintain the patient's serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 for at least 7 days after administration of the bolus dose. In another embodiment, the treatment continues for at least about 3 months from first administration and the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the treatment continues at least about 6 months, at least about 12 months, or at least about 18 months from the first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity of the pediatric patient is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is between about 0.8 mg/kg

and about 6.3 mg/kg. In another embodiment, said hGH-XTEN fusion protein bolus dose is effective to maintain the patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration. In another embodiment, the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein. In another embodiment, the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

In one additional aspect, the present disclosure provides a pediatric bolus dose of an hGH-XTEN fusion protein. In one embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In one embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In another embodiment, the hGH-XTEN fusion protein bolus dose is a therapeutically effective bodyweight adjusted bolus dose comprising between about 0.8 mg/kg and about 6.3 mg/kg of hGH-XTEN fusion protein. In another embodiment, the bolus dose is for use in treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient in need. In another embodiment, the treatment continues for at least about 3 months from first administration and the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity is achieved in the pediatric patient after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient. In another embodiment, the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID

NO:1. In one embodiment, the bolus dose of hGH-XTEN formulated for subcutaneous administration.

In one embodiment, the present disclosure provides for an hGH-XTEN fusion protein for use in a method for the treatment of human pediatric growth hormone deficiency (PGHD) in a human pediatric patient. In one embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In another embodiment, method comprises administering a bodyweight adjusted bolus dose of the hGH-XTEN fusion protein at a dose between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient. In one embodiment, the treatment continues for at least about 3 months from first administration and the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity is achieved in the pediatric patient after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing of the hGH-XTEN fusion protein in the pediatric patient. In another embodiment, the bolus dose is administered once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the bolus dose is administered semimonthly, or monthly. In a preferred embodiment, the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1. In a preferred embodiment, the bolus dose is administered subcutaneously. In another embodiment, the human pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the bolus dose. In another embodiment, the IGF-I SDS is selected from the group consisting of greater than about -1.5, greater than about -1.0, greater than about -0.5, greater than about 0, greater than about 0.5, greater than about 1.0, and greater than about 1.5. In another embodiment, the IGF-I SDS is selected from the group consisting of greater than about -1.0, greater than about 0, and greater than about 1.0. In another embodiment, the administration is once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the administration is once a month, or two-times a month.

In one embodiment, the present disclosure provides for the use of an hGH-XTEN fusion protein in the manufacture of a medicament for the treatment of PGHD in a pediatric patient. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In another embodiment, the hGH-XTEN fusion protein is administered to the pediatric patient as a bodyweight adjusted bolus dose of the hGH-XTEN fusion protein at a dose between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient. In another embodiment, the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity is achieved in the pediatric patient after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient. In another embodiment, the bolus dose is administered once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the bolus dose is administered semimonthly, or monthly. In a preferred embodiment, the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1. In a preferred embodiment, the bolus dose is administered subcutaneously. In another embodiment, the human pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the bolus dose. In another embodiment, the IGF-I SDS is selected from the group consisting of greater than about -1.5, greater than about -1.0, greater than about -0.5, greater than about 0, greater than about 0.5, greater than about 1.0, and greater than about 1.5. In another embodiment, the IGF-I SDS is selected from the group consisting of greater than about -1.0, greater than about 0, and greater than about 1.0. In another embodiment, the administration is once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the administration is once a month, or two-times a month.

In another aspect, the present disclosure provides a kit for the treatment of pediatric growth hormone deficiency (PGHD). In one embodiment, the kit comprises a

a container which holds a pharmaceutical composition comprising a human growth hormone-XTEN (hGH-XTEN) fusion protein. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In one other embodiment, the kit comprises a package insert associated with said container, wherein the package insert indicates that said composition is for the treatment of pediatric growth hormone deficiency (PGHD) in a pediatric patient by administration of an initial dose of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration. In another embodiment, the package insert further indicates administration of a plurality of subsequent doses of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg, wherein the doses are administered once a month, two-times a month, three-times a month, or four-times a month, and wherein the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the administration is once a month, or two-times a month. In another embodiment, the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient. In another embodiment, the container further comprises a pharmaceutically acceptable carrier.

In another aspect, the present disclosure provides a human growth hormone-XTEN (hGH-XTEN) fusion protein for use in a pharmaceutical regimen for treatment of a treatment of pediatric growth hormone deficiency (PGHD) in a pediatric patient. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence comprising the amino acid sequence of SEQ ID NO:1. In another embodiment, the pharmaceutical regimen comprises administering a bolus

dose of the hGH-XTEN fusion protein to treat the pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In another embodiment, the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein. In another embodiment, the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient. In another embodiment, the pharmaceutical regimen further comprises the step of determining the amount of hGH-XTEN fusion protein needed to achieve an IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 in the pediatric patient. In another embodiment, the pharmaceutical regimen for treating the pediatric patient comprises administering the hGH-XTEN fusion protein in an initial bolus dose between about 0.8 mg/kg and about 6.3 mg/kg and a plurality of subsequent bolus doses of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg. In another embodiment, the bolus doses are administered once a month, two-times a month, three-times a month, or four-times a month. In another embodiment, the bolus doses are administered once a month, or two-times a month.

In a preferred embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising the amino acid sequence of SEQ ID NO:1, as a bodyweight adjusted bolus dose administered once a month at about 5.0 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least 12 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

In another preferred embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising the amino acid sequence of SEQ ID NO:1, as a bodyweight adjusted bolus dose administered two-times a month at about 2.5 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least 12 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

In another preferred embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment

comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising the amino acid sequence of SEQ ID NO:1, as a bodyweight adjusted bolus dose administered two-times a month at about 3.5 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least 12 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

In another preferred embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising the amino acid sequence of SEQ ID NO:1, as a bodyweight adjusted bolus dose administered two-times a month at about 3.5 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least 18 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

In another embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90%, or at least 95%, or at least 99% sequence identity to the sequence of SEQ ID NO:1, when optimally aligned, or comprises the sequence of SEQ ID NO:1, as a bodyweight adjusted bolus dose between about 0.80 mg/kg and about 6.3 mg/kg, or from at least about 0.8 mg/kg to at least about 1.5 mg/kg, or at least about 1.8 mg/kg to at least about 3.2 mg/kg, or at least about 3.5 mg/kg to at least about 6.3 mg/kg, wherein the bolus dose is administered once a month, two-times a month, three-times a month, or four-times a month, wherein the treatment is effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration, or at least about 6 months from first administration, or at least about 12 months from first administration, or at least about 18 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In the foregoing embodiment, the pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the hGH-XTEN fusion protein and during the treatment.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by

reference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides the amino acid sequence for VRS-317, an hGH-XTEN fusion protein (hGH sequence is underlined and bold) (SEQ ID NO:1).

FIG. 2 provides a table summarizing the demographics of Phase 2a trial participants. Age, height SDS and GH stimulation test must be comparable for evaluating relative to other pediatric GHD clinical trials. The Phase 2a and Extension Studies generally consisted of pre-pubertal children with moderate GHD, representative of the typical U.S. GHD patient population.

FIG. 3 provides a table summarizing the safety profile of VRS-317 over 6 months in patients enrolled in the Extension Study. The safety/tolerability profile of VRS-317 was found to be comparable to daily rhGH; all related AEs are mild (Grade 1) and transient, no related SAEs, no unexpected AEs, no lipoatrophy, and no nodules were associated with extended VRS-317 treatment over 12 months. The number of AEs decreased from the first to the second 6 months of treatment. A few AEs were observed at the 3.5 mg/kg semi-monthly dose.

FIG. 4 provides the IGF-I response to single dose VRS-317 from the Phase 1b Study. The top graph shows the maximum IGF-I SDS achieved at various single doses of VRS-317, indicating no overexposure, and the bottom graph shows the increase in average IGF-I SDS between 0-30 days achieved at various single doses of VRS-317. After identifying a preferred single dose and showing that VRS-317 treatment at the concentrations tested does not result in IGF-I overexposure, these results were used to establish a PK/PD model for VRS-317 dosing at different intervals and concentrations.

FIG. 5 provides more detailed IGF-I response analyses from patients enrolled in the Phase 2a Study. The PK/PD model indicated that a change in VRS-317 treatment from 2.5 mg/kg semi-monthly to 3.5 mg/kg semi-monthly would increase average IGF-I SDS into the upper half of the normal range. Therefore, patients dosed at 1.15 mg/kg weekly in the Phase 2a Study were switched on their next visit in the Extension Study to 3.5 mg/kg semi-monthly.

FIG. 6 shows the expected dose response increase in IGF-I SDS achieved by changing VRS-317 treatment from 2.5 mg/kg semi-monthly to 3.5 mg/kg semi-monthly, a change predicted from the PK/PD model for VRS-317.

FIG. 7 provides a graph of IGF-I SDS levels over several months of daily rhGH treatment of a patient population having very similar demographics compared to the patients enrolled in the 13VR3 Study and shows that a “conventional” dose of daily rhGH of 40 µg/kg/day yields a comparable IGF-I SDS to 3.5 mg/kg VRS-317.

FIG. 8 shows the dose response of daily rhGH, indicating based on the growth rates of patients treated with different concentrations of daily rhGH that the VRS-317 height velocity results observed correlate to a daily rhGH dose of ~30 µg/kg.

FIG. 9 shows the dose response increase in annualized height velocity in the patients that were previously dosed at 1.15 mg/kg weekly in the Phase 2a Study and were later switched on their next visit in the Extension Study to 3.5 mg/kg semi-monthly.

FIG. 10 provides the annualized height velocities measured after 12 months of continuous VRS-317 therapy monthly at 5 mg/kg or semi-monthly at 2.5 mg/kg compared to publicly available source data on daily rhGH treatment at 34 µg/kg/day. These results indicate that whereas VRS-317 provides consistent rate of growth throughout the first year, daily rhGH results in rapid initial growth that wanes over the first year.

FIG. 11 summarizes a 12 month randomized pediatric Phase 3 Study of VRS-317 administered at 3.5 mg/kg semi-monthly as compared to daily rhGH treatment at 34 µg/kg/day, based on results from Phase 1b, Phase 2a, and Extension Studies on VRS-317 safety and efficacy.

FIG. 12 summarizes the extension study through 18 months of treatment with somavaratan (VRS-317) dosed at various intervals.

FIG. 13 shows the pharmacodynamics response to increased somavaratan dose (n=17).

FIG. 14 illustrates mean height velocity (HV±SD) before and after somavaratan dose increase.

DESCRIPTION OF THE INVENTION

Before the embodiments of the invention are described, it is to be understood that such embodiments are provided by way of example only, and that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention.

DEFINITIONS

As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

The terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids. The terms also encompass an amino acid polymer that has been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

As used herein the term “amino acid” refers to either natural and/or unnatural or synthetic amino acids, including but not limited to glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. Standard single or three letter codes are used to designate amino acids.

The term “natural L-amino acid” means the L optical isomer forms of glycine (G), proline (P), alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M), cysteine (C), phenylalanine (F), tyrosine (Y), tryptophan (W), histidine (H), lysine (K), arginine (R), glutamine (Q), asparagine (N), glutamic acid (E), aspartic acid (D), serine (S), and threonine (T).

The term “non-naturally occurring,” as applied to sequences and as used herein, means polypeptide or polynucleotide sequences that do not have a counterpart to, are not complementary to, or do not have a high degree of homology with a wild-type or naturally-occurring sequence found in a mammal. For example, a non-naturally occurring polypeptide

or fragment may share no more than 99%, 98%, 95%, 90%, 80%, 70%, 60%, 50% or even less amino acid sequence identity as compared to a natural sequence when suitably aligned.

The terms “hydrophilic” and “hydrophobic” refer to the degree of affinity that a substance has with water. A hydrophilic substance has a strong affinity for water, tending to dissolve in, mix with, or be wetted by water, while a hydrophobic substance substantially lacks affinity for water, tending to repel and not absorb water and tending not to dissolve in or mix with or be wetted by water. Amino acids can be characterized based on their hydrophobicity. A number of scales have been developed. An example is a scale developed by Levitt, M, et al., J Mol Biol (1976) 104:59, which is listed in Hopp, TP, et al., Proc Natl Acad Sci U S A (1981) 78:3824. Examples of “hydrophilic amino acids” are arginine, lysine, threonine, alanine, asparagine, and glutamine. Of particular interest are the hydrophilic amino acids aspartate, glutamate, and serine, and glycine. Examples of “hydrophobic amino acids” are tryptophan, tyrosine, phenylalanine, methionine, leucine, isoleucine, and valine.

A “fragment” is a truncated form of a native biologically active protein that retains at least a portion of the therapeutic and/or biological activity. A “variant” is a protein with sequence homology to the native biologically active protein that retains at least a portion of the therapeutic and/or biological activity of the biologically active protein. For example, a variant protein may share at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity with the reference biologically active protein. As used herein, the term “biologically active protein moiety” includes proteins modified deliberately, as for example, by site directed mutagenesis, insertions, or accidentally through mutations.

A “host cell” includes an individual cell or cell culture which can be or has been a recipient for the subject vectors. Host cells include progeny of a single host cell. The progeny may not necessarily be completely identical (in morphology or in genomic of total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a vector described herein.

“Isolated,” when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. As is apparent to those of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, does not require “isolation” to

distinguish it from its naturally occurring counterpart. In addition, a “concentrated”, “separated” or “diluted” polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is generally greater than that of its naturally occurring counterpart. In general, a polypeptide made by recombinant means and expressed in a host cell is considered to be “isolated.”

An “isolated” polynucleotide or polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal or extra-chromosomal location different from that of natural cells.

A “chimeric” protein contains at least one fusion polypeptide comprising regions in a different position in the sequence than that which occurs in nature. The regions may normally exist in separate proteins and are brought together in the fusion polypeptide; or they may normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide. A chimeric protein may be created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.

“Conjugated”, “linked,” “fused,” and “fusion” are used interchangeably herein. These terms refer to the joining together of two or more chemical elements or components, by whatever means including chemical conjugation or recombinant means. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and in reading phase or in-frame. An “in-frame fusion” refers to the joining of two or more open reading frames (ORFs) to form a continuous longer ORF, in a manner that maintains the correct reading frame of the original ORFs. Thus, the resulting recombinant fusion protein is a single protein containing two or more segments that correspond to

polypeptides encoded by the original ORFs (which segments are not normally so joined in nature).

In the context of polypeptides, a “linear sequence” or a “sequence” is an order of amino acids in a polypeptide in an amino to carboxyl terminus direction in which residues that neighbor each other in the sequence are contiguous in the primary structure of the polypeptide. A “partial sequence” is a linear sequence of part of a polypeptide that is known to comprise additional residues in one or both directions.

“Heterologous” means derived from a genotypically distinct entity from the rest of the entity to which it is being compared. For example, a glycine rich sequence removed from its native coding sequence and operatively linked to a coding sequence other than the native sequence is a heterologous glycine rich sequence. The term “heterologous” as applied to a polynucleotide, a polypeptide, means that the polynucleotide or polypeptide is derived from a genotypically distinct entity from that of the rest of the entity to which it is being compared.

The terms “polynucleotides”, “nucleic acids”, “nucleotides” and “oligonucleotides” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

The term “complement of a polynucleotide” denotes a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence, such that it could hybridize with a reference sequence with complete fidelity.

“Recombinant” as applied to a polynucleotide means that the polynucleotide is the product of various combinations of in vitro cloning, restriction and/or ligation steps, and other procedures that result in a construct that can potentially be expressed in a host cell.

The terms “gene” or “gene fragment” are used interchangeably herein. They refer to a polynucleotide containing at least one open reading frame that is capable of encoding a particular protein after being transcribed and translated. A gene or gene fragment may be genomic or cDNA, as long as the polynucleotide contains at least one open reading frame, which may cover the entire coding region or a segment thereof. A “fusion gene” is a gene composed of at least two heterologous polynucleotides that are linked together.

“Homology” or “homologous” refers to sequence similarity or interchangeability between two or more polynucleotide sequences or two or more polypeptide sequences. When using a program such as BestFit to determine sequence identity, similarity or homology between two different amino acid sequences, the default settings may be used, or an appropriate scoring matrix, such as blosum45 or blosum80, may be selected to optimize identity, similarity or homology scores. Preferably, polynucleotides that are homologous are those which hybridize under stringent conditions as defined herein and have at least 70%, preferably at least 80%, more preferably at least 90%, more preferably 95%, more preferably 97%, more preferably 98%, and even more preferably 99% sequence identity to those sequences.

“Ligation” refers to the process of forming phosphodiester bonds between two nucleic acid fragments or genes, linking them together. To ligate the DNA fragments or genes together, the ends of the DNA must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation.

The terms “stringent conditions” or “stringent hybridization conditions” includes reference to conditions under which a polynucleotide will hybridize to its target sequence, to a detectably greater degree than other sequences (e.g., at least 2-fold over background). Generally, stringency of hybridization is expressed, in part, with reference to the temperature and salt concentration under which the wash step is carried out. Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short polynucleotides (e.g., 10 to 50 nucleotides) and at least about 60°C for long polynucleotides (e.g., greater than 50 nucleotides)—for example, “stringent conditions” can include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and three washes for 15 min each in 0.1×SSC/1% SDS at 60°C to 65°C. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be

varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2 and chapter 9. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art.

The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences. Percent identity may be measured over the length of an entire defined polynucleotide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polynucleotide sequence, for instance, a fragment of at least 45, at least 60, at least 90, at least 120, at least 150, at least 210 or at least 450 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Percent (%) amino acid sequence identity,” with respect to the polypeptide sequences identified herein, is defined as the percentage of amino acid residues in a query sequence that are identical with the amino acid residues of a second, reference polypeptide sequence or a portion thereof, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2,

ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Percent identity may be measured over the length of an entire defined polypeptide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

The term “non-repetitiveness” as used herein in the context of a polypeptide refers to a lack or limited degree of internal homology in a peptide or polypeptide sequence. The term “substantially non-repetitive” can mean, for example, that there are few or no instances of four contiguous amino acids in the sequence that are identical amino acid types or that the polypeptide has a subsequence score (defined infra) of 10 or less or that there isn’t a pattern in the order, from N- to C-terminus, of the sequence motifs that constitute the polypeptide sequence. The term “repetitiveness” as used herein in the context of a polypeptide refers to the degree of internal homology in a peptide or polypeptide sequence. In contrast, a “repetitive” sequence may contain multiple identical copies of short amino acid sequences.

For instance, a polypeptide sequence of interest may be divided into n-mer sequences and the number of identical sequences can be counted. Highly repetitive sequences contain a large fraction of identical sequences while non-repetitive sequences contain few identical sequences. In the context of a polypeptide, a sequence can contain multiple copies of shorter sequences of defined or variable length, or motifs, in which the motifs themselves have non-repetitive sequences, rendering the full-length polypeptide substantially non-repetitive. The length of polypeptide within which the non-repetitiveness is measured can vary from 3 amino acids to about 200 amino acids, from about 6 to about 50 amino acids, or from about 9 to about 14 amino acids. “Repetitiveness” used in the context of polynucleotide sequences refers to the degree of internal homology in the sequence such as, for example, the frequency of identical nucleotide sequences of a given length. Repetitiveness can, for example, be measured by analyzing the frequency of identical sequences.

A “vector” is a nucleic acid molecule, preferably self-replicating in an appropriate host, which transfers an inserted nucleic acid molecule into and/or between host cells. The term includes vectors that function primarily for insertion of DNA or RNA into a cell,

replication of vectors that function primarily for the replication of DNA or RNA, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the above functions. An “expression vector” is a polynucleotide which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide(s). An “expression system” usually connotes a suitable host cell comprised of an expression vector that can function to yield a desired expression product.

“Serum degradation resistance,” as applied to a polypeptide, refers to the ability of the polypeptides to withstand degradation in blood or components thereof, which typically involves proteases in the serum or plasma. The serum degradation resistance can be measured by combining the protein with human (or mouse, rat, monkey, as appropriate) serum or plasma, typically for a range of days (e.g. 0.25, 0.5, 1, 2, 4, 8, 16 days), typically at about 37°C. The samples for these time points can be run on a Western blot assay and the protein is detected with an antibody. The antibody can be to a tag in the protein. If the protein shows a single band on the western, where the protein’s size is identical to that of the injected protein, then no degradation has occurred. In this exemplary method, the time point where 50% of the protein is degraded, as judged by Western blots or equivalent techniques, is the serum degradation half-life or “serum half-life” of the protein.

The term “ $t_{1/2}$ ” as used herein means the terminal half-life calculated as $\ln(2)/K_{el}$. K_{el} is the terminal elimination rate constant calculated by linear regression of the terminal linear portion of the log concentration vs. time curve. Half-life typically refers to the time required for half the quantity of an administered substance deposited in a living organism to be metabolized or eliminated by normal biological processes. The terms “ $t_{1/2}$ ”, “terminal half-life”, “elimination half-life” and “circulating half-life” are used interchangeably herein.

“Apparent Molecular Weight Factor” or “Apparent Molecular Weight” are related terms referring to a measure of the relative increase or decrease in apparent molecular weight exhibited by a particular amino acid sequence. The Apparent Molecular Weight is determined using size exclusion chromatography (SEC) and similar methods compared to globular protein standards and is measured in “apparent kD” units. The Apparent Molecular Weight Factor is the ratio between the Apparent Molecular Weight and the actual molecular weight; the latter predicted by adding, based on amino acid composition, the calculated molecular weight of each type of amino acid in the composition.

The “hydrodynamic radius” or “Stokes radius” is the effective radius (R_h in nm) of a molecule in a solution measured by assuming that it is a body moving through the solution

and resisted by the solution's viscosity. In the embodiments of the disclosure, the hydrodynamic radius measurements of the XTEN fusion proteins correlate with the 'Apparent Molecular Weight Factor', which is a more intuitive measure. The "hydrodynamic radius" of a protein affects its rate of diffusion in aqueous solution as well as its ability to migrate in gels of macromolecules. The hydrodynamic radius of a protein is determined by its molecular weight as well as by its structure, including shape and compactness. Methods for determining the hydrodynamic radius are well known in the art, such as by the use of size exclusion chromatography (SEC), as described in U.S. Patent Nos. 6,406,632 and 7,294,513. Most proteins have globular structure, which is the most compact three-dimensional structure a protein can have with the smallest hydrodynamic radius. Some proteins adopt a random and open, unstructured, or 'linear' conformation and as a result have a much larger hydrodynamic radius compared to typical globular proteins of similar molecular weight.

"Physiological conditions" refer to a set of conditions in a living host as well as in vitro conditions, including temperature, salt concentration, pH, that mimic those conditions of a living subject. A host of physiologically relevant conditions for use in in vitro assays have been established. Generally, a physiological buffer contains a physiological concentration of salt and is adjusted to a neutral pH ranging from about 6.5 to about 7.8, and preferably from about 7.0 to about 7.5. A variety of physiological buffers is listed in Sambrook et al. (1989). Physiologically relevant temperature ranges from about 25°C to about 38°C, and preferably from about 35°C to about 37°C.

A "reactive group" is a chemical structure that can be coupled to a second reactive group. Examples for reactive groups are amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups, aldehyde groups, azide groups. Some reactive groups can be activated to facilitate coupling with a second reactive group. Non-limiting examples for activation are the reaction of a carboxyl group with carbodiimide, the conversion of a carboxyl group into an activated ester, or the conversion of a carboxyl group into an azide function.

"Controlled release agent", "slow release agent", "depot formulation" or "sustained release agent" are used interchangeably to refer to an agent capable of extending the duration of release of a polypeptide of the disclosure relative to the duration of release when the polypeptide is administered in the absence of agent. Different embodiments of the present disclosure may have different release rates, resulting in different therapeutic amounts.

The terms "antigen", "target antigen" or "immunogen" are used interchangeably herein to refer to the structure or binding determinant that an antibody fragment or an antibody fragment-based therapeutic binds to or has specificity against.

The term “payload” as used herein refers to a protein or peptide sequence that has biological or therapeutic activity; the counterpart to the pharmacophore of small molecules. Examples of payloads include, but are not limited to, cytokines, enzymes, hormones and blood and growth factors. Payloads can further comprise genetically fused or chemically conjugated moieties such as chemotherapeutic agents, antiviral compounds, toxins, or contrast agents. These conjugated moieties can be joined to the rest of the polypeptide via a linker that may be cleavable or non-cleavable.

The term “antagonist”, as used herein, includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native polypeptide disclosed herein. Methods for identifying antagonists of a polypeptide may comprise contacting a native polypeptide with a candidate antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the native polypeptide. In the context of the present disclosure, antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules that decrease the effect of a biologically active protein.

The term “agonist” is used in the broadest sense and includes any molecule that mimics a biological activity of a native polypeptide disclosed herein. Suitable agonist molecules specifically include agonist antibodies or antibody fragments, fragments or amino acid sequence variants of native polypeptides, peptides, small organic molecules, etc. Methods for identifying agonists of a native polypeptide may comprise contacting a native polypeptide with a candidate agonist molecule and measuring a detectable change in one or more biological activities normally associated with the native polypeptide.

“Activity” for the purposes herein refers to an action or effect of a component of a fusion protein consistent with that of the corresponding native biologically active protein, wherein “biological activity” refers to an in vitro or in vivo biological function or effect, including but not limited to receptor binding, antagonist activity, agonist activity, or a cellular or physiologic response.

As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” is used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the pediatric subject, notwithstanding that the subject may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be

administered to a pediatric subject at risk of developing a particular disease, or to a pediatric subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

A “therapeutic effect”, as used herein, refers to a physiologic effect, including but not limited to the cure, mitigation, amelioration, or prevention of disease in humans or other animals, or to otherwise enhance physical or mental wellbeing of humans or animals, caused by a fusion polypeptide of the disclosure other than the ability to induce the production of an antibody against an antigenic epitope possessed by the biologically active protein.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

The terms “therapeutically effective amount” and “therapeutically effective dose”, as used herein, refers to an amount of a biologically active protein, either alone or as a part of a fusion protein composition, that is capable of having any detectable, beneficial effect on any symptom, aspect, measured parameter or characteristics of a disease state or condition when administered in one or repeated doses to a pediatric subject. Such effect need not be absolute to be beneficial. For example, such effect may entail increasing the height of said pediatric patient.

A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a pediatric subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, an excipient, a stabilizer, or preservative.

The term “therapeutically effective dose regimen”, as used herein, refers to a schedule for consecutively administered doses of a biologically active protein, either alone or as a part of a fusion protein composition, wherein the doses are given in therapeutically effective amounts to result in sustained beneficial effect on any symptom, aspect, measured parameter or characteristics of a disease state or condition.

The term “pediatric patient”, “pediatric subject”, as used herein, refers to an individual who is not an adult. Pediatric patients include infants, children, and adolescents. In one embodiment, the children are pre-adolescent or pre-pubertal individuals. In another embodiment, the pediatric patient is a human patient.

The term “height velocity”, as used herein, refers to the rate of increase of the pediatric patient’s height over a period of time.

I). GENERAL TECHNIQUES

The practice of various embodiments of the present disclosure employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, J. et al., "Molecular Cloning: A Laboratory Manual," 3rd edition, Cold Spring Harbor Laboratory Press, 2001; "Current protocols in molecular biology", F. M. Ausubel, et al. eds., 1987; the series "Methods in Enzymology," Academic Press, San Diego, CA.; "PCR 2: a practical approach", M.J. MacPherson, B.D. Hames and G.R. Taylor eds., Oxford University Press, 1995; "Antibodies, a laboratory manual" Harlow, E. and Lane, D. eds., Cold Spring Harbor Laboratory, 1988; "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 11th Edition, McGraw-Hill, 2005; and Freshney, R.I., "Culture of Animal Cells: A Manual of Basic Technique," 4th edition, John Wiley & Sons, Somerset, NJ, 2000, the contents of which are incorporated in their entirety herein by reference.

II). GROWTH HORMONE

The present disclosure provides, in some embodiments, an improved therapeutic regimen for treating pediatric growth hormone deficiency (PGHD) patients. In some embodiments, the disclosure provides methods for bolus dose administration of a hGH-XTEN fusion protein to a pediatric patient with PGHD. In one aspect, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in pediatric patients with a hGH-XTEN fusion protein.

(a) Growth hormone proteins

"Growth Hormone" or "GH" means a growth hormone protein and species and sequence variants thereof, and includes, but is not limited to, the 191 single-chain amino acid sequence of human GH. The GH can be the native, full-length protein or can be a truncated fragment or a sequence variant that retains at least a portion of the biological activity of the native protein. There are two known types of human GH (hereinafter "hGH") derived from the pituitary gland: one having a molecular weight of about 22,129 daltons (22kD hGH) and the other having a molecular weight of about 20,000 daltons (20kD hGH). The 20kD hGH has an amino acid sequence that corresponds to that of 22kD hGH consisting of 191 amino acids except that 15 amino acid residues from the 32nd to the 46th of 22kD hGH are missing. Some reports have shown that the 20kD hGH has been found to exhibit lower risks and higher activity than 22kD hGH. In some embodiments, the method described herein contemplates use of the 22 kD, the 20kD hGH, as well as species and sequence variants and

truncated fragments thereof as being appropriate for use as a fusion partner with XTEN disclosed herein for hGH-XTEN compositions. The cloned gene for hGH has been expressed in a secreted form in *Escherichia coli* (United States Patent No. 4,898,830; Chang, C. N., et al., *Gene* 55:189 [1987]) and its DNA and amino acid sequence has been reported (Goeddel, et al. *Nature*, 281:544 [1979]); Gray, et al., *Gene* 39: 247[1985]).

In some embodiments, the method described herein contemplates inclusion in the hGH-XTEN compositions sequences with homology to GH sequences, sequence fragments that are natural, such as from humans and non-natural sequence variants which retain at least a portion of the biologic activity or biological function of GH and/or that are useful for preventing, treating, mediating, or ameliorating a GH-related disease, deficiency, disorder or condition in pediatric patients. In addition, native sequences homologous to human GH may be found by standard homology searching techniques, such as NCBI BLAST.

Effects of GH on the tissues of the body can generally be described as anabolic. Like most other protein hormones, native GH acts by interacting with a specific plasma membrane receptor, referred to as growth hormone receptor. GH acts on the liver and other tissues to stimulate production of IGF-I, which is responsible for the growth promoting effects of GH and also reflects the amount produced. IGF-I, in turn, has stimulatory effects on osteoblast and chondrocyte activity to promote bone growth. In one embodiment, the disclosure provides a hGH-XTEN that exhibits at least one of the properties of native GH hereinabove described herein.

In one embodiment, the GH incorporated into the subject compositions is a recombinant polypeptide with a sequence corresponding to a protein found in nature. In another embodiment, the GH is a sequence variant, fragment, homolog, or a mimetics of a natural sequence that retains at least a portion of the biological activity of the corresponding native GH. In one other embodiment, the GH is human GH comprising the following amino acid sequence:

FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIP
TPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDL
EEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKV
ETFLRIVQCRSVEGSCGF (SEQ ID NO:41). Any human GH sequences or homologous

derivatives constructed by shuffling individual mutations between families that retain at least a portion of the biological activity of the native GH may be useful for the fusion proteins of the present disclosure. GH that can be incorporated into a hGH-XTEN fusion protein can include a protein that exhibits at least about 80% sequence identity, or alternatively 81%,

82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:41.

III). HUMAN GROWTH HORMONE-XTEN FUSION PROTEIN COMPOSITIONS FOR TREATING PGHD

In some embodiments, the present disclosure provides an improved therapeutic regimen for pediatric growth hormone deficiency (PGHD) therapy for pediatric patients. In some embodiments, the disclosure provides methods for bolus dose administration of hGH-XTEN fusion proteins to a pediatric patient with PGHD. In one aspect, the hGH fusion proteins suitable for uses described herein comprise a human growth hormone polypeptide and one or more XTEN sequences as described herein, and as disclosed in Schellenberger *et al.* WO10/144502A2 and WO10/091122, which are incorporated herein by reference in their entirety.

In one other aspect, the hGH-XTEN fusion proteins are isolated monomeric fusion proteins of GH comprising the full-length sequence or sequence variants of GH covalently linked to one or more extended recombinant polypeptides ("XTEN" or "XTENS"). In one embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence shown in FIG. 1 (SEQ ID NO:1), or pharmacologically active variants thereof. In another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence selected from Table 1.

For example, the hGH-XTEN fusion protein VRS-317, is composed of recombinant human growth hormone (rhGH) and two recombinant polypeptides, referred to as XTEN as described in Schellenberger *et al.* (2009). *Nat Biotechnol* **27**, 1186-90, Schellenberger *et al.* WO10/144502A2, and WO10/091122, each of which are incorporated herein by reference in their entirety. The XTEN domain, two unstructured hydrophilic chains of amino acids, provides half-life extension for rhGH. The molecular weight of VRS-317 is 118.9 kDa, with rhGH contributing 22.1 kDa and the remaining mass contributed by the XTEN construct. The mass ratio of rhGH to VRS-317 is therefore 1:5.37.

Table 1 - Exemplary hGH-XTEN fusion proteins

hGH-XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
AE912-hGH-AE144	AEPAGSPTSTEEGTPGS GTASSSPGSSTPSGATG SPGASPGTSSTGSPGSP AGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPG SPAGSPTSTEEGTSTEPS	1	ATGGCTGAACCTGCTGGCTCTCCAACCTCCACT GAGGAAGGTACCCCGGTTAGCGGTACTGCTTCT TCCTCTCCAGGTAGCTCTACCCCTTCTGGTGCAA CCGGCTCTCCAGGTGCTTCTCCGGGCACCAGCT CTACCGGTTCTCCAGGTAGCCCGGCTGGCTCTC CTACCTCTACTGAGGAAGGTACTTCTGAAAGCG	7

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	EGSAPGTSTEPSEGSAP GTSESATPESGPGSEPA TSGSETPGSEPATSGSET PGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGS APGTSTEPSEGSAPGSP AGSPTSTEEGTSTEPSE GSAPGTSTEPSEGSAPG TSESATPESGPGTSTEPS EGSAPGTSESATPESGP GSEPATSGSETPGTSTEP SEGSAPGTSTEPSEGS PGTSESATPESGPGTSES ATPESGPGSPAGSPTST EEGTSESATPESGPGSEP ATSGSETPGTSESATPES GPGTSTEPSEGSAPGTS TEPSEGSAPGTSTEPSEG SAPGTSTEPSEGSAPGT STEPSEGSAPGTSTEPSE GSAPGSPAGSPTSTEEG TSTEPSEGSAPGTSESAT PESGPGSEPATSGSETP GTSESATPESGPGSEPA TSGSETPGTSESATPESG PGTSTEPSEGSAPGTSES ATPESGPGSPAGSPTST EEGSPAGSPTSTEEGSP AGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPG TSESATPESGPGSEPAT GSETPGTSESATPESGP GSEPATSGSETPGTSES ATPESGPGTSTEPSEGS APGSPAGSPTSTEEGTS ESATPESGPGSEPATSG SETPGTSESATPESGPGS PAGSPTSTEEGSPAGSP TSTEEGTSTEPSEGSAP GTSESATPESGPGTSES ATPESGPGTSESATPES GPGSEPATSGSETPGSE PATSGSETPGSPAGSPTS TEEGTSTEPSEGSAPGT STEPSEGSAPGSEPAT GSETPGTSESATPESGP GTSTEPSEGSAPGFPTIP LSRLFDNAMLRAHRLH QLAFDTYQEFEEAYIPK EQKYSFLQNPQTSFCFS ESIPTPSNREETQQKSNL ELLRISLLLIQSWLEPVQ FLRSVFANSLVYGASDS NVYDLLKDLEEGIQTL MGRLEDGSPRTGQIFK QTYSKFDTNSHNDDAL LKNYGLLYCFRKDM		CTACTCCTGAGTCTGGTCCAGGTACCTCTACTG AACCGTCCGAAGGTAGCGCTCCAGGTAGCCCA GCAGGCTCTCCGACTTCCACTGAGGAAGGTACT TCTACTGAACCTTCCGAAGGCAGCGCACCAGGT ACCTCTACTGAACCTTCTGAGGGCAGCGCTCCA GGTACTTCTGAAAGCGCTACCCCGGAATCTGGC CCAGGTAGCGAACC GGCTACTTCTGGTTCTGAA ACCCAGGTAGCGAACC GGCTACCTCCGGTTCT GAAACTCCAGGTAGCCCGGCAGGCTCTCCGACC TCTACTGAGGAAGGTACTTCTGAAAGCGCAACC CCGGAGTCCGGCCCAGGTACCTCTACCGAACC TCTGAGGGCAGCGCACCAGGTACTTCTACCGAA CCGTCCGAGGGTAGCGCACCAGGTAGCCAGC AGGTTCTCCTACCTCCACCGAGGAAGGTACTTC TACCGAACCGTCCGAGGGTAGCGCACCAGGTA CCTCTACTGAACCTTCTGAGGGCAGCGCTCCAG GTACTTCTGAAAGCGCTACCCCGGAGTCCGGTC CAGGTACTTCTACTGAACCGTCCGAAGGTAGCG CACCAGGTACTTCTGAAAGCGCAACCCCTGAAT CCGGTCCAGGTAGCGAACC GGCTACTTCTGGCT CTGAGACTCCAGGTACTTCTACCGAACC GTCCG AAGGTAGCGCACCAGGTACTTCTACTGAACCGT CTGAAGGTAGCGCACCAGGTACTTCTGAAAGCG CAACCCCGGAATCCGGCCCAGGTACCTCTGAAA GCGCAACCCCGGAGTCCGGCCCAGGTAGCCCTG CTGGCTCTCCAACCTCCACCGAAGAAGGTACCT CTGAAAGCGCAACCCCTGAATCCGGCCCAGGTA GCGAACC GGCAACCTCCGGTTCTGAAACCCAG GTACCTCTGAAAGCGCTACTCCGGAGTCTGGCC CAGGTACCTCTACTGAACCGTCTGAGGGTAGCG CTCCAGGTACTTCTACTGAACCGTCCGAAGGTA GCGCACCAGGTACTTCTACCGAACC GTCCGAAG GCAGCGCTCCAGGTACCTCTACTGAACCTTCCG AGGGCAGCGCTCCAGGTACCTCTACCGAACCTT CTGAAGGTAGCGCACCAGGTACTTCTACCGAAC CGTCCGAGGGTAGCGCACCAGGTAGCCAGCA GGTTCTCCTACCTCCACCGAGGAAGGTACTTCT ACCGAACCGTCCGAGGGTAGCGCACCAGGTAC CTCTGAAAGCGCAACTCCTGAGTCTGGCCCAGG TAGCGAACCTGCTACCTCCGGCTCTGAGACTCC AGGTACCTCTGAAAGCGCAACCCCGGAATCTGG TCCAGGTAGCGAACCTGCAACCTCTGGCTCTGA AACCCAGGTACCTCTGAAAGCGCTACTCCTGA ATCTGGCCCAGGTACTTCTACTGAACCGTCCGA GGGCAGCGCACCAGGTACTTCTGAAAGCGCTAC TCCTGAGTCCGGCCCAGGTAGCCCGGCTGGCTC TCCGACTTCCACCGAGGAAGGTAGCCCGGCTGG CTCTCCAACCTTCTACTGAAGAAGGTAGCCCGGC AGGCTACTCCGACCTCTACTGAGGAAGGTACTTC TGAAAGCGCAACCCCGGAGTCCGGCCCAGGTA CCTCTACCGAACCGTCTGAGGGCAGCGCACCAG GTACCTCTGAAAGCGCAACTCCTGAGTCTGGCC CAGGTAGCGAACCTGCTACCTCCGGCTCTGAGA CTCCAGGTACCTCTGAAAGCGCAACCCCGGAAT CTGGTCCAGGTAGCGAACCTGCAACCTCTGGCT CTGAAACCCAGGTACCTCTGAAAGCGCTACTC CTGAATCTGGCCCAGGTACTTCTACTGAACCGT	

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	KVETFLRIVQCRSVEGS CGFGGTSESATPESGPG TSTEPSEGSAPGTSTEPS EGSAPGTSESATPESGP GTSTEPSEGSAPGTSTEP SEGSAPGTSESATPESG PGTSTEPSEGSAPGTSTE PSEGSAPGTSTEPSEGS APGSPAGSPTSTEEGTS TEPSEGSAPG		CCGAGGGCAGCGCACCAGGTAGCCCTGCTGGCT CTCCAACCTCCACCGAAGAAGGTACCTCTGAAA GCGCAACCCCTGAATCCGGCCAGGTAGCGAA CCGGCAACCTCCGGTTCTGAAACCCAGGTACT TCTGAAAGCGCTACTCCTGAGTCCGGCCAGGT AGCCCGGCTGGCTCTCCGACTTCCACCGAGGAA GGTAGCCCGGCTGGCTCTCCAACCTTCTACTGAA GAAGGTACTTCTACCGAACCTTCCGAGGGCAGC GCACCAGGTACTTCTGAAAGCGCTACCCCTGAG TCCGGCCAGGTACTTCTGAAAGCGCTACTCCT GAATCCGGTCCAGGTACTTCTGAAAGCGCTACC CCGGAATCTGGCCAGGTAGCGAACCCGGCTACT TCTGGTTCTGAAACCCAGGTAGCGAACCCGGCT ACCTCCGGTTCTGAAACTCCAGGTAGCCAGCA GGCTCTCCGACTTCCACTGAGGAAGGTACTTCT ACTGAACCTTCCGAAGGCAGCGCACCAGGTACC TCTACTGAACCTTCTGAGGGCAGCGCTCCAGGT AGCGAACCTGCAACCTCTGGCTCTGAAACCCCA GGTACCTCTGAAAGCGCTACTCCTGAATCTGGC CCAGGTACTTCTACTGAACCGTCCGAGGGCAGC GCACCAGGTTTTCCGACTATTCCGCTGTCTCGTC TGTTTGATAATGCTATGCTGCGTGCGCACCGTC TGCACCAGCTGGCCTTTGATACTTACCAGGAAT TTGAAGAAGCCTACATTCTAAAGAGCAGAAGT ACTCTTTCTGCAAAACCCACAGACTTCTCTCTG CTTCAGCGAATCTATTCCGACGCTTCCAATCG CGAGGAAACTCAGCAAAAGTCCAATCTGGAAC TACTCCGCATTTCTCTGCTTCTGATTGAGAGCTG GCTAGAACCAGTGCAATTTCTGCGTTCCGTCTT CGCCAATAGCCTAGTTTATGGCGCATCCGACAG CAACGTATACGATCTCCTGAAAGATCTCGAGGA AGGCATTCAGACCCTGATGGGTCGTCTCGAGGA TGGCTCTCCGCGTACTGGTCAGATCTTCAAGCA GACTTACTCTAAATTTGATACTAACAGCCACAA TGACGATGCGCTTCTAAAAAACTATGGTCTGCT GTATTGTTTTTCGTAAAGATATGGACAAAGTTGA AACCTTCCTGCGTATTGTTTCAGTGTCGTTCCGTT GAGGGCAGCTGTGGTTTCTAAGGTGGTAGCGAA CCGGCAACTTCCGGCTCTGAAACCCAGGTACT TCTGAAAGCGCTACTCCTGAGTCTGGCCAGGT AGCGAACCTGCTACCTCTGGCTCTGAAACCCCA GGTAGCCCGGAGGCTCTCCGACTTCCACCGAG GAAGGTACCTCTACTGAACCTTCTGAGGGTAGC GCTCCAGGTAGCGAACCGGCAACCTCTGGCTCT GAAACCCAGGTAGCGAACCTGCTACCTCCGGC TCTGAAACTCCAGGTAGCGAACCGGCTACTTCC GGTTCTGAAACTCCAGGTACCTCTACCGAACCT TCCGAAGGCAGCGCACCAGGTACTTCTGAAAGC GCAACCCCTGAATCCGGTCCAGGTAGCGAACCG GCTACTTCTGGCTCTGAGACTCCAGGTACTTCT ACCGAACCGTCCGAAGGTAGCGCACCA	
AM864- hGH	GGSPGTSTEPSEGSAPG SEPATSGSETPGSPAGSP TSTEEGSTSSTAESP TSTPESGSASPGSTSESP SGTAPGSTSESPSGTAP	2	ggTGGGTCTCCAGGTACTTCTACTGAACCGTCTG AAGGCAGCGCACCAGGTAGCGAACCCGGCTACT TCCGGTTCTGAAACCCAGGTAGCCAGCAGGT TCTCCAACCTTCTACTGAAGAAGGTTCTACCAGC TCTACCGCAGAATCTCCTGGTCCAGGTACCTCT	8

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	GTSTPESGSASPGTSTPE SGSASPGSEPATSGSETP GTSESATPESGPGSPAG SPTSTEEGTSTEPSEGS PGTSESATPESGPGTSTE PSEGSAPGTSTEPSEGS APGSPAGSPTSTEEGTS TEPSEGSAPGTSTEPSEG SAPGTSESATPESGPGT SESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPG TSESATPESGPGTSTEPS EGSAPGSEPATSGSETP GSPAGSPTSTEEGSSTPS GATGSPGTPGSGTASSS PGSSTPSGATGSPGTST EPSEGSAPGTSTEPSEGS APGSEPATSGSETPGSP AGSPTSTEEGSPAGSPT STEEGTSTEPSEGSAPG ASASGAPSTGGTSESAT PESGPGSPAGSPTSTEE GSPAGSPTSTEEGSTSST AESP GPGSTSESPSGTAP GTSPSGESTAPGTPGS GTASSSPGSSTPSGATG SPGSSPSASTGTGPGSEP ATSGSETPGTSESATPES GPGSEPATSGSETPGST SSTAESP GPGSTSSTAES PGPGTSPSGESSTAPGSE PATSGSETPGSEPATSG SETPGTSTEPSEGSAPGS TSSTAESP GPGTSTEPSE SASPGSTSESPSGTAPGT STEPSEGSAPGTSTEPSE GSAPGTSTEPSEGSAPG SSTPSGATGSPGSSPAS TGTGPGASPGTSSSTGSP GSEPATSGSETPGTSES ATPESGPGSPAGSPTST EEGSSTPSGATGSPGSSP SASTGTGPGASPGTSSST GSPGTSESATPESGPGT STEPSEGSAPGTSTEPSE GSAPGFPTIPLSRLFDNA MLRAHRLHQLAFD TYQ EFEEAYIPKEQKYSFLQ NPQTSLSLCFSEIPTPSNR EETQQKSNLELLRISLL LIQSWLEPVQFLRSVFA NSLVYGASDSNVYDLL KDLEEGIQTL MGRLED GSPRTGQIFKQ TYSKFD TNSHNDDALLKNYGLL YCFRKDMDKVETFLRI VQCRSVEGSCGF		ACTCCGGAAAGCGGCTCTGCATCTCCAGGTTCT ACTAGCGAATCTCCTTCTGGCACTGCACCAGGT TCTACTAGCGAATCCCCGTCTGGTACTGCTCCA GGTACTTCTACTCCTGAAAGCGGTTCCGCTTCTC CAGGTACCTCTACTCCGGAAAGCGGTTCTGCAT CTCCAGGTAGCGAACC GGCAACCTCCGGCTCTG AAACCCAGGTACCTCTGAAAGCGCTACTCCTG AATCCGGCCCAGGTAGCCCGGCAGGTTCTCCGA CTTCCACTGAGGAAGGTACCTCTACTGAACCTT CTGAGGGCAGCGCTCCAGGTACTTCTGAAAGCG CTACCCCGGAGTCCGGTCCAGGTACTTCTACTG AACCGTCCGAAGGTAGCGCACCAGGTACTTCTA CCGAACCGTCCGAGGGTAGCGCACCAGGTAGC CCAGCAGGTTCTCCTACCTCCACCGAGGAAGGT ACTTCTACCGAACCGTCCGAGGGTAGCGACCA GGTACTTCTACCGAACCTTCCGAGGGCAGCGCA CCAGGTACTTCTGAAAGCGCTACCCCTGAGTCC GGCCCAGGTACTTCTGAAAGCGCTACTCCTGAA TCCGGTCCAGGTACCTCTACTGAACCTTCCGAA GGCAGCGCTCCAGGTACCTCTACCGAACCGTCC GAGGGCAGCGCACCAGGTACTTCTGAAAGCGC AACCCCTGAATCCGGTCCAGGTACTTCTACTGA ACCTTCCGAAGGTAGCGCTCCAGGTAGCGAACC TGCTACTTCTGGTTCTGAAACCCAGGTAGCCC GGCTGGCTCTCCGACCTCCACCGAGGAAGGTAG CTCTACCCCGTCTGGTGTCTACTGGTTCTCCAGGT ACTCCGGGCAGCGGTACTGCTTCTTCTCTCCA GGTAGCTCTACCCCTTCTGGTGCTACTGGCTCTC CAGGTACCTCTACCGAACCGTCCGAGGGTAGCG CACCAGGTACCTCTACTGAACCGTCTGAGGGTA GCGCTCCAGGTAGCGAACC GGCAACCTCCGGTT CTGAAACTCCAGGTAGCCCTGCTGGCTCTCCGA CTTCTACTGAGGAAGGTAGCCCGGCTGGTTCTC CGACTTCTACTGAGGAAGGTACTTCTACCGAAC CTTCCGAAGGTAGCGCTCCAGGTGCAAGCGCAA GCGGCGCGCCAAGCACGGGAGGTACTTCTGAA AGCGCTACTCCTGAGTCCGGCCCAGGTAGCCCG GCTGGCTCTCCGACTTCCACCGAGGAAGGTAGC CCGGCTGGCTCTCCAATTCTACTGAAGAAGGT TCTACCAGCTCTACCGCTGAATCTCCTGGCCCA GGTTCTACTAGCGAATCTCCGTCTGGCACC GCA CCAGGTACTTCCCCTAGCGGTGAATCTTCTACT GCACCAGGTACCCCTGGCAGCGGTACCGCTTCT TCCTCTCCAGGTAGCTCTACCCCGTCTGGTGCTA CTGGCTCTCCAGGTTCTAGCCCGTCTGCATCTAC CGGTACCGGCCAGGTAGCGAACC GGCAACCT CCGGCTCTGAAACTCCAGGTACTTCTGAAAGCG CTACTCCGGAATCCGGCCCAGGTAGCGAACC GG CTACTTCCGGCTCTGAAACCCAGGTTCACCA GCTCTACTGCAGAATCTCCGGGCCAGGTTCTA CTAGCTCTACTGCAGAATCTCCGGGTCCAGGTA CTTCTCCTAGCGGCGAATCTTCTACCGCTCCAG GTAGCGAACC GGCAACCTCTGGCTCTGAAACTC CAGGTAGCGAACCTGCAACCTCCGGCTCTGAAA CCCCAGGTACTTCTACTGAACCTTCTGAGGGCA GCGCACCAGGTTCTACCAGCTCTACCGCAGAAT CTCCTGGTCCAGGTACCTCTACTCCGGAAAGCG	

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
			GCTCTGCATCTCCAGGTTCTACTAGCGAATCTC CTTCTGGCACTGCACCAGGTACTTCTACCGAAC CGTCCGAAGGCAGCGCTCCAGGTACCTCTACTG AACCTTCCGAGGGCAGCGCTCCAGGTACCTCTA CCGAACCTTCTGAAGGTAGCGCACCAGGTAGCT CTACTCCGTCTGGTGCAACCGGCTCCCCAGGTT CTAGCCCGTCTGCTTCCACTGGTACTGGCCAG GTGCTTCCCCGGGCACCAGCTCTACTGGTTCTC CAGGTAGCGAACCTGCTACCTCCGGTTCTGAAA CCCCAGGTACCTCTGAAAGCGCAACTCCGGAGT CTGGTCCAGGTAGCCCTGCAGGTTCTCCTACCT CCACTGAGGAAGGTAGCTCTACTCCGTCTGGTG CAACCGGCTCCCCAGGTTCTAGCCCGTCTGCTT CCACTGGTACTGGCCAGGTGCTTCCCCGGGCA CCAGCTCTACTGGTTCTCCAGGTACCTCTGAAA GCGCTACTCCGGAGTCTGGCCAGGTACCTCTA CTGAACCGTCTGAGGGTAGCGCTCCAGGTACTT CTACTGAACCGTCCGAAGGTAGCGCACCAGGTT TTCCGACTATTCCGCTGTCTCGTCTGTTTGATAA TGCTATGCTGCGTGCGCACCGTCTGCACCAGCT GGCCTTTGATACTTACCAGGAATTTGAAGAAGC cTACATTCTAAAGAGCAGAAGTACTCTTTCCTG CAAAACCCACAGACTTCTCTCTGCTTCAGCGAA TCTATTCCGACGCCTTCCAATCGCGAGGAAACT CAGCAAAAGTCCAATCTGGAATACTCCGCATT TCTCTGCTTCTGATTAGAGCTGGCTAGAACCA GTGCAATTTCTGCGTTCCGTCTTCGCCAATAGCC TAGTTTATGGCGCATCCGACAGCAACGTATACG ATCTCCTGAAAGATCTCGAGGAAGGCATTGAGA CCCTGATGGGTCGTCTCGAGGATGGCTCTCCGC GTACTGGTCAGATCTTCAAGCAGACTTACTCTA AATTTGATACTAACAGCCACAATGACGATGCGC TTCTAAAAAACTATGGTCTGCTGTATTGTTTCG TAAAGATATGGACAAAGTTGAAACCTTCCTGCG TATTGTTCAAGTGTGCTTCCGTTGAGGGCAGCTG TGGTTTC	
Y576- hGH	GEGSGEGSEGEGSEGS EGEGSEGSSEGESEGGSE GSEGESEGSSEGESEGG EGSGEGEGSGEGSEGE GGEGSEGESEGSSEGE GEGSEGGSEGESEGGSE GEGEGSEGSSEGESE GGSEGESEGGSEGESE EGSGEGEGSEGSSEGE GSEGSSEGESEGSSEGE EGSEGGSEGESEGGSE GEGSGEGSEGESEGGSE EGEGGGEGSEGESEGS GSEGESEGGSEGESEGS EGSEGESEGGSEGESE SEGSSEGESEGSSEGE GSEGSSEGESEGSSEGE EGGSEGESEGSSEGESE GEGSEGSSEGESEGSSE EGEGGSEGESEGGSE	3	GGTGAGGGTTCTGGCGAAGGTTCCGAAGGTGA GGGCTCCGAAGGATCTGGCGAAGGTGAGGGTT CCGAAGGTTCTGGCGAAGGTGAAGGCGGTTCTG AGGGATCCGAAGGTGAAGGCTCCGAAGGATCT GGCGAAGGTGAAGGTGGTGAAGGTTCTGGCGA AGGTGAGGGATCTGGCGAAGGCTCTGAAGGTG AAGGTGGTGGTGAAGGCTCTGAAGGTGAAGGA TCTGGTGAAGGTGGCGAAGGTGAGGGATCTGA AGGCGGCTCCGAAGGTGAAGGCGGATCTGAAG GCGGCGAAGGTGAAGGTTCCGAAGGTTCTGGT GAAGGTGAAGGATCTGAAGGTGGCTCCGAAGG TGAAGGATCTGAAGGCGGTTCCGAAGGTGAGG GCTCTGAAGGTTCTGGCGAAGGTGAAGGCTCTG AAGGATCTGGTGAAGGTGAAGGTTCCGAAGGT TCTGGTGAAGGTGAAGGTTCCGAAGGTTCTGGC GAAGGTGAAGGTTCTGAAGGTGGCTCTGAAGG TGAAGGCGGCTCTGAAGGATCCGAAGGTGAAG GTTCTGGTGAAGGCTCTGAAGGTGAAGGCGGCT CTGAGGGTTCCGAAGGTGAAGGCGGAGGCGAA GGTTCTGAAGGTGAGGGATCTGGTGAAGGTTCT	9

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	GSEGE G GSEGE GEGG EGSGEGEGSEGS GEGE GSGEGSEGE GSEGS GEG EGSEGS GEGEGGSEGE GEGSEGS GEGEGGEGS GEGEGSGEGSE GEGGG EGSEGE GSEGS GEGEGS EGSGEGEGSEGGSEGE GGSEGE GEGEGSEGGSE EGSEGGSEGE GSEGS GE GEGSEGS GEGEGSGEGS EGEGGSEGE GEGEGSEGE GSEGE GSEGGSEGE GEG EGSGEGEGGGEGSEGE GSEGS GEGEGSGEGSEGE FPTIPLSRLFDNAMLRA HRLHQLAFDTYQEFEE AYIPKEQKYSFLQNPQT SLCFSESIPTPSNREETQ QKSNLELLRISLLLIQS WLEPVQFLRSVFANSL VYGASDSNVYDLLKDL EEGIQTL MGRLEDGSPR TGQIFKQTYSKFDTNH NDDALLKNYGLLYCFR KDMDKVETFLRIVQCR SVEGSCGF		GAAGGTGAAGGCGGTTCTGAAGGTTCCGAAGG TGAAGGTGGCTCTGAGGGATCCGAAGGTGAAG GTGGCGAAGGATCTGGTGAAGGTGAAGGTTCT GAAGGTTCTGGCGAAGGTGAGGGTTCTGGCGA AGGTTCCGAAGGTGAGGGCTCCGAAGGATCTG GCGAAGGTGAGGGTTCCGAAGGTTCTGGCGAA GGTGAAGGCGGTTCTGAGGGATCCGAAGGTGA GGGTTCTGGCGAAGGTTCGAAGGTGAGGGCTC CGAAGGATCTGGCGAAGGTGAGGGTTCCGAAG GTTCTGGCGAAGGTGAAGGCGGTTCTGAGGGAT CCGAAGGTGAAGGCGGTTCTGAAGGTTCCGAA GGTGAAGGTGGCTCTGAGGGATCCGAAGGTGA AGGTGGCGAAGGATCTGGTGAAGGTGAAGGTT CTGAAGGTTCTGGCGAAGGTGAGGGTTCTGGCG AAGGTTCCGAAGGTGAGGGCTCCGAAGGATCT GGCGAAGGTGAGGGTTCCGAAGGTTCTGGCGA AGGTGAAGGCGGTTCTGAGGGATCCGAAGGTG AAGGCTCCGAAGGATCTGGCGAAGGTGAAGGT GGTGAAGGTTCTGGCGAAGGTGAGGGATCTGG CGAAGGCTCTGAAGGTGAAGGTGGTGGTGAAG GCTCTGAAGGTGAAGGTTCCGAAGGTTCTGGTG AAGGTGAAGGTTCCGAAGGTTCTGGCGAAGGT GAAGGTTCTGAAGGTGGCTCTGAAGGTGAAGG CGGCTCTGAAGGATCCGAAGGTGAAGGATCTG AAGGTGGCTCCGAAGGTGAAGGATCTGAAGGC GGTTCGCGAAGGTGAGGGCTCTGAAGGTTCTGGC GAAGGTGAAGGCTCTGAAGGATCTGGTGAAGG TGAAGGATCTGGCGAAGGCTCCGAAGGTGAAG GCGGTTCTGAAGGTGGCGAAGGTGAAGGATCT GAAGGTGGTTCGAAGGTGAGGGATCTGAAGG TGGCTCTGAAGGTGAAGGTGGCGAAGGTTCTGG CGAAGGTGAAGGTGGAGGCGAAGGTTCTGAAG GTGAAGGTTCCGAAGGTTCTGGTGAAGGTGAG GGATCTGGCGAAGGTTCTGAAGGTTTTCCGACT ATTCCGCTGTCTCGTCTGTTTGATAACGCTATGC TGCGTGCGCACCGTCTGCACCAGCTGGCGTTTCG ACACTTACCAGGAATTTGAAGAAGCGTACATTC CGAAGGAACAGAAGTACTCTTTCTGCAAAACC CGCAGACCTCCCTGTGCTTCAGCGAATCTATTC CGACTCCGTCCAATCGTGAAGAACTCAGCAAA AGTCCAATCTGGAGCTGCTGCGCATCTCTCTGC TGCTGATT CAGAGCTGGCTGGAGCCTGTT CAGT TTCTGCGTTCGCTCTTCGCCAACAGCCTGGTTTA TGGTGCTTCCGACAGCAACGTATACGATCTGCT GAAAGATCTGGAAGAAGGCATTCAGACCCTGA TGGGTCGTCTGGAAGATGGTTCCTCCGCGTACTG GTCAGATCTTCAAACAACTTACTCCAAATTTG ATACTAACAGCCATAACGACGATGCTCTGCTGA AAACTATGGTCTGCTGTATTGCTTCCGCAAGG ATATGGACAAAGTTGAAACCTTCTGCGTATTG TGCAGTGTGCTTCCGTTGAGGGCAGCTGTGGTT TC	
AE912- hGH	AEPAGSPTSTEEGTPGS GTASSSPGSSTPSGATG SPGASPGTSSTGSPGSP AGSPTSTEEGTSESATP	4	ATGGCTGAACCTGCTGGCTCTCCAACCTCCACT GAGGAAGGTACCCCGGGTAGCGGTACTGCTTCT TCCTCTCCAGGTAGCTCTACCCCTTCTGGTGCAA CCGGCTCTCCAGGTGCTTCTCCGGGCACCAGCT	10

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	ESGPGTSTEPSEGSAPG SPAGSPTSTEEGTSTEPS EGSAPGTSTEPSEGSAP GTSESATPESGPGSEPA TSGSETPGSEPATSGSET PGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGS APGTSTEPSEGSAPGSP AGSPTSTEEGTSTEPSE GSAPGTSTEPSEGSAPG TSESATPESGPGTSTEPS EGSAPGTSESATPESGP GSEPATSGSETPGTSTEP SEGSAPGTSTEPSEGSA PGTSESATPESGPGTSES ATPESGPGSPAGSPTST EEGTSESATPESGPGSEP ATSGSETPGTSESATPES GPGTSTEPSEGSAPGTS TEPSEGSAPGTSTEPSEG SAPGTSTEPSEGSAPGT STEPSEGSAPGTSTEPSE GSAPGSPAGSPTSTEEG TSTEPSEGSAPGTSESAT PESGPGSEPATSGSETP GTSESATPESGPGSEPA TSGSETPGTSESATPESG PGTSTEPSEGSAPGTSES ATPESGPGSPAGSPTST EEGSPAGSPTSTEEGSP AGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPG TSESATPESGPGSEPATSG GSETPGTSESATPESGP GSEPATSGSETPGTSES ATPESGPGTSTEPSEGS APGSPAGSPTSTEEGTS ESATPESGPGSEPATSG SETPGTSESATPESGPGS PAGSPTSTEEGSPAGSP TSTEEGTSTEPSEGSAP GTSESATPESGPGTSES ATPESGPGTSESATPES GPGSEPATSGSETPGSE PATSGSETPGSPAGSPTS TEEGTSTEPSEGSAPGT STEPSEGSAPGSEPATSG GSETPGTSESATPESGP GTSTEPSEGSAPGFPTIP LSRLFDNAMLRAHRLH QLAFDITYQEFEEAYIPK EQKYSFLQNPQTSLCFS ESIPTPSNREETQQKSNL ELLRISLLLIQSWLEPVQ FLRSVFANSLVYGASDS NVYDLLKDLEEGIQL MGRLEDGSPRTGQIFK		CTACCGGTTCTCCAGGTAGCCCGGCTGGCTCTC CTACCTCTACTGAGGAAGGTACTTCTGAAAGCG CTACTCCTGAGTCTGGTCCAGGTACCTCTACTG AACCGTCCGAAGGTAGCGCTCCAGGTAGCCCA GCAGGCTCTCCGACTTCCACTGAGGAAGGTACT TCTACTGAACCTTCCGAAGGCAGCGCACCAGGT ACCTCTACTGAACCTTCTGAGGGCAGCGCTCCA GGTACTTCTGAAAGCGCTACCCCGGAATCTGGC CCAGGTAGCGAACC GGCTACTTCTGGTTCTGAA ACCCAGGTAGCGAACC GGCTACCTCCGGTTCT GAAACTCCAGGTAGCCCGGCAGGCTCTCCGACC TCTACTGAGGAAGGTACTTCTGAAAGCGCAACC CCGGAGTCCGGCCCAGGTACCTCTACCGAACC TCTGAGGGCAGCGCACCAGGTACTTCTACCGAA CCGTCCGAGGGTAGCGCACCAGGTAGCCACG AGGTTCTCCTACCTCCACCGAGGAAGGTACTTC TACCGAACCGTCCGAGGGTAGCGCACCAGGTA CCTCTACTGAACCTTCTGAGGGCAGCGCTCCAG GTACTTCTGAAAGCGCTACCCCGGAGTCCGGTC CAGGTACTTCTACTGAACCGTCCGAAGGTAGCG CACCAGGTACTTCTGAAAGCGCAACCCCTGAAT CCGGTCCAGGTAGCGAACC GGCTACTTCTGGCT CTGAGACTCCAGGTACTTCTACCGAACC GTCCG AAGGTAGCGCACCAGGTACTTCTACTGAACCGT CTGAAGGTAGCGCACCAGGTACTTCTGAAAGCG CAACCCCGGAATCCGGCCCAGGTACCTCTGAAA GCGCAACCCCGGAGTCCGGCCCAGGTAGCCCTG CTGGCTCTCCAACCTCCACCGAAGAAGGTACCT CTGAAAGCGCAACCCCTGAATCCGGCCCAGGTA GCGAACC GGCAACCTCCGGTTCTGAAACCCAG GTACCTCTGAAAGCGCTACTCCGGAGTCTGGCC CAGGTACCTCTACTGAACCGTCTGAGGGTAGCG CTCCAGGTACTTCTACTGAACCGTCCGAAGGTA GCGCACCAGGTACTTCTACCGAACC GTCCGAAG GCAGCGCTCCAGGTACCTCTACTGAACCTTCCG AGGGCAGCGCTCCAGGTACCTCTACCGAACCTT CTGAAGGTAGCGCACCAGGTACTTCTACCGAAC CGTCCGAGGGTAGCGCACCAGGTAGCCACGCA GGTTCTCCTACCTCCACCGAGGAAGGTACTTCT ACCGAACCGTCCGAGGGTAGCGCACCAGGTAC CTCTGAAAGCGCAACTCCTGAGTCTGGCCCAGG TAGCGAACCTGCTACCTCCGGCTCTGAGACTCC AGGTACCTCTGAAAGCGCAACCCCGGAATCTGG TCCAGGTAGCGAACCTGCAACCTCTGGCTCTGA AACCCAGGTACCTCTGAAAGCGCTACTCCTGA ATCTGGCCCAGGTACTTCTACTGAACCGTCCGA GGCAGCGCACCAGGTACTTCTGAAAGCGCTAC TCCTGAGTCCGGCCCAGGTAGCCCGGCTGGCTC TCCGACTTCCACCGAGGAAGGTAGCCCGGCTGG CTCTCCAACCTTCTACTGAAGAAGGTAGCCCGGC AGGCTCTCCGACCTCTACTGAGGAAGGTACTTC TGAAAGCGCAACCCCGGAGTCCGGCCCAGGTA CCTCTACCGAACCGTCTGAGGGCAGCGCACCAG GTACCTCTGAAAGCGCAACTCCTGAGTCTGGCC CAGGTAGCGAACCTGCTACCTCCGGCTCTGAGA CTCCAGGTACCTCTGAAAGCGCAACCCCGGAAT CTGGTCCAGGTAGCGAACCTGCAACCTCTGGCT	

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	QTYSKFDTNSHNDDAL LKNYGLLYCFRKDMD KVETFLRIVQCRSVEGS CGF		CTGAAACCCAGGTACCTCTGAAAGCGCTACTC CTGAATCTGGCCCAGGTACTTCTACTGAACCGT CCGAGGGCAGCGCACCAGGTAGCCCTGCTGGCT CTCCAACCTCCACCGAAGAAGGTACCTCTGAAA GCGCAACCCCTGAATCCGGCCCAGGTAGCGAA CCGGCAACCTCCGGTTCTGAAACCCAGGTACT TCTGAAAGCGCTACTCCTGAGTCCGGCCCAGGT AGCCCGGCTGGCTCTCCGACTTCCACCGAGGAA GGTAGCCCGGCTGGCTCTCCAATTCTACTGAA GAAGGTACTTCTACCGAACCTTCCGAGGGCAGC GCACCAGGTACTTCTGAAAGCGCTACCCCTGAG TCCGGCCCAGGTACTTCTGAAAGCGCTACTCCT GAATCCGGTCCAGGTACTTCTGAAAGCGCTACC CCGGAATCTGGCCCAGGTAGCGAACCGGCTACT TCTGGTTCTGAAACCCAGGTAGCGAACCGGCT ACCTCCGGTTCTGAAACTCCAGGTAGCCCAGCA GGCTCTCCGACTTCCACTGAGGAAGGTACTTCT ACTGAACCTTCCGAAGGCAGCGCACCAGGTACC TCTACTGAACCTTCTGAGGGCAGCGCTCCAGGT AGCGAACCTGCAACCTCTGGCTCTGAAACCCCA GGTACCTCTGAAAGCGCTACTCCTGAATCTGGC CCAGGTACTTCTACTGAACCGTCCGAGGGCAGC GCACCAGGTTTTCCGACTATTCCGCTGTCTCGTC TGTTTGATAATGCTATGCTGCGTGCGCACCGTC TGCACCAGCTGGCCTTTGATACTTACCAGGAAT TTGAAGAAGCCTACATTCTAAAGAGCAGAAGT ACTCTTTCCTGCAAAACCCACAGACTTCTCTCTG CTTCAGCGAATCTATTCCGACGCCTTCCAATCG CGAGGAACTCAGCAAAAGTCCAATCTGGAAC TACTCCGCATTTCTCTGCTTCTGATTGAGAGCTG GCTAGAACCAGTGCAATTTCTGCGTTCCGTCTT CGCCAATAGCCTAGTTTATGGCGCATCCGACAG CAACGTATACGATCTCCTGAAAGATCTCGAGGA AGGCATTGAGACCCTGATGGGTGCTCTCGAGGA TGGCTCTCCGCGTACTGGTCAGATCTTCAAGCA GACTTACTCTAAATTTGATACTAACAGCCACAA TGACGATGCGCTTCTAAAAAACTATGGTCTGCT GTATTGTTTTTCGTAAAGATATGGACAAAGTTGA AACCTTCCTGCGTATTGTTTCAGTGTCGTTCCGTT GAGGGCAGCTGTGGTTTCTAA	
AE912- hGH- AE288	AEPAGSPTSTEEGTPGS GTASSSPGSSTPSGATG SPGASPGTSSTGSPGSP AGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPG SPAGSPTSTEEGTSTEPS EGSAPGTSTEPSEGSAP GTSESATPESGPGSEPA TSGSETPGSEPATSGSET PGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGS APGTSTEPSEGSAPGSP AGSPTSTEEGTSTEPSE GSAPGTSTEPSEGSAPG TSESATPESGPGTSTEPS EGSAPGTSESATPESGP	5	ATGGCTGAACCTGCTGGCTCTCCAACCTCCACT GAGGAAGGTACCCCGGCTAGCGGTACTGCTTCT TCCTCTCCAGGTAGCTCTACCCCTTCTGGTGCAA CCGGCTCTCCAGGTGCTTCTCCGGGCACCAGCT CTACCGGTTCTCCAGGTAGCCCGGCTGGCTCTC CTACCTCTACTGAGGAAGGTACTTCTGAAAGCG CTACTCCTGAGTCTGGTCCAGGTACCTCTACTG AACCGTCCGAAGGTAGCGCTCCAGGTAGCCCA GCAGGCTCTCCGACTTCCACTGAGGAAGGTACT TCTACTGAACCTTCCGAAGGCAGCGCACCAGGT ACCTCTACTGAACCTTCTGAGGGCAGCGCTCCA GGTACTTCTGAAAGCGCTACCCCGGAATCTGGC CCAGGTAGCGAACCGGCTACTTCTGGTTCTGAA ACCCAGGTAGCGAACCGGCTACCTCCGGTTCT GAAACTCCAGGTAGCCCGGCAGGCTCTCCGACC TCTACTGAGGAAGGTACTTCTGAAAGCGCAACC	11

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	GSEPATSGSETPGTSTEP SEGSAPGTSTEPSEGS PGTSESATPESGPGTSES ATPESGPGSPAGSPTST EEGTSESATPESGPGSEP ATSGSETPGTSESATPES GPGTSTEPSEGSAPGTS TEPSEGSAPGTSTEPSEG SAPGTSTEPSEGSAPGT STEPSEGSAPGTSTEPSE GSAPGSPAGSPTSTEEG TSTEPSEGSAPGTSESAT PESGPGSEPATSGSETP GTSESATPESGPGSEPA TSGSETPGTSESATPESG PGTSTEPSEGSAPGTSES ATPESGPGSPAGSPTST EEGSPAGSPTSTEEGSP AGSPTSTEEGTSESATP ESGPGTSTEPSEGSAPG TSESATPESGPGSEPATS GSETPGTSESATPESGP GSEPATSGSETPGTSES ATPESGPGTSTEPSEGS APGSPAGSPTSTEEGTS ESATPESGPGSEPATSG SETPGTSESATPESGPGS PAGSPTSTEEGSPAGSP TSTEEGTSTEPSEGSAP GTSESATPESGPGTSES ATPESGPGTSESATPES GPGSEPATSGSETPGSE PATSGSETPGSPAGSPTS TEEGTSTEPSEGSAPGT STEPSEGSAPGSEPATS GSETPGTSESATPESGP GTSTEPSEGSAPGFPTIP LSRLFDNAMLRAHRLH QLAFDITYQEFEEAYIPK EQKYSFLQNPQTSLCFS ESIPTPSNREETQKSNL ELLRISLLLIQSWLEPVQ FLRSVFANSLVYGASDS NVYDLLKDLEEGIQL MGRLEDGSPRTGQIFK QTYSKFDTNSHNDDAL LKNYGLLYCFRKDMD KVETFLRIVQCRSVEGS CGFGGTSESATPESGPG SEPATSGSETPGTSESAT PESGPGSEPATSGSETP GTSESATPESGPGTSTEP SEGSAPGSPAGSPTSTE EGTSESATPESGPGSEP ATSGSETPGTSESATPES GPGSPAGSPTSTEEGSP AGSPTSTEEGTSTEPSE		CCGGAGTCCGGCCCAGGTACCTCTACCGAACCG TCTGAGGGCAGCGCACCAGGTACTTCTACCGAA CCGTCCGAGGGTAGCGCACCAGGTAGCCACG AGGTTCTCCTACCTCCACCGAGGAAGGTACTTC TACCGAACCGTCCGAGGGTAGCGCACCAGGTA CCTCTACTGAACCTTCTGAGGGCAGCGCTCCAG GTACTTCTGAAAGCGCTACCCCGGAGTCCGGTC CAGGTACTTCTACTGAACCGTCCGAAGGTAGCG CACCAGGTACTTCTGAAAGCGCAACCCCTGAAT CCGGTCCAGGTAGCGAACCGGCTACTTCTGGCT CTGAGACTCCAGGTACTTCTACCGAACCGTCCG AAGGTAGCGCACCAGGTACTTCTACTGAACCGT CTGAAGGTAGCGCACCAGGTACTTCTGAAAGCG CAACCCCGGAATCCGGCCCAGGTACCTCTGAAA GCGCAACCCCGGAGTCCGGCCCAGGTAGCCCTG CTGGCTCTCCAACCTCCACCGAAGAAGGTACCT CTGAAAGCGCAACCCCTGAATCCGGCCCAGGTA GCGAACCCGGCAACCTCCGGTTCTGAAACCCAG GTACCTCTGAAAGCGCTACTCCGGAGTCTGGCC CAGGTACCTCTACTGAACCGTCTGAGGGTAGCG CTCCAGGTACTTCTACTGAACCGTCCGAAGGTA GCGCACCAGGTACTTCTACCGAACCGTCCGAAG GCAGCGCTCCAGGTACCTCTACTGAACCTTCCG AGGGCAGCGCTCCAGGTACCTCTACCGAACCTT CTGAAGGTAGCGCACCAGGTACTTCTACCGAAC CGTCCGAGGGTAGCGCACCAGGTAGCCAGCA GGTTCTCCTACCTCCACCGAGGAAGGTACTTCT ACCGAACCGTCCGAGGGTAGCGCACCAGGTAC CTCTGAAAGCGCAACTCCTGAGTCTGGCCCAGG TAGCGAACCTGCTACCTCCGGCTCTGAGACTCC AGGTACCTCTGAAAGCGCAACCCCGGAATCTGG TCCAGGTAGCGAACCTGCAACCTCTGGCTCTGA AACCCAGGTACCTCTGAAAGCGCTACTCCTGA ATCTGGCCCAGGTACTTCTACTGAACCGTCCGA GGGCAGCGCACCAGGTACTTCTGAAAGCGCTAC TCCTGAGTCCGGCCCAGGTAGCCCGGCTGGCTC TCCGACTTCCACCGAGGAAGGTAGCCCGGCTGG CTCTCCAACCTTCTACTGAAGAAGGTAGCCCGGC AGGCTCTCCGACCTCTACTGAGGAAGGTACTTC TGAAAGCGCAACCCCGGAGTCCGGCCCAGGTA CCTCTACCGAACCGTCTGAGGGCAGCGCACCAG GTACCTCTGAAAGCGCAACTCCTGAGTCTGGCC CAGGTAGCGAACCTGCTACCTCCGGCTCTGAGA CTCCAGGTACCTCTGAAAGCGCAACCCCGGAAT CTGGTCCAGGTAGCGAACCTGCAACCTCTGGCT CTGAAACCCAGGTACCTCTGAAAGCGCTACTC CTGAATCTGGCCCAGGTACTTCTACTGAACCGT CCGAGGGCAGCGCACCAGGTAGCCCTGTGGCT CTCCAACCTCCACCGAAGAAGGTACCTCTGAAA GCGCAACCCCTGAATCCGGCCCAGGTAGCGAA CCGGCAACCTCCGGTTCTGAAACCCAGGTACT TCTGAAAGCGCTACTCCTGAGTCCGGCCCAGGT AGCCCGGCTGGCTCTCCGACTTCCACCGAGGAA GGTAGCCCGGCTGGCTCTCCAACCTTCTACTGAA GAAGGTACTTCTACCGAACCTTCCGAGGGCAGC GCACCAGGTACTTCTGAAAGCGCTACCCCTGAG TCCGGCCCAGGTACTTCTGAAAGCGCTACTCCT	

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	GSAPGTSESATPESGPG TSESATPESGPGTSESAT PESGPGSEPATSGSETP GSEPATSGSETPGSPAG SPTSTEEGTSTEPSEGS PGTSTEPSEGSAPGSEP ATSGSETPGTSESATPES GPGTSTEPSEGSAPG		GAATCCGGTCCAGGTACTTCTGAAAGCGCTACC CCGGAATCTGGCCCAGGTAGCGAACC GGCTACT TCTGGTTCTGAAACCCAGGTAGCGAACC GGCT ACCTCCGGTTCTGAAACTCCAGGTAGCCAGCA GGCTCTCCGACTTCCACTGAGGAAGGTACTTCT ACTGAACCTTCCGAAGGCAGCGCACCAGGTACC TCTACTGAACCTTCTGAGGGCAGCGCTCCAGGT AGCGAACCTGCAACCTCTGGCTCTGAAACCCCA GGTACCTCTGAAAGCGCTACTCCTGAATCTGGC CCAGGTACTTCTACTGAACCGTCCGAGGGCAGC GCACCAGGTTTTCCGACTATTCCGCTGTCTCGTC TGTTTGATAATGCTATGCTGCGTGCGCACCGTC TGCACCAGCTGGCCTTTGATACTTACCAGGAAT TTGAAGAAGC ₂ TACATTCTAAAGAGCAGAAGT ACTCTTTCCTGCAAAACCCACAGACTTCTCTCTG CTTCAGCGAATCTATTCCGACGCCTTCCAATCG CGAGGAACTCAGCAAAAGTCCAATCTGGAAC TACTCCGCATTTCTCTGCTTCTGATTGAGAGCTG GCTAGAACCAGTGCAATTTCTGCGTTCCGTCTT CGCCAATAGCCTAGTTTATGGCGCATCCGACAG CAACGTATACGATCTCCTGAAAGATCTCGAGGA AGGCATTGAGACCCTGATGGGTGCTCTCGAGGA TGGCTCTCCGCGTACTGGTCAGATCTTCAAGCA GACTTACTCTAAATTTGATACTAACAGCCACAA TGACGATGCGCTTCTAAAAAAGTATGGTCTGTCT GTATTGTTTTTCGTAAAGATATGGACAAAGTTGA AACCTTCCTGCGTATTGTTTCAAGTGTCTGTTCCGTT GAGGGCAGCTGTGGTTTCTAAGGTGGTACCTCT GAAAGCGCAACTCCTGAGTCTGGCCCAGGTAGC GAACCTGCTACCTCCGGCTCTGAGACTCCAGGT ACCTCTGAAAGCGCAACCCCGGAATCTGGTCCA GGTAGCGAACCTGCAACCTCTGGCTCTGAAACC CCAGGTACCTCTGAAAGCGCTACTCCTGAATCT GGCCCAGGTACTTCTACTGAACCGTCCGAGGGC AGCGCACCAAGGTAGCCCTGCTGGCTCTCCAACC TCCACCGAAGAAGGTACCTCTGAAAGCGCAAC CCCTGAATCCGGCCCAGGTAGCGAACC GGCAA CCTCCGGTTCTGAAACCCAGGTACTTCTGAAA GCGCTACTCCTGAGTCCGGCCCAGGTAGCCCGG CTGGCTCTCCGACTTCCACCGAGGAAGGTAGCC CGGCTGGCTCTCCAACCTTCTACTGAAGAAGGTA CTTCTACCGAACCTTCCGAGGGCAGCGCACCAG GTACTTCTGAAAGCGCTACCCCTGAGTCCGGCC CAGGTACTTCTGAAAGCGCTACTCCTGAATCCG GTCCAGGTACTTCTGAAAGCGCTACCCCGGAAT CTGGCCCAGGTAGCGAACC GGCTACTTCTGGTT CTGAAACCCAGGTAGCGAACC GGCTACTTCTCG GTTCTGAAACTCCAGGTAGCCAGCAGGCTCTC CGACTTCCACTGAGGAAGGTACTTCTACTGAAC CTTCCGAAGGCAGCGCACCAAGGTACCTCTACTG AACCTTCTGAGGGCAGCGCTCCAGGTAGCGAAC CTGCAACCTCTGGCTCTGAAACCCAGGTACCT CTGAAAGCGCTACTCCTGAATCTGGCCCAGGTA CTTCTACTGAACCGTCCGAGGGCAGCGCACCA	
AM875- hGH	GTSTEPSEGSAPGSEPA TSGSETPGSPAGSPTSTE	6	GGTACTTCTACTGAACCGTCTGAAGGCAGCGCA CCAGGTAGCGAACC GGCTACTTCCGGTTCTGAA	12

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	EGSTSSTAESP GPGTSTP ESGSASPGSTSESPSGTA PGSTSESPSGTAPGTSTP ESGSASPGTSTPESGSAS PGSEPATSGSETPGTSES ATPESGPGSPAGSPTST EEGTSTEPSEGSAPGTS ESATPESGPGTSTEPSEG SAPGTSTEPSEGSAPGSP AGSPTSTEEGTSTEPSE GSAPGTSTEPSEGSAPG TSESATPESGPGTSESAT PESGPGTSTEPSEGSAP GTSTEPSEGSAPGTS ATPESGPGTSTEPSEGS APGSEPATSGSETPGSP AGSPTSTEEGSSTPSGA TGSPGTPGSGTASSSPG SSTPSGATGSPGTSTEPS EGSAPGTSTEPSEGSAP GSEPATSGSETPGSPAG SPTSTEEGSPAGSPTSTE EGTSTEPSEGSAPGASA SGAPSTGGTSESATPES GPGSPAGSPTSTEEGSP AGSPTSTEEGSTSSTAES PGPGSTSESPSGTAPGTS PSGESSTAPGTPGSGTA SSSPGSSTPSGATGSPGS SPSASTGTGPGSEPAT GSETPGTSESATPESGP GSEPATSGSETPGSTSST AESP GPGSTSSTAESGP GTSPSGESSTAPGSEPA TSGSETPGSEPATSGSET PGTSTEPSEGSAPGSTSS TAESP GPGTSTPESGSA SPGSTSESPSGTAPGTST EPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGSS TPSGATGSPGSSPSAST GTGPGASPGTSSTGSPG SEPATSGSETPGTSESAT PESGPGSPAGSPTSTEE GSSTPSGATGSPGSSPS ASTGTGPGASPGTSSTG SPGTSESATPESGPGTST EPSEGSAPGTSTEPSEGS APGFPTIPLSRLFDNAM LRAHRLHQLAFDITYQE FEEAYIPKEQKYSFLQN PQTS LCFSESIPTPSNRE ETQKQSNLELLRISLLLI QSWLEPVQFLRSVFAN SLVYGASDSNVYDLLK DLEEGIQTL MGRLEDGS PRTGQIFKQTYSKFDTN		ACCCAGGTAGCCCAGCAGGTTCTCCA ACTTCT ACTGAAGAAGGTTCTACCAGCTCTACCGCAGAA TCTCCTGGTCCAGGTACCTCTACTCCGGAAAGC GGCTCTGCATCTCCAGGTTCTACTAGCGAATCT CCTTCTGGCACTGCACCAGGTTCTACTAGCGAA TCCCCGCTCTGGTACTGCTCCAGGTACTTCTACTC CTGAAAGCGGTTCCGCTTCTCCAGGTACCTCTA CTCCGGAAAGCGGTTCTGCATCTCCAGGTAGCG AACCGGCAACCTCCGGCTCTGAAACCCAGGTA CCTCTGAAAGCGCTACTCCTGAATCCGGCCCCAG GTAGCCCCGGCAGGTTCTCCGACTTCCACTGAGG AAGGTACCTCTACTGAACCTTCTGAGGGCAGCG CTCCAGGTACTTCTGAAAGCGCTACCCCGGAGT CCGGTCCAGGTACTTCTACTGAACCGTCCGAAG GTAGCGCACCAGGTACTTCTACCGAACCGTCCG AGGGTAGCGCACCAGGTAGCCCAGCAGGTTCTC CTACCTCCACCGAGGAAGGTACTTCTACCGAAC CGTCCGAGGGTAGCGCACCAGGTACTTCTACCG AACCTTCCGAGGGCAGCGCACCAGGTACTTCTG AAAGCGCTACCCCTGAGTCCGGCCCCAGGTACTT CTGAAAGCGCTACTCCTGAATCCGGTCCAGGTA CCTCTACTGAACCTTCCGAAGGCAGCGCTCCAG GTACCTCTACCGAACCGTCCGAGGGCAGCGCAC CAGGTACTTCTGAAAGCGCAACCCCTGAATCCG GTCCAGGTACTTCTACTGAACCTTCCGAAGGTA GCGCTCCAGGTAGCGAACCTGCTACTTCTGGTT CTGAAACCCAGGTAGCCCCGGCTGGCTCTCCGA CCTCCACCGAGGAAGGTAGCTCTACCCCGTCTG GTGCTACTGGTTCTCCAGGTACTCCGGGCAGCG GTACTGCTTCTTCTCTCCAGGTAGCTCTACCCC TTCTGGTGCTACTGGCTCTCCAGGTACCTCTACC GAACCGTCCGAGGGTAGCGCACCAGGTACCTCT ACTGAACCGTCTGAGGGTAGCGCTCCAGGTAGC GAACCGGCAACCTCCGGTTCTGAAACTCCAGGT AGCCCTGCTGGCTCTCCGACTTCTACTGAGGAA GGTAGCCCCGGCTGGTTCTCCGACTTCTACTGAG GAAGGTACTTCTACCGAACCTTCCGAAGGTAGC GCTCCAGGTGCAAGCGCAAGCGGCGCGCCAAG CACGGGAGGTACTTCTGAAAGCGCTACTCCTGA GTCCGGCCCCAGGTAGCCCCGGCTGGCTCTCCGAC TTCCACCGAGGAAGGTAGCCCCGGCTGGCTCTCC A ACTTCTACTGAAGAAGGTTCTACCAGCTCTAC CGCTGAATCTCCTGGCCCCAGGTTCTACTAGCGA ATCTCCGTCTGGCACCGCACCAGGTACTTCCCC TAGCGGTGAATCTTCTACTGCACCAGGTACCCC TGGCAGCGGTACCGCTTCTCCTCTCCAGGTAG CTCTACCCCGTCTGGTGCTACTGGCTCTCCAGGT TCTAGCCCGTCTGCATCTACCGGTACCGGCCCA GGTAGCGAACCGGCAACCTCCGGCTCTGAAACT CCAGGTACTTCTGAAAGCGCTACTCCGGAATCC GGCCCAGGTAGCGAACCGGCTACTTCCGGCTCT GAAACCCAGGTTCCACCAGCTCTACTGCAGAA TCTCCGGGGCCCAGGTTCTACTAGCTCTACTGCA GAATCTCCGGGTCCAGGTACTTCTCCTAGCGGC GAATCTTCTACCGTCCAGGTAGCGAACCGGCA ACCTCTGGCTCTGAAACTCCAGGTAGCGAACCT GCAACCTCCGGCTCTGAAACCCAGGTACTTCT	

hGH- XTEN Name*	Amino Acid Sequence	SEQ ID NO:	DNA Nucleotide Sequence	SEQ ID NO:
	SHNDDALLKNYGLLYC FRKDMDKVETFLRIVQ CRSVEGSCGF		ACTGAACCTTCTGAGGGCAGCGCACCAGGTTCT ACCAGCTCTACCGCAGAATCTCCTGGTCCAGGT ACCTCTACTCCGAAAGCGGCTCTGCATCTCCA GGTTCTACTAGCGAATCTCCTTCTGGCACTGCA CCAGGTACTTCTACCGAACCCTCCGAAGGCAGC GCTCCAGGTACCTCTACTGAACCTTCCGAGGGC AGCGCTCCAGGTACCTCTACCGAACCCTTCTGAA GGTAGCGCACCAGGTAGCTCTACTCCGTCTGGT GCAACCGGCTCCCCAGGTTCTAGCCCGTCTGCT TCCACTGGTACTGGCCCAGGTGCTTCCCCGGGC ACCAGCTCTACTGGTTCTCCAGGTAGCGAACCT GCTACCTCCGGTTCTGAAACCCAGGTACCTCT GAAAGCGCAACTCCGAGTCTGGTCCAGGTAG CCCTGCAGGTTCTCCTACCTCCACTGAGGAAGG TAGCTCTACTCCGTCTGGTGCAACCGGCTCCCC AGGTTCTAGCCCGTCTGCTTCCACTGGTACTGG CCCAGGTGCTTCCCCGGGCACCAGCTCTACTGG TTCTCCAGGTACCTCTGAAAGCGCTACTCCGGA GTCTGGCCCAGGTACCTCTACTGAACCGTCTGA GGGTAGCGCTCCAGGTACTTCTACTGAACCGTC CGAAGGTAGCGCACCAGGTTTTCCGACTATTCC GCTGTCTCGTCTGTTTGATAATGCTATGCTGCGT GCGCACCGTCTGCACCAGCTGGCCTTTGATACT TACCAGGAATTTGAAGAAGC _c TACATTCCTAAA GAGCAGAAGTACTCTTTCTGCAAAACCCACAG ACTTCTCTGCTTCAGCGAATCTATTCCGACGC CTTCCAATCGCGAGGAACTCAGCAAAAGTCCA ATCTGGAACCTACTCCGCATTTCTCTGCTTCTGAT TCAGAGCTGGCTAGAACCAGTGCAATTTCTGCG TTCCGTCTTCGCCAATAGCCTAGTTTATGGCGC ATCCGACAGCAACGTATACGATCTCCTGAAAGA TCTCGAGGAAGGCATTCAGACCCTGATGGGTCG TCTCGAGGATGGCTCTCCGCGTACTGGTCAGAT CTTCAAGCAGACTTACTCTAAATTTGATACTAA CAGCCACAATGACGATGCGCTTCTAAAAAACTA TGGTCTGCTGTATTGTTTTCTGTAAGATATGGA CAAAGTTGAAACCTTCTGCGTATTGTTTCAGTG TCGTTCCGTTGAGGGCAGCTGTGGTTTCTAA	

Further characterization of the exemplary hGH-XTEN fusion proteins provided in Table 1 can be found in the examples (*e.g.*, Examples 27-35) of Schellenberger et al. WO10/144502A2, which is incorporated herein by reference in its entirety.

5

In some embodiments, methods described herein contemplate use of hGH-XTEN fusion proteins comprising one of the amino acid sequences shown in FIG. 1, Table 1, or as described in Schellenberger et al. WO10/144502A2 (which is incorporated herein by reference in its entirety). In addition, pharmacologically active variants of any of the hGH-XTEN fusion proteins described and referred to herein are also contemplated.

As described more fully below, the fusion proteins optionally include spacer sequences that further comprise cleavage sequences to release the GH from the fusion protein when acted on by a protease, releasing GH from the XTEN sequence(s).

In one aspect, the disclosure provides an isolated fusion protein comprising at least a first biologically active growth hormone protein covalently linked to one or more extended recombinant polypeptides ("XTEN"), resulting in a growth hormone-XTEN fusion protein composition (hereinafter "hGH-XTEN"). In one embodiment, the growth hormone is human growth hormone or a sequence variant of hGH. As described more fully below, the fusion proteins optionally include spacer sequences that further comprise cleavage sequences to release the GH from the fusion protein when acted on by a protease.

The term "hGH-XTEN", as used herein, is meant to encompass fusion polypeptides that comprise a payload region comprising a biologically active GH that mediates one or more biological or therapeutic activities associated with growth hormone and at least one other region comprising at least a first XTEN polypeptide that serves as a carrier. In one embodiment, the disclosure provides an hGH-XTEN fusion protein comprising the sequence set forth in Table 1.

The GH of the subject compositions, together with their corresponding nucleic acid and amino acid sequences, are well known in the art and descriptions and sequences are available in public databases such as Chemical Abstracts Services Databases (e.g., the CAS Registry), GenBank, The Universal Protein Resource (UniProt) and subscription provided databases such as GenSeq (e.g., Derwent). Polynucleotide sequences may be a wild type polynucleotide sequence encoding a given GH (e.g., either full length or mature), or in some instances the sequence may be a variant of the wild type polynucleotide sequence (e.g., a polynucleotide which encodes the wild type biologically active protein, wherein the DNA sequence of the polynucleotide has been optimized, for example, for expression in a particular species; or a polynucleotide encoding a variant of the wild type protein, such as a site directed mutant or an allelic variant. It is well within the ability of the skilled artisan to use a wild-type or consensus cDNA sequence or a codon-optimized variant of a GH to create fusion protein constructs contemplated by the invention using methods known in the art and/or in conjunction with the guidance and methods provided herein, and described more fully in the Examples of Schellenberger et al. WO10/144502A2 which is incorporated herein by reference in its entirety.

The GH for inclusion in a hGH-XTEN of the present disclosure includes any growth hormone or sequence variant of biologic, therapeutic, prophylactic, or diagnostic interest or

function, or that is useful for mediating or preventing or ameliorating a disease, disorder or condition associated with growth, growth hormone deficiency or defect when administered to a pediatric subject. Of particular interest are hGH-XTEN fusion protein compositions for which an increase in a pharmacokinetic parameter, increased solubility, increased stability, or some other enhanced pharmaceutical or pharmacodynamic property compared to native GH is sought, or for which increasing the terminal half-life would improve efficacy, safety, or result in reduce dosing frequency and/or improve pediatric patient compliance. Thus, the hGH-XTEN fusion protein compositions are prepared with various objectives in mind, including improving the therapeutic efficacy of the bioactive GH by, for example, increasing the in vivo exposure or the length that the hGH-XTEN remains within the therapeutic window when administered to a pediatric subject, compared to a GH not linked to XTEN.

In one embodiment, the GH incorporated into the subject compositions can be a recombinant polypeptide with a sequence corresponding to a protein found in nature, such as human growth hormone. In one embodiment, the GH is human GH comprising the following amino acid sequence:

FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIP
TPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDL
EEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKV
ETFLRIVQCRSVEGSCGF (SEQ ID NO:41).

In another embodiment, the GH is a sequence variant, fragment, homolog, or mimetic of a natural sequence that retain at least a portion of the biological activity of the native GH. In non-limiting examples, a GH is a sequence that exhibits at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity to the protein sequence of SEQ ID NO:41. In one embodiment, the hGH-XTEN fusion protein comprises a single GH molecule linked to an XTEN (as described more fully below). In another embodiment, the hGH-XTEN fusion protein comprises a single GH molecule linked to a first and a second XTEN, with an N- to C-terminus configuration of XTEN-GH-XTEN, in which the GH is a sequence that exhibits at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity to the human growth hormone protein sequence (SEQ ID NO:41), and the first and/or the second XTEN are sequences that exhibits at least about 80% sequence identity, or alternatively 81%, 82%,

83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99%, or 100% sequence identity to a sequence selected from Table 2.

In general, the GH fusion partner component of the hGH-XTEN exhibits a binding specificity to a given target or another desired biological characteristic when used in vivo or when utilized in an in vitro assay. For example, the hGH-XTEN is an agonist, having the ability to bind to a transmembrane receptor for growth hormone. In one embodiment, the binding of hGH-XTEN to growth receptor leads to receptor dimerization and lead to at least a portion of the activation of intercellular signal transduction pathway compared to native growth hormone. In one embodiment, the hGH-XTEN bound to a transmembrane receptor for growth hormone would exhibit at least about 1%, or about 5%, or about 10%, or about 15%, or about 20%, or about 25%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or at least about 95% of the activation of intercellular signal transduction pathway compared to native growth hormone not linked to XTEN.

In some embodiments, the subject hGH-XTEN of the present disclosure exhibits an enhancement of one or more pharmacokinetic or pharmacodynamic parameters, which optionally is enhanced by release of GH from the fusion protein by cleavage of a spacer sequence. The hGH-XTEN with enhanced pharmacokinetic parameters permits less frequent dosing or an enhanced pharmacologic effect, such as but not limited to maintaining the biologically active hGH-XTEN within the therapeutic window between the minimum effective dose or blood concentration (Cmin) and the maximum tolerated dose or blood concentration (Cmax). In addition, the hGH-XTEN with enhanced pharmacodynamic parameters permits lower and/or less frequent dosing or an enhanced pharmacodynamic effect, such as but not limited to a sustained or normalized IGF-I standard deviation score (IGF-I SDS). In such cases, the linking of the GH to a fusion protein comprising a select XTEN sequence(s) can result in an improvement in these properties, making them more useful as therapeutic or preventive agents compared to GH not linked to XTEN.

IV). XTENDED RECOMBINANT POLYPEPTIDES

The present disclosure provides, in some embodiments, an improved therapeutic regimen for PGHD therapy. In some embodiments, the present disclosure provides methods for bolus dose administration of a human growth hormone-XTEN (hGH-XTEN) fusion protein to a pediatric patient with PGHD. Accordingly, in one aspect, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) with a hGH-XTEN recombinant polypeptide or fusion protein.

In one aspect, the present disclosure provides XTEN polypeptide compositions that are useful as a fusion protein partner to which GH is linked, resulting in a hGH-XTEN fusion protein. As provided herein, XTENs are generally extended length polypeptides with non-naturally occurring, substantially non-repetitive sequences that are composed mainly of small hydrophilic amino acids, with the sequence having a low degree or no secondary or tertiary structure under physiologic conditions.

XTENs have utility as a fusion protein partners in that they serve as a “carrier”, conferring certain desirable pharmacokinetic, physicochemical and pharmaceutical properties when linked to a GH protein to create a fusion protein. Such desirable properties include but are not limited to enhanced pharmacokinetic parameters and solubility characteristics the compositions, amongst other properties described herein. Such fusion protein compositions have utility to treat certain growth hormone-related diseases, disorders or conditions, as described herein. As used herein, “XTEN” specifically excludes antibodies or antibody fragments such as single-chain antibodies or Fc fragments of a light chain or a heavy chain.

In some embodiments, XTEN are long polypeptides having greater than about 100 to about 3000 amino acid residues, preferably greater than 400 to about 3000 residues when used as a carrier or cumulatively when more than one XTEN unit is used in a single fusion protein. In other embodiments, when used as a linker between fusion protein components or where an increase in half-life of the fusion protein is not needed but where an increase in solubility or other physico/chemical property for the GH fusion partner component is desired, an XTEN sequence shorter than 100 amino acid residues, such as about 96, or about 84, or about 72, or about 60, or about 48, or about 36 amino acid residues are incorporated into a fusion protein composition with the GH to effect the property.

The selection criteria for the XTEN to be linked to the biologically active proteins used to create the inventive fusion proteins compositions generally relate to attributes of physical/chemical properties and conformational structure of the XTEN that is, in turn, used to confer enhanced pharmaceutical and pharmacokinetic properties to the fusion proteins. In some embodiments, the XTENs described herein exhibit one or more of the following advantageous properties: conformational flexibility, enhanced aqueous solubility, high degree of protease resistance, low immunogenicity, low binding to mammalian receptors, and increased hydrodynamic (or Stokes) radii; properties that make them particularly useful as fusion protein partners. Non-limiting examples of the properties of the fusion proteins comprising GH that is enhanced by XTEN include increases in the overall solubility and/or metabolic stability, reduced susceptibility to proteolysis, reduced immunogenicity, reduced

rate of absorption when administered subcutaneously or intramuscularly, and enhanced pharmacokinetic properties such as longer terminal half-life and increased area under the curve (AUC), slower absorption after subcutaneous or intramuscular injection (compared to GH not linked to XTEN and administered by a similar route) such that the Cmax is lower, which, in turn, results in reductions in adverse effects of the GH that, collectively, results in an increased period of time that a fusion protein of a hGH-XTEN composition administered to a pediatric patient retains therapeutic activity.

1. Non-repetitive Sequences

In some embodiments, XTEN sequences of the compositions are substantially non-repetitive. In general, repetitive amino acid sequences have a tendency to aggregate or form higher order structures, as exemplified by natural repetitive sequences such as collagens and leucine zippers, or form contacts resulting in crystalline or pseudocrystalline structures. In contrast, the low tendency of non-repetitive sequences to aggregate enables the design of long-sequence XTENs with a relatively low frequency of charged amino acids that would be likely to aggregate if the sequences were otherwise repetitive. Typically, the hGH-XTEN fusion proteins comprise XTEN sequences of greater than about 100 to about 3000 amino acid residues, preferably greater than 400 to about 3000 cumulative residues, wherein the sequences are substantially non-repetitive. In one embodiment, the XTEN sequences have greater than about 100 to about 3000 amino acid residues, preferably greater than 400 to about 3000 amino acid residues, in which no three contiguous amino acids in the sequence are identical amino acid types unless the amino acid is serine, in which case no more than three contiguous amino acids are serine residues. In the foregoing embodiment, the XTEN sequence would be substantially non-repetitive.

The degree of repetitiveness of a polypeptide or a gene are measured by computer programs or algorithms or by other means known in the art, including subsequence scores (see Example 44 of Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety). In some embodiments, the present invention provides hGH-XTEN each comprising one or more XTEN in which the XTEN have a subsequence score less than 12, more preferably less than 10, more preferably less than 9, more preferably less than 8, more preferably less than 7, more preferably less than 6, and most preferably less than 5. In the embodiments hereinabove described in this paragraph, an XTEN with a subsequence score less than about 10 (i.e., 9, 8, 7, etc.) is “substantially non-repetitive.”

The non-repetitive characteristic of XTEN impart to fusion proteins with GH a greater degree of solubility and less tendency to aggregate compared to polypeptides having repetitive sequences. These properties facilitate the formulation of XTEN-comprising pharmaceutical preparations containing extremely high drug concentrations, in some cases exceeding 100 mg/ml.

2. Exemplary Sequence Motifs

In some embodiments, the XTEN comprises multiple units of shorter sequences, or motifs, in which the amino acid sequences of the motifs are non-repetitive. In designing XTEN sequences, it was discovered that the non-repetitive criterion may be met despite the use of a “building block” approach using a library of sequence motifs that are multimerized to create the XTEN sequences. Thus, while an XTEN sequence may consist of multiple units of as few as four different types of sequence motifs, because the motifs themselves generally consist of non-repetitive amino acid sequences, the overall XTEN sequence is rendered substantially non-repetitive (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety).

3. Length of Sequence

In one aspect, the present disclosure, provides hGH-XTEN compositions comprising carriers of XTEN polypeptides with extended length sequences. (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. PCT/US2013/031673, each of which is incorporated herein by reference in its entirety) Non-limiting examples of XTEN contemplated for inclusion in the hGH-XTEN described herein are presented in Table 2. In one embodiment, the present disclosure provides hGH-XTEN compositions wherein the XTEN sequence length of the fusion protein(s) is greater than about 100 to about 3000 amino acid residues, and in some cases is greater than 400 to about 3000 amino acid residues, wherein the XTEN confers enhanced pharmacokinetic properties on the hGH-XTEN in comparison to GH not linked to XTEN. In some embodiments, the XTEN sequences of the hGH-XTEN compositions described herein can be about 100, or about 144, or about 288, or about 401, or about 500, or about 600, or about 700, or about 800, or about 900, or about 1000, or about 1500, or about 2000, or about 2500 or up to about 3000 amino acid residues in length. In other cases, the XTEN sequences can be about 100 to 150, about 150 to 250, about 250 to 400, 401 to about 500, about 500 to 900, about 900 to 1500, about 1500 to 2000, or about 2000 to about 3000 amino acid residues in length. In one embodiment, the hGH-XTEN comprises an XTEN sequence that exhibits at least about 80% sequence identity, or

alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a XTEN selected from Table 2. In some embodiments, the XTEN sequence is designed for optimized expression as the N-terminal component of the hGH-XTEN by inclusion of encoding nucleotides for an optimized N-terminal leader sequence (NTS) in the XTEN portion of the gene encoding the fusion protein. In another embodiment, the N-terminal XTEN sequence of the expressed hGH-XTEN has at least 90% sequence identity to any sequence selected from Table 2. In one embodiment, the N-terminal XTEN sequence of the expressed hGH-XTEN has at least 90% sequence identity to the sequence of AE48 or AM48, AE624, AE911, AE912 or AM923.

In other embodiments, the hGH-XTEN fusion protein comprises a first and a second XTEN sequence, wherein the cumulative total of the residues in the XTEN sequences is greater than about 400 to about 3000 amino acid residues. In embodiments of the foregoing, the hGH-XTEN fusion protein comprises a first and a second XTEN sequence wherein the sequences each exhibit at least about 80% sequence identity, or alternatively 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to at least a first or additionally a second XTEN selected from Table 2. Examples where more than one XTEN is used in a hGH-XTEN composition include, but are not limited to constructs with an XTEN linked to both the N- and C-termini of at least one GH.

As described more fully below, the invention provides methods in which the hGH-XTEN is designed by selecting the length of the XTEN to confer a target half-life on a fusion protein administered to a pediatric subject. In general, XTEN lengths longer than about cumulative 400 residues incorporated into the hGH-XTEN compositions result in longer half-life compared to shorter cumulative lengths; e.g., shorter than about 280 residues. However, in another embodiment, hGH-XTEN fusion proteins are designed to comprise XTEN with a longer sequence length that is selected to additionally confer slower rates of systemic absorption after subcutaneous or intramuscular administration to a pediatric subject. In such embodiments, the C_{max} is reduced in comparison to a comparable dose of a GH not linked to XTEN, thereby contributing to the ability to keep the hGH-XTEN within the therapeutic window for the composition. Thus, the XTEN confers the property of a depot to the administered hGH-XTEN, in addition to the other physical/chemical properties described herein.

Table 2: XTEN Polypeptides

XTEN Name	SEQ ID NO:	Amino Acid Sequence
AE48	13	MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGS
AM48	14	MAEPAGSPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGS
AE144	15	GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGS APGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSEGSAPGTSESATP ESGPGSEPATSGSETPGTSTEPSEGSAP
AF144	16	GTSTPESGSASPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESP GPGSTSESPSGTA PGSTSSTAESP GPGTSPSGESSTAPGTSTPESGSASPGSTSSTAESP GPGTSPSGESST APGTSPSGESSTAPGTSPSGESSTAP
AE288	17	GTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPES GPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATP ESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESA TPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTST EPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP
AF504	18	GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATG SPGSXPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGT ASSSPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPG TSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSXPSASTGTGPGSSPSASTGTGPGSS TPSGATGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPG TPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSASTGTG PGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSGAT GSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSG ATGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSP
AF540	19	GSTSSTAESP GPGSTSSTAESP GPGTSESPSGTAPGSTSSTAESP GPGSTSSTAESP G PGTSTPESGSASPGTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGT APGTSPSGESSTAPGSTSESPSGTAPGTSESPSGTAPGTSPSGESSTAPGSTSESPSG TAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSESPSGTAPGTSTPESG SASPGSTSSTAESP GPGSTSSTAESP GPGTSTPESGSASPGTSTPESGSASPGTSESP SGTAPGTSTPESGSASPGTSTPESGSASPGTSESPSGTAPGSTSESPSGTAPGSTSES PSGTAPGSTSSTAESP GPGTSTPESGSASPGTSTPESGSASPGTSESPSGTAPGSTSE SPSGTAPGTSTPESGSASPGTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSP SGESSTAPGSTSSTAESP GPGTSPSGESSTAPGSTSSTAESP GPGTSTPESGSASPGT SESPSGTAP
AD576	20	GSSGESGSEGGPGSGGEPSESGSSGESGSEGGPGSSESGSSEGGPGSSESGSSEGG GPGSSESGSSEGGPGSSESGSSEGGPGSGGEPSESGSSGESPGGSSGESGESPG EGGPGSSESGSSEGGPGSSESGSSEGGPGSGGEPSESGSSGESPGGSSGESGESPG GSSGESGSGGEPSESGSSGESGSEGGPGSGGEPSESGSSGSGGEPSESGSSGSE GSSGPGESSGESPGGSSGESGSGGEPSESGSSGSGGEPSESGSSGSGGEPSESGSSG SSESGSSEGGPGSGSGGEPSESGSSGESGSGGEPSESGSSGSGGEPSESGSSGSE SGESPGGSSGESGSSGESGSEGGPGSGGEPSESGSSGSEGGPGESSGESGSSSE GGPGSGGEPSESGSSGESGSEGGPGSGGEPSESGSSGESPGGSSGESGESPGG SSGESGSSGESGSEGGPGSGGEPSESGSSGESGSEGGPGSGGEPSESGSSGSGG EPSESGSSGESPGGSSGESGSEGGPGESSGESGSSGESGSEGGPGSEGGPGESS
AE576	21	GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGS APGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPS EGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSP AGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAP PGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP
AF576	22	GSTSSTAESP GPGSTSSTAESP GPGTSESPSGTAPGSTSSTAESP GPGSTSSTAESP G PGTSTPESGSASPGTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGT

XTEN Name	SEQ ID NO:	Amino Acid Sequence
		APGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSG TAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGTSTPESG SASPGTSSSTAESP GPGTSSSTAESP GPGTSTPESGSASPGTSTPESGSASPGTSTPES SGTAPGTSTPESGSASPGTSTPESGSASPGTSTPESPSGTAPGSTSESPSGTAPGSTSES PSGTAPGSTSSSTAESP GPGTSTPESGSASPGTSTPESGSASPGTSTPESPSGTAPGSTSE SPSGTAPGTSTPESGSASPGTSTPESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSP SGESSTAPGSTSSSTAESP GPGTSPSGESSTAPGSTSSSTAESP GPGTSTPESGSASPGT SESPSGTAPGSTSSSTAESP GPGTSTPESGSASPGTSTPESGSASP
AE624	23	MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSSTGSPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS EGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT TEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPG TSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTE EGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSE SAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSE TSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPA TSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSP AGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP
AD836	24	GSSGESGSGGPGSSGESGSGGPGGESPGGSSGESGSGGEPSESGSSGESPGGSSGS ESGESPGGSSGESGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGES GSGESPGGSSGESGSGGPGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESG SSEGGPGSSGESGSGGPGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSS GGSSGESGSGGPGSSGESGSGGEPSESGSSGESGSGGPGSSGESGSGGEPSESGSS GGEPSESGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGESPGGSSGS ESGSGEPSESGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGESPGG SSGSESSGPGESSGESPGGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSE SGSSGESGSGGPGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGES GPGESSGESPGGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGESGSS GESSGSESSGPGESSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGES SSGESGSGGPGSSGESGSGGEPSESGSSGESGSGGPGSSGESGSGGEPSESGSSGES SGSSEGGPGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSSGESGSGG SPGGSSGESGSGGEPSESGSSGESGSGGPGSSGESGSGGPGSSGESGSGGEPSESGSS GESPGGSSGESGSGGEPSESGSS
AE864	25	GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGS APGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPS EGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSP AGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPG TSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS PGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPE SGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSES ATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGT TEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPG SPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESG PGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSE SAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP
AF864	26	GSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSAS PGTSTPESGSASPGTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGT APGTSPSGESSTAPGTSPSGESSTAPGSTSSSTAESP GPGTSPSGESSTAPGTSPSGESS TAPGSTSSSTAESP GPGTSTPESGSASPGTSTPESGSASPGTSESPSGTAPGSTSESPS GTAPGTSTPESGSASPGTSSSTAESP GPGTSTPESGSASPGTSESPSGTAPGTSPSG ESSTAPGSTSSSTAESP GPGTSPSGESSTAPGTSTPESGSASPGTSSSTAESP GPGTSS TAESP GPGTSSSTAESP GPGTSSSTAESP GPGTSPSGESSTAPGSTSESPSGTAPGSTS ESPSGTAPGTSTPESGPXXXGASASGAPSTXXXXSESPSGTAPGSTSESPSGTAPGS

XTEN Name	SEQ ID NO:	Amino Acid Sequence
		TSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPG TSPSGESSTAPGTSPSGESSTAPGSTSSTAESP GPGTSPSGESSTAPGTSTPESGSASP GSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGSTSESPSGTAPGTSTPESGSAS PGTSTPESGSASPGSTSESPSGTAPGTSTPESGSASPGSTSSTAESP GPGTSESPSGT APGSTSESPSGTAPGTSPSGESSTAPGSTSSTAESP GPGTSPSGESSTAPGTSTPESGS ASPGTSPSGESSTAPGTSPSGESSTAPGTSPSGESSTAPGSTSSTAESP GPGTSSSTAE SPGPGTSPSGESSTAPGSSPSASTGTGPGSSTPSGATGSPGSSTPSGATGSP
AG864	27	GASPGTSSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSSPGSSTPSGATG SPGSSPSASTGTGPGASPGTSSSTGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTA SSSPGASPGTSSSTGSPGASPGTSSSTGSPGTPGSGTASSSPGSSTPSGATGSPGASPGT SSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSST PSGATGSPGSSTPSGATGSPGASPGTSSSTGSPGASPGTSSSTGSPGASPGTSSSTGSPGT PGSGTASSSPGASPGTSSSTGSPGASPGTSSSTGSPGASPGTSSSTGSPGSSTPSASTGTG GTPGSGTASSSPGASPGTSSSTGSPGASPGTSSSTGSPGASPGTSSSTGSPGSSTPSGATG SPGSSTPSGATGSPGASPGTSSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGA TGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSSTGSPGASPGTSSSTGSPGTPGSG TASSSPGASPGTSSSTGSPGASPGTSSSTGSPGASPGTSSSTGSPGASPGTSSSTGSPGTPG SGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGS STPSGATGSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSSTGSP GTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSSTG SPGASPGTSSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSSTGSPGSSPSAST GTGPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSSTGSP
AM87 5	28	GTSTEPSEGSAPGSEATSGSETPGSPAGSPTSTEEGSTSSTAESP GPGTSTPESGSA SPGSTSESPSGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSEATSGS ETPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESA TPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTST EPSEGSAPGSEATSGSETPGSPAGSPTSTEEGSTPSGATGSPGTPGSGTASSSPGS STPSGATGSPGTSTEPSEGSAPGTSTEPSEGSAPGSEATSGSETPGSPAGSPTSTEE GSPAGSPTSTEEGTSTEPSEGSAPGASASGAPSTGGTSESATPESGPGSPAGSPTSTE EGSPAGSPTSTEEGSTSSTAESP GPGTSESPSGTAPGTSPSGESSTAPGTPGSGTAS SSPGSSTPSGATGSPGSSPSASTGTGPGSEATSGSETPGTSESATPESGPGSEPA TSGSETPGTSTEPSEGSAPGTSSTAESP GPGTSTPESGSASPGTSESPSGTAPGTST EPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSSSTPSGATGSPGSSPSASTGTGPGA SPGTSSSTGSPGSEATSGSETPGTSESATPESGPGSPAGSPTSTEEGSTPSGATGSP GSSPSASTGTGPGASPGTSSSTGSPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS AP
AE912	29	MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSSTGSPGSPAGSPT STEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPS EGSAPGTSESATPESGPGSEATSGSETPGSEATSGSETPGSPAGSPTSTEEGTSES ATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGT TEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEATSGSETPG TSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS SAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSP TSTEEGTSTEPSEGSAPGTSESATPESGPGSEATSGSETPGTSESATPESGPGSEPA TSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSP AGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPG SEATSGSETPGTSESATPESGPGSEATSGSETPGTSESATPESGPGTSTEPSEGS PGSPAGSPTSTEEGTSESATPESGPGSEATSGSETPGTSESATPESGPGSPAGSPTS TEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESAT PESGPGSEATSGSETPGSEATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTE PSEGSAPGSEATSGSETPGTSESATPESGPGTSTEPSEGSAP
AM92 3	30	MAEPAGSPTSTEEGASPGTSSSTGSPGSSTPSGATGSPGSSTPSGATGSPGTSTEPSE GSAPGSEATSGSETPGSPAGSPTSTEEGSTSSTAESP GPGTSTPESGSASPGTSESP SGTAPGSTSESPSGTAPGTSTPESGSASPGTSTPESGSASPGSEATSGSETPGTSES

XTEN Name	SEQ ID NO:	Amino Acid Sequence
		ATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTS TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPG TSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGS PGSEPATSGSETPGSPAGSPTSTEEGSSTPSGATGSPGTPGSGTASSSPGSSTPSGAT GSPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSPAGSP TSTEEGTSTEPSEGSAPGASASGAPSTGGTSESATPESGPGSPAGSPTSTEEGSPAGS PTSTEEGSTSSTAESP GPGSTSESPSGTAPGTSPSGESSTAPGTPGSGTASSSPGSSTP SGATGSPGSSPSASTGTGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGST SSTAESP GPGSTSSAESP GPGTSPSGESSTAPGSEPATSGSETPGSEPATSGSETPG TSTEPSEGSAPGTSSTAESP GPGTSTEPESGASPGTSESPSGTAPGTSTEPSEGSAP GTSTEPSEGSAPGTSTEPSEGSAPGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTG SPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSSTPSGATGSPGSSPSAST GTGPGASPGTSSTGSPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAP
AM13 18	31	GTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSTSSTAESP GPGTSTEPESGSA SPGSTSESPSGTAPGSTSESPSGTAPGTSTEPESGASPGTSTEPESGASPGSEPATSGS ETPGTSESATPESGPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSTEPSE GSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESA TPESGPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTST EPSEGSAPGSEPATSGSETPGSPAGSPTSTEEGSSTPSGATGSPGTPGSGTASSSPGS STPSGATGSPGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGSPAGSPTSTEE GSPAGSPTSTEEGTSTEPSEGSAPGPEPTGPAPSGGSEPATSGSETPGTSESATPESG PGSPAGSPTSTEEGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPE SGPGSPAGSPTSTEEGSPAGSPTSTEEGSTSSTAESP GPGSTSESPSGTAPGTSPSGES STAPGSTSESPSGTAPGSTSESPSGTAPGTSPSGESSTAPGTSTEPSEGSAPGTSESA TPESGPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSESATPESGPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSPSGESSTAPGTSPSGESSTAPGT SPSGESSTAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGSSPSASTGTGP GSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTG SPGASASGAPSTGGTSPSGESSTAPGSTSSTAESP GPGTSPSGESSTAPGTSESATPE SGPGTSTEPSEGSAPGTSTEPSEGSAPGSSPSASTGTGPGSSTPSGATGSPGASPGTS STGSPGTSTEPESGASPGTSPSGESSTAPGTSPSGESSTAPGTSESATPESGPGSEPAT SGSETPGTSTEPSEGSAPGTSSESPSGTAPGSTSESPSGTAPGTSTEPESGASPGSPA GSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGS EPATSGSETPGSSTPSGATGSPGASPGTSSTGSPGSSTPSGATGSPGTSSESPSGTAP GTSPSGESSTAPGSTSSTAESP GPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASS SPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAP
BC 864	32	GTSTEPSEPGSAGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGSEPATSGTE PSGSEPATSGTEPSGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGSEPATSG TEPSAGTSTEPSEPGSAGSEPATSGTEPSGSEPATSGTEPSGAGTSTEPSEPGSAGTSEPS EPGSAGSEPATSGTEPSGSEPATSGTEPSGTSEPSTSEPGAGSGASEPTSTEPGTSEP STSEPGAGSEPATSGTEPSGSEPATSGTEPSGTSTEPSEPGSAGTSTEPSEPGSAGSG ASEPTSTEPGSEPATSGTEPSGSEPATSGTEPSGSEPATSGTEPSGSEPATSGTEPSG TSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGSEPATSGTEP SGSGASEPTSTEPGTSTEPSEPGSAGSGASEPTSTEPGSEPATSGTEPSGSGASEPTS TEPGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSAGSEPATSGTEPSGSGASEP TSTEPGTSTEPSEPGSAGSEPATSGTEPSGTSTEPSEPGSAGSEPATSGTEPSGTSTEP SEPGSAGTSTEPSEPGSAGTSTEPSEPGSAGTSTEPSEPGSAGTSTEPSEPGSAGTST EPSEPGSAGTSEPSTSEPGAGSGASEPTSTEPGTSTEPSEPGSAGTSTEPSEPGSAGT STEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGSEPATSGTEPSGSEPATSGTEPS GSEPATSGTEPSGSEPATSGTEPSGTSEPSTSEPGAGSEPATSGTEPSGSGASEPTST EPGTSTEPSEPGSAGSEPATSGTEPSGSGASEPTSTEPGTSTEPSEPGSA
BD864	33	GSETATSGSETAGTSESATSESGAGTAGSETSTEAGTSESATSESGAGSETATSGS ETAGSETATSGSETAGTSTEASEGSASGTSTEASEGSASGTSESATSESGAGSETAT SGSETAGTSTEASEGSASGTAGSETSTEAGTSESATSESGAGTSESATSESGAGSE TATSGSETAGTSESATSESGAGTSTEASEGSASGTATSGSETAGSETATSGSETA GTSTEASEGSASGTAGSETSTEAGTSESATSESGAGTSTEASEGSASGTATSGS ETAGTAGSETSTEAGTAGSETSTEAGSETATSGSETAGTSESATSESGAGTSESA

XTEN Name	SEQ ID NO:	Amino Acid Sequence
		TSESGAGSETATSGSETAGTSESATSESGAGTSESATSESGAGSETATSGSETAGSE TATSGSETAGTSTEASEGSASGSTAGSETSTEAGSETATSGSETAGTSESATSESGA GSTAGSETSTEAGTAGSETSTEAGTAGSETSTEAGTSTEASEGSASGSTAGSETS TEAGTAGSETSTEAGTSTEASEGSASGSTAGSETSTEAGSETATSGSETAGTSTEA SEGSASGTSESATSESGAGSETATSGSETAGTSESATSESGAGTSESATSESGAGSE TATSGSETAGTSESATSESGAGSETATSGSETAGTSTEASEGSASGTSTEASEGSAS GSTAGSETSTEAGTAGSETSTEAGSETATSGSETAGTSESATSESGAGTSESATSE SGAGSETATSGSETAGSETATSGSETAGSETATSGSETAGTSTEASEGSASGTSESA TSESGAGSETATSGSETAGSETATSGSETAGTSESATSESGAGTSESATSESGAGSE TATSGSETA
AE911	34	AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTST EEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESA TPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGT STEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEE GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPT STEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP GSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTST EEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATP ESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP SEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP
AE146	35	GGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEG SAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPS EGSAPGSPAGSPTSTEEGTSTEPSEGSAPG
AE48. 1	36	AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGS
AM48. 1	37	AEPAGSPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGS
AE912 .1	38	AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTST EEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESA TPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGT STEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEE GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPT STEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPAT SGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPA GSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGS EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP GSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTST EEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATP ESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEP SEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP
AE912 .2	39	AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTST EEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSE GSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESA TPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTST EPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGT STEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEE GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPT GTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGS APGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPT

XTEN Name	SEQ ID NO:	Amino Acid Sequence
		STEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPG
AE146.1	40	TSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPG

In those embodiments wherein the XTEN component of the hGH-XTEN fusion protein has less than 100% of its amino acids consisting of 4, 5, or 6 types of amino acid selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), or less than 100% of the sequence consisting of the XTEN sequences of Table 2, the other amino acid residues of the XTEN are selected from any of the other 14 natural L-amino acids, but are preferentially selected from hydrophilic amino acids such that the XTEN sequence contains at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% hydrophilic amino acids. The XTEN amino acids that are not glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) are either interspersed throughout the XTEN sequence, are located within or between the sequence motifs, or are concentrated in one or more short stretches of the XTEN sequence, e.g., to create a linker between the XTEN and the hGH components. In such cases where the XTEN component of the hGH-XTEN comprises amino acids other than glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P), it is preferred that less than about 2% or less than about 1% of the amino acids be hydrophobic residues such that the resulting sequences generally lack secondary structure, e.g., not having more than 2% alpha helices or 2% beta-sheets, as determined by the methods disclosed herein. Hydrophobic residues that are less favored in construction of XTEN include tryptophan, phenylalanine, tyrosine, leucine, isoleucine, valine, and methionine. Additionally, one can design the XTEN sequences to contain less than 5% or less than 4% or less than 3% or less than 2% or less than 1% or none of the following amino acids: cysteine (to avoid disulfide formation and oxidation), methionine (to avoid oxidation), asparagine and glutamine (to avoid desamidation). Thus, in some embodiments, the XTEN component of the hGH-XTEN fusion protein comprising other amino acids in addition to glycine (G), alanine (A), serine (S), threonine (T), glutamate

(E) and proline (P) have a sequence with less than 5% of the residues contributing to alpha-helices and beta-sheets as measured by the Chou-Fasman algorithm and have at least 90%, or at least about 95% or more random coil formation as measured by the GOR algorithm.

4. XTEN segments

In one embodiment, the present disclosure provides an isolated hGH-XTEN fusion protein wherein the cumulative length of the XTEN component is greater than about 100 to about 3000 amino acid residues containing at least one polypeptide sequence segment selected from Table 2 (and Tables 8, 9, 10, 11, and 12 of Schellenberger et al.

WO10/144502A2, which is incorporated herein by reference in its entirety) and wherein at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98% or more of the remainder of the XTEN sequence by and large contains hydrophilic amino acids and less than about 2% of the remainder of the XTEN consists of hydrophobic or aromatic amino acids, or cysteine. In some embodiments, the XTEN contains multiple segments wherein the segments are identical or different (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety).

5. N-terminal XTEN expression-enhancing sequences

In some embodiments, the present disclosure provides a short-length XTEN sequence incorporated as the N-terminal portion of the hGH-XTEN fusion protein. The expression of the fusion protein is enhanced in a host cell transformed with a suitable expression vector comprising an optimized N-terminal leader polynucleotide sequence (that encodes the N-terminal XTEN) incorporated into the polynucleotide encoding the binding fusion protein. It has been discovered, as described in Examples 14-17 of Schellenberger et al.

WO10/144502A2 (which is incorporated herein by reference in its entirety), that a host cell transformed with such an expression vector comprising an optimized N-terminal leader sequence (NTS) in the binding fusion protein gene results in greatly-enhanced expression of the fusion protein compared to the expression of a corresponding fusion protein from a polynucleotide not comprising the NTS, and obviates the need for incorporation of a non-XTEN leader sequence used to enhance expression (see Schellenberger et al.

WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety).

In one embodiment, the N-terminal XTEN polypeptide of the hGH-XTEN comprises a sequence that exhibits at least about 80%, more preferably at least about 90%, more

preferably at least about 91%, more preferably at least about 92%, more preferably at least about 93%, more preferably at least about 94%, more preferably at least about 95%, more preferably at least about 96%, more preferably at least about 97%, more preferably at least about 98%, more preferably at least 99%, or exhibits 100% sequence identity to the amino acid sequence of AE48, AE48.1, AM48, or AM48.1, the respective amino acid sequences of which are as follows:

AE48: MAEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGS (SEQ ID NO:13)

AE48.1: AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGS (SEQ ID NO:36)

AM48: MAEPAGSPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGS (SEQ ID NO:14)

10 AM48.1: AEPAGSPTSTEEGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGS (SEQ ID NO:37).

In another embodiment, the N-terminal XTEN polypeptide of the hGH-XTEN comprises a sequence exhibiting at least 90% identity to AE48, AM48 or AE912, as described herein, wherein the N-terminal M residue is absent (*e.g.*, AE48.1 - SEQ ID NO:36; AM48.1 - SEQ ID NO:37; and AE912.1 - SEQ ID NO:38). In an additional embodiment, the C-terminal XTEN polypeptide of the hGH-XTEN comprises a sequence exhibiting at least 90% identity to AE146, as described herein, (*e.g.*, AE146 - SEQ ID NO:35; or AE146.1 - SEQ ID NO:40).

In another embodiment, the short-length N-terminal XTEN is linked to an XTEN of longer length to form the N-terminal region of the hGH-XTEN fusion protein, wherein the polynucleotide sequence encoding the short-length N-terminal XTEN confers the property of enhanced expression in the host cell, and wherein the long length of the expressed XTEN contributes to the enhanced properties of the XTEN carrier in the fusion protein, as described above. In some embodiments, the N-terminal XTEN polypeptide with long length exhibits at least about 80%, or at least about 90%, or at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least 99%, or exhibits 100% sequence identity to an amino acid sequence selected from the group consisting of the sequences AE624, AE911, AE912, and AM923.

6. Net charge

30 In other embodiments, the XTEN polypeptides have an unstructured characteristic imparted by incorporation of amino acid residues with a net charge and/or reducing the proportion of hydrophobic amino acids in the XTEN sequence. The overall net charge and net charge density is controlled by modifying the content of charged amino acids in the XTEN sequences. In some embodiments, the net charge density of the XTEN of the

compositions may be above +0.1 or below -0.1 charges/residue. In other embodiments, the net charge of a XTEN can be about 0%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10% about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% or more (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. PCT/US2013/031673, each of which is incorporated herein by reference in its entirety).

7. Low immunogenicity

In another aspect, the present disclosure provides compositions in which the XTEN sequences have a low degree of immunogenicity or are substantially non-immunogenic.

Several factors can contribute to the low immunogenicity of XTEN, e.g., the non-repetitive sequence, the unstructured conformation, the high degree of solubility, the low degree or lack of self-aggregation, the low degree or lack of proteolytic sites within the sequence, and the low degree or lack of epitopes in the XTEN sequence (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. PCT/US2013/031673, each of which is incorporated herein by reference in its entirety).

8. Increased hydrodynamic radius

In another aspect, the present disclosure provides XTEN in which the XTEN polypeptides have a high hydrodynamic radius that confers a corresponding increased Apparent Molecular Weight to the hGH-XTEN fusion protein incorporating the XTEN. As detailed in Example 37 of Schellenberger et al. WO10/144502A2, the linking of XTEN to GH sequences results in hGH-XTEN compositions that can have increased hydrodynamic radii, increased Apparent Molecular Weight, and increased Apparent Molecular Weight Factor compared to a GH not linked to an XTEN (see Schellenberger et al. WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety).

V). hGH-XTEN STRUCTURAL CONFIGURATIONS AND PROPERTIES

The human growth hormone (GH) of the subject compositions are not limited to native, full-length polypeptides, but also include recombinant versions as well as biologically and/or pharmacologically active variants or fragments thereof. For example, it will be appreciated that various amino acid deletions, insertions and substitutions can be made in the GH to create variants without departing from the spirit of the invention with respect to the biological activity or pharmacologic properties of the GH. Examples of conservative substitutions for amino acids in polypeptide sequences are shown in Table 3. However, in embodiments of the hGH-XTEN in which the sequence identity of the GH is less than 100%

compared to a specific sequence disclosed herein, the invention contemplates substitution of any of the other 19 natural L-amino acids for a given amino acid residue of the given GH, which may be at any position within the sequence of the GH, including adjacent amino acid residues. If any one substitution results in an undesirable change in biological activity, then one of the alternative amino acids can be employed and the construct evaluated by the methods described herein, or using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Pat. No. 5,364,934, the content of which is incorporated by reference in its entirety, or using methods generally known in the art. In addition, variants can include, for instance, polypeptides wherein one or more amino acid residues are added or deleted at the N- or C-terminus of the full-length native amino acid sequence of a GH that retains some if not all of the biological activity of the native peptide.

Table 3: Exemplary conservative amino acid substitutions

Original Residue	Exemplary Substitutions
Ala (A)	val; leu; ile
Arg (R)	lys; gin; asn
Asn (N)	gin; his; lys; arg
Asp (D)	glu
Cys (C)	ser
Gln (Q)	asn
Glu (E)	asp
Gly (G)	pro
His (H)	asn; gin; lys; arg
Ile (I)	leu; val; met; ala; phe; norleucine
Leu (L)	norleucine; ile; val; met; ala; phe
Lys (K)	arg; gin; asn
Met (M)	leu; phe; ile
Phe (F)	leu; val; ile; ala
Pro (P)	gly
Ser (S)	thr
Thr (T)	ser
Trp (W)	tyr
Tyr (Y)	trp; phe; thr; ser
Val (V)	ile; leu; met; phe; ala; norleucine

(a) Fusion Protein Configurations

In some embodiments, the present disclosure provides fusion protein compositions with the GH and XTEN components linked in specific N- to C-terminus configurations. In some embodiments, one or more GHs are linked to one or more XTENs, either at the N-terminus or at the C-terminus, with or without a spacer, to form a block copolymer, and the sequential arrangement of the GHs and the XTENs in the fusion protein are the same as the configuration known in the block

copolymer chemistry. When there is more than one GH, XTEN, or spacer, each of the GH, the XTEN, or the spacer have the same or different sequences, and the GHs and/or XTENs are linked either continuously or alternately (regular or irregular). Thus, in all of the formulae provided herein, when there is more than one GH, XTEN, or spacer, each of the GH, XTEN, and spacer are the same or different. In some embodiments, the fusion protein is a monomeric fusion protein with a GH linked to one XTEN polypeptide. In other embodiments, the fusion protein is a monomeric fusion protein with a GH linked to two or more XTEN polypeptides. In still other embodiments, the fusion protein is a monomeric fusion protein with two or more GH linked to one XTEN polypeptide. In still other embodiments, the fusion protein is a monomeric fusion protein with two or more GH linked to two or more XTEN polypeptide. Table 4 provides non-limiting examples of configurations that are encompassed by the invention; numerous other variations will be apparent to the ordinarily skilled artisan, including the incorporation of the spacer and cleavage sequences disclosed herein or known in the art.

Table 4: hGH-XTEN configurations

Components*	Configuration**
Single GH; Single XTEN	GH-XTEN
	XTEN-GH
Single GH; Multiple XTEN	XTEN-GH-XTEN
	GH-XTEN-XTEN
	XTEN-XTEN-GH
	XTEN-GH-XTEN-XTEN
	XTEN-XTEN-GH-XTEN
Multiple GH, Single XTEN	GH-XTEN-GH
	XTEN-GH-GH
	GH-GH-XTEN
	GH-XTEN-GH-GH
Multiple GH; Multiple XTEN	GH-XTEN-GH-XTEN
	XTEN-GH-XTEN-GH
	XTEN-XTEN-GH-XTEN-GH
	XTEN-XTEN-GH-GH

Components*	Configuration**
	GH-XTEN-XTEN-GH
	GH-GH-XTEN-XTEN
	GH-GH-XTEN-XTEN-GH
	GH-XTEN-GH-XTEN-GH

* Characterized as single for 1 component or multiple for 2 or more of that component

** Reflects N- to C-terminus configuration of the growth factor and XTEN components


5 In some embodiments, are provided fusion proteins compositions that are in a configuration shown in Table 4 and that retain at least a portion of the biological activity of the corresponding GH not linked to the XTEN. In other embodiments, the GH component either becomes biologically active or has an increase in activity upon its release from the XTEN by cleavage of an optional cleavage sequence incorporated within spacer sequences
10 into the hGH-XTEN, described more fully below.

In one embodiment of the hGH-XTEN composition, is provided a fusion protein of formula I:




wherein independently for each occurrence, GH is a human growth hormone; x is either 0 or
15 1 and y is either 0 or 1 wherein $x+y \geq 1$; and XTEN is an extended recombinant polypeptide.

In another embodiment of the hGH-XTEN composition, is provided a fusion protein of formula II:



wherein independently for each occurrence, GH is a human growth hormone; S is a spacer
20 sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1 and y is either 0 or 1 wherein $x+y \geq 1$; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula III:



wherein independently for each occurrence, GH is a human growth hormone; S is a spacer
sequence having between 1 to about 50 amino acid residues that can optionally include a


cleavage sequence; x is either 0 or 1; y is either 0 or 1; z is either 0 or 1; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula IV:




wherein independently for each occurrence, GH is a human growth hormone; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1; y is either 0 or 1; z is either 0 or 1; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula V:




wherein independently for each occurrence, GH is a growth hormone; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1; y is either 0 or 1; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula VI:




wherein independently for each occurrence, GH is a growth hormone; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1; y is either 0 or 1; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula VII:




wherein independently for each occurrence, GH is a growth hormone; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1; y is either 0 or 1; and XTEN is an extended recombinant polypeptide.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula VIII:



wherein t is an integer that is greater than 0 (1, 2, 3, etc.); independently each of m , n , o , x , and y is an integer (0, 1, 2, 3, etc.), GH is a growth hormone; S is a spacer, optionally comprising a cleavage site; and XTEN is an extended recombinant polypeptide, with the proviso that: (1) $x + y > 1$, (2) when $t = 1$, $x > 0$ and $y > 0$, (3) when there is more than one GH, S, or XTEN, each GH, XTEN, or S are the same or are independently different; and (4) when $t > 1$, each m , n , o , x , or y within each subunit are the same or are independently different.

In another embodiment, is provided an isolated fusion protein, wherein the fusion protein is of formula IX:



wherein independently for each occurrence, GH is a human growth hormone; S is a spacer sequence having between 1 to about 50 amino acid residues that can optionally include a cleavage sequence; x is either 0 or 1 and y is either 0 or 1 wherein $x + y > 1$; and XTEN is an extended recombinant polypeptide.

Any spacer sequence group is optional in the fusion proteins encompassed by the invention. The spacer is provided to enhance expression of the fusion protein from a host cell or to decrease steric hindrance such that the GH component may assume its desired tertiary structure and/or interact appropriately with its target receptor. For spacers and methods of identifying desirable spacers, see, for example, George, et al. (2003) Protein Engineering 15:871–879, specifically incorporated by reference herein. In one embodiment, the spacer comprises one or more peptide sequences that are between 1–50 amino acid residues in length, or about 1–25 residues, or about 1–10 residues in length. Spacer sequences, exclusive of cleavage sites, can comprise any of the 20 natural L amino acids, and will preferably comprise hydrophilic amino acids that are sterically unhindered that can include, but not be limited to, glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P). In some cases, the spacer can be polyglycines or polyalanines, or is predominately a mixture of combinations of glycine and alanine residues. The spacer polypeptide exclusive of a cleavage sequence is largely to substantially devoid of secondary structure; e.g., less than about 10%, or less than about 5% as determined by the Chou-Fasman and/or GOR algorithms. In one embodiment, one or both spacer sequences in a hGH-XTEN fusion protein composition each further contains a cleavage sequence, which are identical or different, wherein the cleavage sequence may be acted on by a protease to release the GH from the fusion protein.

In one embodiment, a GH incorporated into a hGH-XTEN fusion protein has a sequence that exhibits at least about 80% sequence identity to a sequence shown as SEQ ID

NO:41, alternatively at least about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%, or about 100% sequence identity as compared with the sequence of

5 SEQ ID NO:41. The GH of the foregoing embodiment can be evaluated for activity using assays or measured or determined parameters as described herein, and those sequences that retain at least about 40%, or about 50%, or about 55%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95% or more activity compared to the corresponding native GH sequence would be considered suitable for inclusion in the subject hGH-XTEN. The GH
10 found to retain a suitable level of activity can be linked to one or more XTEN polypeptides described hereinabove. In one embodiment, a GH found to retain a suitable level of activity can be linked to one or more XTEN polypeptides having at least about 80% sequence identity to a sequence from Table 3, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100%
15 sequence identity as compared with a sequence of Table 3, resulting in a chimeric fusion protein.

Non-limiting examples of sequences of fusion proteins containing a single GH linked to a single XTEN are presented in Table 35 of Schellenberger et al. WO10/144502A2, which is incorporated herein by reference in its entirety. In one embodiment, a hGH-XTEN

20 composition would comprise a fusion protein having at least about 80% sequence identity to a hGH-XTEN from Table 35 of Schellenberger et al. WO10/144502A2 (which is incorporated herein by reference in its entirety), alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% sequence identity as compared with a hGH-XTEN from Table 35 of

25 Schellenberger et al. WO10/144502A2, which is incorporated herein by reference in its entirety. Non-limiting examples of sequences of fusion proteins containing two molecules of XTEN linked to one or more GH are presented in Table 36 of Schellenberger et al.

WO10/144502A2 (which is incorporated herein by reference in its entirety), but the invention also contemplates substitution of other GH with sequences exhibiting at least about 90%

30 sequence identity to the sequence of SEQ ID NO:41 linked to one or two XTEN, which may be the same or different, exhibiting at least about 90% sequence identity to sequences selected from Table 2. Non-limiting examples of hGH-XTEN comprising GH, XTEN, and spacer amino acids are presented in Table 37 of Schellenberger et al. WO10/144502A2, which is incorporated herein by reference in its entirety. (see also Schellenberger et al.

WO10/144502A2; Cleland et al. U.S. 13/829,369; and Cleland et al. WO13/184216, each of which is incorporated herein by reference in its entirety).

VI. USES OF THE COMPOSITIONS OF THE PRESENT INVENTION

Most processes involved in growth of the body are regulated by multiple peptides and hormones, and such peptides and hormones, as well as analogues thereof, have found utility in the treatment of growth hormone-related diseases, disorders and conditions. However, the use of commercially-available growth hormones to treat pediatric patients, has met with less than optimal success in the management of pediatric patients afflicted with such diseases, disorders and conditions. In particular, dose optimization and frequency of dosing is important for peptide and hormone biologics used in the treatment of growth hormone-related diseases and disorders in pediatric patients. The fact that growth hormone has a short half-life (e.g., usually less than 4 hours when administered subcutaneously), necessitates frequent (e.g., daily) dosing in order to achieve clinical benefit, which results in difficulties in the management of such pediatric patients. Non-compliance with daily growth hormone (GH) injections can lead to loss of treatment effects.

When compared to the current treatment protocol for recombinant hGH (rhGH), the benefit of an hGH-XTEN fusion protein to pediatric PGHD patients may include a substantial reduction in the number and frequency of injections. For example, in the Phase 2a stage of the clinical trial (see Example 2), pediatric PGHD patients will receive significantly fewer total injections (e.g., 6 total injections, once per month for 6 months) of an hGH-XTEN fusion protein compared to the 180 total injections of rhGH that these patients would have received on daily rhGH therapy over 6 months) than a pediatric patient undergoing daily rhGH therapy would receive over the same time period. The frequency of injection with rhGH in current clinical practice often leads to a lack of compliance. Compliance with daily therapy is crucial in order to realize the full potential for normal growth (Rosenfeld, R. G. & Bakker, B. (2008). *Endocr Pract* **14**, 143-54; Desrosiers, P. et al. (2005). *Pediatr Endocrinol Rev* **2 Suppl 3**, 327-31). An hGH-XTEN fusion protein is expected to provide the advantage of non-daily (e.g., bi-weekly, weekly, every two weeks, every three weeks, or monthly) administration to children with PGHD, and to offer a safe alternative to the current daily injections. An hGH product administered less frequently than daily rhGH therapy may provide greater compliance and therefore better long-term treatment outcomes for PGHD children.

In one aspect, the present disclosure provides a method for achieving a beneficial effect in a disease, disorder or condition mediated by GH including, but not limited to growth

hormone deficiency in a pediatric human patient. In another aspect, the invention provides a method for achieving a beneficial effect in a disease, disorder or condition mediated by GH including, but not limited to growth hormone deficiency in pediatric patients. The beneficial effect includes, without limitation, treating, mediating, or ameliorating a GH-related disease, deficiency, disorder or condition. The present disclosure addresses disadvantages and/or limitations of GH that have a relatively short terminal half-life and/or a narrow therapeutic window.

1. Pediatric Growth Hormone Deficiency (PGHD)

“Pediatric Growth Hormone Deficiency” or “PGHD” as used herein refers to a disease, deficiency, disorder or condition in a human pediatric patient that would benefit from treatment with growth hormone. PGHD includes disorders that are classified based on the source of the GH deficiency (*e.g.*, pituitary PGHD, hypothalamic PGHD, functional PGHD, and idiopathic PGHD). Pituitary or “classic” PGHD is the incapacity of the pituitary to produce growth hormone. “Hypothalamic PGHD” is the failure of the hypothalamus to produce and/or transmit the neuroendocrine messaging hormone, growth hormone releasing hormone (GHRH), which directs a properly functioning pituitary to produce GH; “functional PGHD” is the failure of other hormone and of metabolic functions related to the failure of the pituitary to produce, uptake, and/or utilize GH. PGHD also includes, without limitation, idiopathic short stature, Turner syndrome, Prader Willi syndrome, small for gestational age (SGA), growth failure as a result of a deficiency in the short stature homeobox-containing gene (SHOX deficiency); and chronic kidney disease (CKD). The PGHD may be congenital or acquired in nature.

PGHD may also occur as a result of intrauterine growth retardation, congenital hypopituitarism or acquired hypopituitarism (including hypopituitarism caused by a tumor, *e.g.*, craniopharyngioma); small for gestational age, developmental defects in or near the pituitary gland; genetic problems with the production of GH; Prader-Willi syndrome; Turner syndrome; idiopathic short stature; intrauterine growth retardation; midline facial defects; and damage to the pituitary gland or the surrounding area due to tumors, infection, radiation treatment, or severe head injury.

PGHD may be classified based on the stage of life the GH deficiency became manifest. For example, an adolescent may have PGHD that is a continuation of childhood onset PGHD (including child-onset PGHD and child-onset idiopathic PGHD), which began in infancy or pre-adolescent childhood. The causes of childhood-onset PGHD are provided above. Adolescents who survived brain tumors as pre-adolescent children may be at risk of

developing PGHD from the effects of surgery, cranial radiation or chemotherapy. PGHD can develop in an adolescent, *i.e.*, childhood-onset PGHD, who was not diagnosed as being GH-deficient as a pre-adolescent child. PGHD may be caused by damage or trauma to the pituitary gland. The damage is typically caused by a tumor (*e.g.*, a tumor in and/or around the pituitary gland; or a tumor in the hypothalamus). Pituitary tumors can compress the gland or damage can occur when the tumor is removed via neurosurgery. The pituitary can also be damaged by infection, blood vessel disease, severe head injury, or cranial radiation or chemotherapy for treating tumors of the head and neck. PGHD may be caused by: trauma that occurred in a child or adolescent at their birth or soon after their birth; central nervous system infection; tumors of the hypothalamus or pituitary glands; infiltrative or granulomatous disease; cranial irradiation; surgery; or idiopathic causes.

2. hGH-XTEN Bolus Doses and Dosage Regimens

In one aspect, the present disclosure provides a method of treating pediatric growth hormone deficiency (PGHD) in a human pediatric patient by administering a human growth hormone-XTEN (hGH-XTEN) fusion protein to the patient. In one embodiment, the method comprises administering the hGH-XTEN fusion protein to the pediatric patient as a bolus dose. In another embodiment, the bolus dose is a therapeutically effective bodyweight adjusted bolus dose. In one other embodiment, the bolus dose is between about 0.8 mg/kg and about 6.3 mg/kg. In one embodiment, the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1. In another embodiment, the fusion protein comprises an amino acid sequence having at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity to SEQ ID NO:1. In another embodiment, the fusion protein comprises an amino acid sequence having the sequence of SEQ ID NO:1.

In one aspect, the bolus dose may be administered over a range of doses. It should be noted that where reference is made to the administration of a bolus dose between about a first mg/kg and about a second mg/kg, the “first mg/kg” term may include the first mg/kg value and the “second mg/kg” term may include the second mg/kg value.

In one embodiment, the hGH-XTEN fusion protein comprises (i) an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1; (ii) the amino acid sequence of SEQ ID NO:1; (iii) an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:4 (AE912-hGH); (iv) the amino acid sequence of SEQ ID NO:4

(AE912-hGH); (v) an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:38; or (vi) the amino acid sequence of SEQ ID NO:38.

In one other aspect, the bolus dose of the hGH-XTEN fusion protein is administered to a human pediatric patient on a regular basis over a suitable time period, which can be finite or indefinite. In one embodiment, the bolus dose is administered every week, every two weeks, every three weeks, or monthly. In other embodiments, the bolus dose is administered once a month, twice a month, three times a month, or four times a month. In another embodiment, the bolus dose is administered about every 7 days, about every 10 days, about every 14 days, about every 21 days, about every 28 days, or about every 30 days. In one embodiment, the bolus dose is administered on a non-daily basis, or is a non-daily bolus dose.

In an additional aspect, the bolus dose of the hGH-XTEN fusion protein is administered to a human pediatric patient at a dose (i) between about 1.0 mg/kg and about 6.3 mg/kg; (ii) between about 1.0 mg/kg and about 1.5 mg/kg; (iii) between about 2.0 mg/kg and about 3 mg/kg, or (iv) between about 4.5 mg/kg and about 5.5 mg/kg, wherein the dose is administered on a monthly, semimonthly, or weekly basis. In one embodiment, the fusion protein is administered at a dose of about 1.0 mg/kg, about 1.05 mg/kg, about 1.10 mg/kg, about 1.15 mg/kg, about 1.20 mg/kg, about 1.25 mg/kg, about 1.30 mg/kg, about 1.35 mg/kg, about 1.40 mg/kg, about 1.45 mg/kg, and about 1.50 mg/kg, wherein the dose is administered on a monthly, semimonthly, or weekly basis. In another embodiment, the fusion protein is administered at a dose of about 2.0 mg/kg, about 2.10 mg/kg, about 2.20 mg/kg, about 2.30 mg/kg, about 2.40 mg/kg, about 2.50 mg/kg, about 2.60 mg/kg, about 2.70 mg/kg, about 2.80 mg/kg, about 2.90 mg/kg, and about 3.0 mg/kg, wherein the dose is administered on a monthly, semimonthly, or weekly basis. In one other embodiment, the fusion protein is administered at a dose of about 4.50 mg/kg, about 4.60 mg/kg, about 4.70 mg/kg, about 4.80 mg/kg, about 4.90 mg/kg, about 5.0 mg/kg, about 5.10 mg/kg, about 5.20 mg/kg, about 5.30 mg/kg, about 5.40 mg/kg, about 5.50 mg/kg, about 6.0 mg/kg, and about 6.3 mg/kg wherein the dose is administered on a monthly, semimonthly, or weekly basis. In preferred embodiments, the fusion protein is administered (i) at a dose of about 1.15 mg/kg on a weekly basis; (ii) at a dose of about 2.5 mg/kg on a semimonthly basis; and/or (iii) at a dose of about 5.0 mg/kg on a monthly basis.

In another embodiment, the fusion protein is administered at a dose of about 0.8 mg/kg, about 0.9 mg/kg, about 1.60 mg/kg, about 1.70 mg/kg, about 1.80 mg/kg, about 1.90 mg/kg, about 3.10 mg/kg, about 3.20 mg/kg, about 3.30 mg/kg, about 3.40 mg/kg, about 3.50 mg/kg, about 3.60 mg/kg, about 3.70 mg/kg, about 3.80 mg/kg, about 3.9 mg/kg, about 4.0 mg/kg,

about 4.10 mg/kg, about 4.20 mg/kg, about 4.30 mg/kg, about 4.40 mg/kg, about 5.60 mg/kg, about 5.70 mg/kg, about 5.80 mg/kg, and about 5.90 mg/kg, wherein the dose is administered on a monthly, semimonthly, or weekly basis.

In another aspect, additional bolus doses and ranges of bolus doses of the hGH-XTEN fusion protein for a human pediatric patient are suitable. In one embodiment, the bolus dose of hGH-XTEN is

(i) between about 0.8 mg/kg and about 1.2 mg/kg, about 1.2 mg/kg and about 1.8 mg/kg, about 1.8 mg/kg and about 2.7 mg/kg, about 2.7 mg/kg and about 4 mg/kg, about 4 mg/kg and about 6 mg/kg, about 0.8 mg/kg and about 1.8 mg/kg, about 0.8 mg/kg and about 2.7 mg/kg, or about 0.8 mg/kg and about 4 mg/kg;

(ii) between about 1.2 mg/kg and about 1.8 mg/kg, about 1.2 mg/kg and about 2.7 mg/kg, about 1.2 mg/kg and about 4 mg/kg, or about 1.2 mg/kg and about 6.3 mg/kg;

(iii) between about 1.8 mg/kg and about 2.7 mg/kg, about 1.8 mg/kg and about 4 mg/kg, or about 1.8 mg/kg and about 6 mg/kg;

(iv) between about 2.7 mg/kg and about 4 mg/kg, about 2.7 mg/kg and about 6 mg/kg; or

(v) between about 4 mg/kg and about 6 mg/kg.

In another embodiment, the bolus dose of hGH-XTEN is selected from the group consisting of about 0.8 mg/kg, about 1.0 mg/kg, about 1.2 mg/kg, about 1.4 mg/kg, about 1.6 mg/kg, about 1.8 mg/kg, about 2.0 mg/kg, about 2.2 mg/kg, about 2.4 mg/kg, about 2.6 mg/kg, about 2.7 mg/kg, about 2.8 mg/kg, about 3 mg/kg, about 3.2 mg/kg, about 3.4 mg/kg, about 3.6 mg/kg, about 3.8 mg/kg, about 4 mg/kg, about 4.2 mg/kg, about 4.4 mg/kg, about 4.6 mg/kg, about 4.8 mg/kg, about 5 mg/kg, about 5.2 mg/kg, about 5.4 mg/kg, about 5.6 mg/kg, about 5.8 mg/kg, about 6 mg/kg, and about 6.3 mg/kg.

In one embodiment, the method comprises administering to a human pediatric patient with PGHD at least two bolus doses of a human growth hormone hGH-XTEN fusion protein, wherein said administration is separated by: at least about 7 days, at least about 10 days, at least about 14 days, at least about 21 days, at least about 28 days, or at least about 30 days.

In one other embodiment, the bolus dose is a therapeutically effective bodyweight adjusted bolus dose (as described herein). In one other embodiment, the administering step comprises administering a pharmaceutical composition comprising an effective amount of hGH-XTEN fusion protein comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1). In another embodiment, the methods described herein comprise the use of a fusion protein having at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%,

or at least about 98%, or at least about 99% sequence identity to the sequence as set forth in FIG. 1 (SEQ ID NO:1).

In another embodiment, the administration of bolus doses is separated by: at least about a month, at least about 31 days, at least about 30 days, at least about 29 days, at least about 28 days, at least about 27 days, at least about 26 days, at least about 25 days, at least about 24 days, at least about 23 days, at least about 22 days, at least about 21 days, at least about 20 days, at least about 19 days, at least about 18 days, at least about 17 days, at least about 16 days, at least about 15 days, at least about 14 days, at least about 13 days, at least about 12 days, at least about 11 days, at least about 10 days, at least about 9 days, at least about 8 days, at least about 7 days, at least about 6 days, at least about 5 days, at least about 4 days, at least about 3 days, or at least about 2 days.

In another embodiment, the therapeutically effective bodyweight adjusted bolus doses of hGH-XTEN fusion protein are administered subcutaneously to the human pediatric patient.

In general, a “bolus dose” is a dose administered within a short period of time. In another embodiment, the bolus dose is administered within about 1 to about 30 minutes, about 1 to about 20 minutes, about 1 to about 15 minutes, about 1 to about 10 minutes, or about 1 to about 5 minutes. In one embodiment, the bolus dose is administered within about 1 to about 5 minutes. In one other embodiment, the bolus dose is a subcutaneous bolus dose.

In some embodiments, the present disclosure provides methods to establish a dose regimen for the hGH-XTEN pharmaceutical compositions described herein for human pediatric patients. The methods include administration of consecutive doses of a therapeutically effective amount of the hGH-XTEN composition using variable periods of time between doses to determine that interval of dosing sufficient to achieve and/or maintain the desired parameter, blood level or clinical effect; such consecutive doses of a therapeutically effective amount at the effective interval establishes the therapeutically effective dose regimen for the hGH-XTEN for a PGHD condition. Thus, in one aspect, the disclosure provides an hGH-XTEN composition for use in a treatment regimen that is therapeutically effective for human growth hormone deficiency (PGHD).

In another aspect, the present disclosure provides an hGH-XTEN fusion protein for use in a treatment regimen for human pediatric growth hormone deficiency (PGHD), which regimen comprises administering a hGH-XTEN fusion protein to a human pediatric patient. In one embodiment, the treatment regimen comprises administering a bolus dose (as described herein) of the hGH-XTEN fusion protein to the human pediatric patient at certain time intervals (as described herein). In one additional embodiment, the treatment regimen

comprises subcutaneous administration of the bolus dose of hGH-XTEN. In one embodiment, the regimen comprises administering at least two bolus doses (as described herein) of the hGH-XTEN fusion protein to a human pediatric patient separated by an appropriate time interval (as described herein).

5 In another embodiment, the present disclosure provides a consecutive dose regimen wherein each bolus dose of the hGH-XTEN is administered every week (or weekly), every two weeks, every three weeks, every four weeks, or monthly.

In one embodiment of the hGH-XTEN composition for use in a treatment regimen, the hGH-XTEN fusion protein comprises the amino acid sequence shown as set forth in FIG. 1 (SEQ ID NO:1). In one embodiment, the therapeutically effective dose treatment regimen comprises the administration of at least two therapeutically effective bodyweight adjusted bolus doses to a pediatric subject, wherein the doses are administered subcutaneously.

3. hGH-XTEN Equivalency to rhGH

In another aspect, the present invention provides methods of treating human growth hormone deficiency (PGHD) in pediatric patients with a therapeutically effective amount of an hGH-XTEN fusion protein as a bolus dose that is equivalent to, or equivalent to less than, an effective amount of a corresponding hGH (not linked to XTEN) administered daily. In one embodiment, the bolus dose of the fusion protein is equivalent to an amount that is less than between about 4.8 µg hGH/kg/day and about 37 µg hGH/kg/day; or less than or
20 equivalent to about 4.8 µg hGH/kg/day, about 7.4 µg hGH/kg/day, about 11.1 µg hGH/kg/day, about 16.7 µg hGH/kg/day, about 24.7 µg hGH/kg/day, or about 37 µg hGH/kg/day. The approximate mean pediatric rhGH daily dose is 40 µg hGH/kg/day to 43 µg hGH/kg/day. In another embodiment, the bolus dose is a therapeutically effective bodyweight adjusted bolus dose of the hGH-XTEN fusion protein.

25 In one aspect, the present disclosure provides methods of treating human pediatric growth hormone deficiency (PGHD), comprising administering to a human pediatric patient with PGHD an hGH-XTEN fusion protein at a dosage that is below or less than an equivalent daily dose of recombinant hGH (*e.g.*, a recommended daily dose of rhGH).

In another embodiment, the administration of said bolus doses is separated by at least
30 about 7 days, at least about 10 days, at least about 14 days, at least about 21 days, at least about 28 days, at least about 30 days, or at least about a month.

In one embodiment, the bolus dose of the hGH-XTEN is equivalent to an hGH/kg/day dosage that is less than about 43 µg hGH/kg/day. In another embodiment, the bolus dose of the hGH-XTEN is equivalent to an hGH/kg/day dosage that is less than about 40 µg

hGH/kg/day. In another embodiment, the dosage of the hGH-XTEN is equivalent to less than about 39 µg hGH/kg/day, about 38 µg hGH/kg/day, about 36 µg hGH/kg/day, about 34 µg hGH/kg/day, about 32 µg hGH/kg/day, about 30 µg hGH/kg/day, about 28 µg hGH/kg/day, about 26 µg hGH/kg/day, about 25 µg hGH/kg/day, about 24 µg hGH/kg/day, about 22 µg hGH/kg/day, about 20 µg hGH/kg/day, about 18 µg hGH/kg/day, about 17 µg hGH/kg/day, about 16 µg hGH/kg/day, about 14 µg hGH/kg/day, about 12 µg hGH/kg/day, about 11 µg hGH/kg/day, about 8 µg hGH/kg/day, about 7 µg hGH/kg/day, about 6 µg hGH/kg/day, about 5 µg hGH/kg/day, about 4 µg hGH/kg/day, or about 2 µg hGH/kg/day.

In one other embodiment, the bolus dose of the hGH-XTEN is the same or less than the cumulative equivalent hGH/kg/day dosages administered over about 7 days, about 14 days, about 21 days, about 28 days, or about 30 days.

In yet another embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence shown as set forth in FIG. 1 (SEQ ID NO:1). In other embodiments, the administration is subcutaneous administration.

In one aspect, the bolus dose of the hGH-XTEN may be administered over a range of doses that are equivalent to less than an hGH/kg/day dosage. It should be noted that where reference is made to a bolus dose that is equivalent to less than an hGH/kg/day dosage that is between about a first µg hGH/kg/day and about a second µg hGH/kg/day, the “first µg hGH/kg/day” term may include the first µg hGH/kg/day value and the “second µg hGH/kg/day” term may include the second µg hGH/kg/day value.

4. hGH-XTEN and IGF-I Levels

The methods of the present disclosure are advantageous with respect to resulting IGF-I levels in the human pediatric patient following treatment with hGH-XTEN fusion protein. A high level of blood IGF-I is undesirable since high IGF-I is believed to be a risk factor for cancer (Svensson *et al.* J Clin Endocrin Metab. epub September 26, 2012 as doi:10.1210/jc.2012-2329). IGF-I generation in humans is largely the result of GH signaling and IGF-I is an important mediator for anabolic actions observed during GH therapy (Le Roith *et al.* (2001). Endocr Rev 22, 53-74). Accordingly, IGF-I is an important pharmacodynamic marker for hGH-XTEN fusion protein bioactivity. In practice, IGF-I responses to GH (*e.g.*, daily rhGH therapy) are interpreted in terms of age- and gender-specific normative data (Vance *et al.* (1999). N Engl J Med 341, 1206-16; Molitch *et al.* (2011). J Clin Endocrinol Metab 96, 1587-609). The interpretation is most readily done with the use of IGF-I standard deviation scores (IGF-I SDS). Further, pediatric patients with GH deficiency, as with healthy individuals, have a range of baseline IGF-I values in their blood

or serum. Because pediatric IGF-I levels vary by age and sex, each patient must be characterized by their individual age and sex-adjusted IGF-I SDS. Accordingly, IGF-I SDS, corrected for baseline at time 0, can be used to examine potential hGH-XTEN fusion protein dose effects on IGF-I responses.

5 In one aspect, the present disclosure provides methods of treatment of PGHD in which the human pediatric patient maintains an IGF-I response (e.g., as measured by mean IGF-I SDS) in a normal range after administration of the hGH-XTEN fusion protein. For an IGF-I SDS, a normal range is generally between about -1.5 and about 1.5 but can also be between about -2.0 and about 2.0.

10 It should be noted that where reference is made to an IGF-I SDS between about a first value (e.g., -2.0) and about a second value (e.g., 2.0), the “first value” may include the first value and the “second value” may include the second value.

In one embodiment, the present disclosure provides a method of treating pediatric growth hormone deficiency (PGHD) in a human pediatric patient by administering an hGH-XTEN fusion protein to the patient, wherein the human patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration. In one
15 embodiment, the method comprises administering the hGH-XTEN fusion protein to the pediatric patient as a bolus dose (as described herein). In another embodiment, the bolus dose is a therapeutically effective bodyweight adjusted bolus dose. In other embodiments, the pediatric patient has a serum IGF-I SDS of greater than about -2.0, greater than about -
20 1.5, greater than about -1.0, greater than about -0.5, or greater than about 0, greater than about 0.5, greater than about 1.0, greater than about 1.5, greater than about 1.6, greater than about 1.7, greater than about 1.8, or greater than about 1.9 following administration of the hGH-XTEN.

25 In another embodiment, the bolus dose of the hGH-XTEN is effective to maintain the pediatric patient’s serum IGF-I standard deviation score (SDS) (a) between about -2.0 and about 2.0, or (b) between about 0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at
30 least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days following administration of the bolus dose.

In another embodiment, administration of multiple consecutive hGH-XTEN bolus doses is effective to maintain the pediatric patient's serum IGF-I standard deviation score (SDS) (a) between about -2.0 and about 2.0, or (b) between about 0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days between administrations of the bolus doses. In the foregoing embodiment, the bolus doses are administered weekly, every two weeks, every three weeks, or monthly.

In another embodiment, administration of multiple consecutive hGH-XTEN bolus doses is effective to maintain the pediatric patient's mean serum IGF-I standard deviation score (SDS) (a) between about -2.0 and about 2.0, or (b) between about -1.0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days between administrations of the bolus doses. In the foregoing embodiment, the bolus doses are administered weekly, every two weeks, every three weeks, or monthly.

In another embodiment, administration of multiple consecutive hGH-XTEN bolus doses is effective to maintain the pediatric patient's serum IGF-I standard deviation score (SDS) (a) above about -2.0, or (b) above about 0, or (c) above about 1.0, or (d) above about 1.5 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days between administrations of the bolus doses. In the foregoing embodiment, the bolus doses are administered weekly, every two weeks, every three weeks, or monthly.

In another embodiment, administration of multiple consecutive hGH-XTEN bolus doses is effective to maintain the pediatric patient's serum IGF-I standard deviation score (SDS) (a) below about 1.5, or (b) below about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days between administrations of the bolus doses. In the foregoing embodiment, the bolus doses are administered weekly, every two weeks, every three weeks, or monthly.

In another embodiment, administration of multiple consecutive hGH-XTEN bolus doses is effective to maintain the pediatric patient's change in mean maximum serum IGF-I standard deviation score (SDS) compared to baseline SDS (a) between about 0.5 and 3.0, or (b) between about 1.0 and 2.5 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, or at least about 30 days between administrations of the bolus doses. In the foregoing embodiment, the bolus doses are administered weekly, every two weeks, every three weeks, or monthly.

In another embodiment, the administering step comprises administering a pharmaceutical composition comprising an effective amount of hGH-XTEN fusion protein comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).

In one other aspect, the present disclosure provides methods of treating pediatric patients by administering an hGH-XTEN fusion protein to provide a normal serum IGF-I level in the pediatric patient. In one embodiment, the hGH-XTEN fusion protein is administered as a bolus dose (as described herein). In another embodiment, at least two bolus doses are administered separated by a time interval (as described herein). In one other embodiment, the bolus dose(s) is a therapeutically effective bodyweight adjusted bolus dose of the fusion protein. In an additional other embodiment, the administration of said bolus dose(s) of the hGH-XTEN results in a normalization of serum IGF-I levels in the a pediatric

subject for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about a month following administration of the bolus dose. In one other embodiment, a normal serum IGF-I level is characterized by a serum IGF-I standard deviation (SD) that is above about -2.0; above about -1.5; above about -1.0; above about 0; above about 0.5; above about 1.0; or above about 1.5. In another embodiment, a normal serum IGF-I level is characterized by a serum IGF-I standard deviation (SD) that is between about -1.5 and about 1.5; between about -1.5 and about 1.0; between about -1.5 and about 0.5; between about -1.5 and about 0; between about -1.5 and about -0.5; and between about -1.5 and about -1.0.

In an additional embodiment, the extent of normalization of IGF-I serum levels is dependent on the dose of the therapeutically effective bodyweight adjusted bolus dose of hGH fusion protein. In one other embodiment, the duration of the IGF-I normalization increases with the therapeutically effective bodyweight adjusted bolus dose of hGH fusion protein.

In some embodiments, methods of the present disclosure provide a particular advantage in that the administration of hGH-XTEN fusion protein provides an observable and prolonged IGF-I response in the human pediatric patient (*e.g.*, as measured by IGF-I SDS) that is not accompanied by, or at the expense of, over-exposure to high levels of IGF-I, which is undesirable. In other words, the IGF-I response is maintained at an elevated level that is still considered acceptable by current standards, *e.g.*, as indicated by an IGF-I SDS of 1.5 or less, or an IGF-I SDS of 2.0 or less.

5. Plasma concentration of hGH-XTEN fusion protein

In another aspect, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient by administering an hGH-XTEN fusion protein to the patient, wherein the patient has a plasma concentration of said fusion protein of at least about 10 ng/mL following administration. In one embodiment, the method comprises administering the hGH-XTEN fusion protein to the pediatric patient as a bolus dose (as described herein). In another embodiment, the bolus dose of the hGH-XTEN is a therapeutically effective bodyweight adjusted bolus dose (as

described herein). In one embodiment, the bolus dose is selected from the group consisting of about 0.8 mg/kg, about 1.0 mg/kg, about 1.2 mg/kg, about 1.4 mg/kg, about 1.6 mg/kg, about 1.8 mg/kg, about 2.0 mg/kg, about 2.2 mg/kg, about 2.4 mg/kg, about 2.6 mg/kg, about 2.7 mg/kg, about 2.8 mg/kg, about 3 mg/kg, about 3.2 mg/kg, about 3.4 mg/kg, about 3.6 mg/kg, about 3.8 mg/kg, about 4.0 mg/kg, about 4.2 mg/kg, about 4.4 mg/kg, about 4.6 mg/kg, about 4.8 mg/kg, about 5.0 mg/kg, about 5.2 mg/kg, about 5.4 mg/kg, about 5.6 mg/kg, about 5.8 mg/kg, about 6.0 mg/kg, and about 6.3 mg/kg. In another embodiment, the bolus dose of the hGH-XTEN is effective to maintain a plasma concentration of the fusion protein of at least about 10 ng/mL for: at least about 5 days, at least about 7 days, at least about 10 days, at least about 14 days, at least about 20 days, at least about 25 days, at least about 30 days, or at least about a month. In another embodiment, the bolus dose is effective to maintain a plasma concentration of the fusion protein of at least about 100 ng/mL for: at least about 5 days, at least about 7 days, at least about 10 days, at least about 14 days, or at least about 20 days. In one other embodiment, the administering step comprises administering a pharmaceutical composition comprising an effective amount of hGH-XTEN fusion protein comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).

6. Absence of Side Effects

In one embodiment, the present disclosure provides a method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient comprising administering to the patient an hGH-XTEN fusion protein in the absence of one or more side effects. In one other embodiment, the absence of one or more side effects is the absence of a clinically significant level of one or more side effects. In another embodiment, the one or more side effects that are absent are selected from the group consisting of headache, arthralgia, myalgia, edema, nausea, and muscle fatigue after administration of the fusion protein. As used herein, "clinically significant level of a side-effect" means that the side-effect(s) is/are not unexpected or is/are not serious adverse event(s). Side-effects that are mild and transient, even if one of headache, arthralgia, myalgia, edema, nausea, and muscle fatigue or those otherwise known to be associated with the administration of growth hormone, would not be considered a clinically significant level. In one embodiment, the method comprises administering the hGH-XTEN fusion protein to the pediatric patient as a bolus dose (as described herein). In another embodiment, the bolus dose of the hGH-XTEN fusion protein is a therapeutically effective bodyweight adjusted bolus dose (as described herein). In one other embodiment, the bolus dose is administered subcutaneously. In one other embodiment, the administering step comprises administering a pharmaceutical

composition comprising an effective amount of hGH-XTEN fusion protein comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).

7. Parameters following Administration

In one embodiment, the present disclosure provides a method for achieving a beneficial effect in a human pediatric patient with growth hormone deficiency, comprising the step of administering to the pediatric patient a therapeutically-effective amount of a hGH-XTEN fusion protein wherein said administration results in the improvement of one or more biochemical or physiological parameters or clinical endpoints associated with a growth hormone-related disease, disorder or condition, including a PGHD (as described herein). The effective amount produces a beneficial effect in helping to treat (e.g., cure or reduce the severity) the deleterious effects of a growth hormone-related disease, disorder or condition. In some cases, the method for achieving a beneficial effect includes administering a therapeutically effective amount of a hGH-XTEN fusion protein composition to treat a pediatric patient with a growth hormone-related disease, disorder, or condition, including a PGHD (as described herein).

In some embodiments, methods described herein include the administration to a human pediatric patient successive or consecutive doses of a therapeutically effective amount of the hGH-XTEN for a period of time sufficient to achieve and/or maintain the desired parameter or clinical effect, and such consecutive doses of a therapeutically effective amount establishes the therapeutically effective dose regimen for the hGH-XTEN; i.e., the schedule for consecutively administered doses of the fusion protein composition, wherein the doses are given in therapeutically effective amounts to result in a sustained beneficial effect on any clinical sign or symptom, aspect, measured parameter or characteristic of a metabolic disease state or condition, including, but not limited to, those described herein. In one embodiment of the method, the parameters include but are not limited to mean (SD) height standard deviation score (HT-SDS), changes in height velocity, IGF-I concentration, ratio of IGF-I/IGFBP-3, IGFBP3 concentration, change in weight, lean body mass, change in body mass index, total body fat (adipose fat/tissue), trunk fat, response to insulin challenge, rate of division of chondrocytes, chondrocyte numbers, bone density, bone age, bone growth, bone turnover, increase in epiphyseal plate width, reduction in cholesterol, reduction in triglycerides, and reduction in LDL. In another embodiment of the method, the administration to a human pediatric patient of successive or consecutive doses of a therapeutically effective amount of the hGH-XTEN results in a beneficial effect in two or more of the parameters including, but not limited to mean (SD) height standard deviation

score (HT-SDS), changes in height velocity, IGF-I concentration, ratio of IGF-I/IGFBP-3, IGFBP3 concentration, change in weight, lean body mass, change in body mass index, total body fat (adipose fat/tissue), trunk fat, response to insulin challenge, rate of division of chondrocytes, chondrocyte numbers, bone density, bone age, bone growth, bone turnover, increase in epiphyseal plate width, reduction in cholesterol, reduction in triglycerides, and reduction in LDL.

Height velocity data in pediatric patients treated with recombinant human growth hormone (rhGH) has been compiled into various databases. The National Cooperative Growth Study (NCGS) database contains 220,000 patient-years of growth data on children receiving rhGH therapy. The NCGS database was initiated in December 1985 to collect data in children treated with rhGH for evaluation of safety and efficacy. Anonymous data were entered by clinical investigators in the US including date of birth, sex, height, weight, etiology of short stature, peak serum GH response to stimulation testing, Tanner pubertal stages, parental heights, and GH dose for patients treated with Genentech's rhGH products (Shulman, DI, et al. *Int J Pediatr Endocrinol.* 2013; 2013(1): 2). It has been shown that height velocity observed during the first year of treatment ("first year height velocity") with GH is the major determinant of the second pre-pubertal year growth response to GH in small for gestational age (SGA) children (Ranke MB, et al. *J Clin Endocrinol Metab.* 2003;88:125–131). The first year height velocity can be measured in the pediatric patient over a period of 3 months, 4 months, 6 months, or other period up to 12 months to ascertain the annualized first year height velocity, expressed as "cm/yr".

In other embodiments of the method for achieving a beneficial effect in a human pediatric patient with growth hormone deficiency, the methods comprise the step of administering to the pediatric patient a therapeutically-effective amount of a hGH-XTEN fusion protein wherein said administration results in the improvement in height velocity rate in the pediatric patient. In one embodiment of the method, the method is effective to achieve a height velocity equivalent to 7 cm/yr to 12 cm/yr in a pediatric patient. In another embodiment of the method, the method is effective to achieve a height velocity equivalent to 8 cm/yr to 11 cm/yr in a pediatric patient. In one embodiment, the height velocity is achieved (or determined) after at least about 3 months, or at least about 6 months, or at least about 12 months of dosing in the pediatric patient. In another embodiment, the height velocity achieved is a first year height velocity. In another embodiment, the method is not inferior to the height velocity achieved with daily injections of hGH not linked to XTEN over the same period and administered using comparable equivalent doses on a molar basis. In another

embodiment, the method is effective to maintain the pediatric patient's annualized height velocity after at least 3 months of dosing within 10%, 20%, or 30% of that compared to the height velocity achieved with daily injections of an hGH not linked to XTEN of an equivalent amount, on a molar basis, over the same period. In one embodiment of the foregoing, the pediatric patients administered daily injections of hGH not linked to XTEN receive a dose of at least about 25, at least about 30, at least about 33, at least about 35 μg rhGH/kg/day, at least at least about 37 μg rhGH/kg/day, or at least about 43 μg rhGH/kg/day. In the foregoing embodiments of this paragraph, the bolus dose of the hGH-XTEN fusion protein is a therapeutically effective bodyweight adjusted bolus dose comprising between about 0.8 mg/kg and about 6.3 mg/kg of hGH-XTEN fusion protein. In another embodiment, the bolus dose of the hGH-XTEN fusion protein is a therapeutically effective bodyweight adjusted bolus dose comprising between about 0.8 mg/kg and about 7.0 mg/kg of hGH-XTEN fusion protein. In another embodiment, the bolus doses are administered every week, every two weeks, every three weeks, semimonthly or monthly. In another embodiment, the pediatric patients are administered bolus doses of about 1.15 mg/kg of hGH-XTEN fusion protein weekly, or about 2.5 mg/kg of hGH-XTEN fusion protein every two weeks, or about 5.0 mg/kg of hGH-XTEN fusion protein monthly. In another embodiment, the pediatric patients are administered bolus doses selected from about 0.8 mg/kg to about 1.5 mg/kg, about 1.8 mg/kg to about 3.2 mg/kg, or about 3.5 mg/kg to about 6.3 mg/kg. In a preferred embodiment, the pediatric patients are administered bolus doses of at least about 5.0 mg/kg of hGH-XTEN fusion protein monthly.

In another embodiment of the regimen, the human pediatric patient achieves an improvement after two or more bolus doses in at least one parameter selected from bone density, bone growth, and increase in epiphyseal plate width. In one other embodiment, the foregoing improvement(s) is at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% compared to a human pediatric patient not receiving human growth hormone. In another embodiment, the foregoing percentage improvement(s) is similar to, or not inferior to, an improvement achieved by an hGH not linked to XTEN and administered daily using daily dosage equivalent amounts of hGH.

8. hGH-XTEN Medicaments

In another embodiment, the present disclosure provides an hGH-XTEN fusion protein for use as a medicament, or for the treatment of PGHD in pediatric patients. In another embodiment, the present invention provides the use of an hGH-XTEN fusion protein for the

manufacture of a medicament for treating PGHD in a human pediatric patient with PGHD. In one other embodiment, the present invention provides the use of the fusion protein having the sequence set forth in FIG. 1 (SEQ ID NO:1) in the manufacture of a medicament for the treatment of PGHD in pediatric patients. In other embodiments, the hGH-XTEN fusion protein is provided as a bolus dose (as described herein). In another embodiment, the bolus dose is a therapeutically effective bodyweight adjusted dose. In another embodiment, the medicament is formulated for subcutaneous administration. In one other embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence shown as set forth in FIG. 1 (SEQ ID NO:1).

9. Treatment of Indicia of pediatric GH-related conditions

In another aspect, the present invention provides hGH-XTEN fusion protein-based therapeutic agents for treating diseases or conditions related to pediatric growth hormone deficiency (PGHD) in a pediatric patient. For the prevention, treatment or reduction in the severity of a given disease or condition, the appropriate dosage of a therapeutic agent of the invention will depend on the type of disease or condition to be treated, as defined above, the severity and course of the disease or condition, whether the agent is administered for therapeutic purposes, previous therapy, the pediatric patient's clinical history and response to the agent, and the discretion of the attending physician.

In another aspect, the present disclosure provides a method for the delaying or slowing down of the progression of a disease or condition related to PGHD in a pediatric patient. In one embodiment, the method comprises administering to pediatric subject diagnosed with the disease, condition, or disorder, an effective amount of an hGH-XTEN fusion protein. In another aspect, the present disclosure provides a method for treating or ameliorating indicia of a disease or condition related to PGHD. In one embodiment, the method comprises administering an effective amount of an hGH-XTEN fusion protein to a pediatric subject at risk of the disease or condition, wherein the hGH-XTEN fusion protein is effective against the development of indicia of the disease or condition.

In one additional aspect, the hGH-XTEN fusion proteins provide an ameliorative effect against the development of, or the progression of, clinical and/or histological and/or biochemical and/or pathological indicia (including both symptoms and signs) of diseases or conditions related to PGHD in a human pediatric patient. In one embodiment, the disease or condition is PGHD. In one embodiment, the indicia in pediatric patients include small stature, an increased level of body fat (especially central or trunk adiposity, *i.e.*, the waist), slow rate of growth of all body parts, leveling off or falling away from an established growth

curve for height, delayed bone age, decreased IGF-I SDS, and below average height SDS. In another embodiment, the pediatric subject is at risk for a disease or condition related to PGHD. In general, a pediatric subject at risk will previously have incurred some damage to the pituitary gland and/or the hypothalamus. In one embodiment, the pediatric subject at risk was previously diagnosed as having a tumor associated with the pituitary gland, and/or underwent surgery, chemotherapy, or radiation therapy to treat the tumor. In another embodiment, the pediatric subject at risk previously had or presently has a reduced blood supply to the pituitary gland. In one other embodiment, the pediatric subject at risk previously suffered cranial ablation or has a history of head trauma. In some embodiments, the pediatric subject at risk previously or presently suffers from a hypothalamic-pituitary disease or disorder.

The efficacy of the treatment of diseases and conditions described herein (including PGHD) can be measured by various assessments commonly used in evaluating PGHD in pediatric patients. For example, the health of hormone-secreting glands can be evaluated by, but not limited to, *e.g.*, IGF-I standard deviation score (SDS), mean (SD) height standard deviation score (HT-SDS), growth hormone stimulation test (GHST), growth hormone releasing hormone (GHRH), stimulation tests, monitoring or measurement of endogenous hHG pulses, IGF-I levels, IGF-I binding protein levels, other blood or biochemical tests (*e.g.*, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and lipids).

In one additional aspect, the present disclosure provides methods of increasing the efficacy of human growth hormone (hGH) therapy in a human pediatric patient. In another aspect, the present disclosure provides methods of determining a subsequent dose of an hGH-XTEN fusion protein administered over a subsequent dosage period when treating a human pediatric patient with PGHD with the hGH-XTEN fusion protein. The “dosage period” means the time between the administration of a bolus dose (*e.g.*, initial dose) and the next successive administration of a bolus dose (*e.g.*, subsequent dose). The dosage period may change with one or more further successive dose or doses, or may remain constant.

In one embodiment, the foregoing methods of increasing efficacy comprise the step of monitoring the IGF-I standard deviation score (SDS) in a plasma or serum sample obtained from the pediatric patient during an initial dosage period of administration of an initial dose of human growth hormone-XTEN (hGH-XTEN) fusion protein. In one embodiment, the hGH-XTEN fusion protein comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1. In another embodiment, the method further comprises

the step of determining a subsequent dose of hGH-XTEN fusion protein administered over a subsequent dosage period based on the IGF-I SDS observed during the initial dosage period. In one additional embodiment, the method further comprises administering the subsequent dose over a subsequent dosage period. In one other embodiment, the subsequent dose improves the efficacy of the treatment during the subsequent dosage period. In another embodiment, the subsequent dose is higher, lower, or equivalent to the initial dose. The initial dose or subsequent dose may be any of the bolus doses described herein. In one additional embodiment, the subsequent dosage period is longer, shorter, or equivalent to the initial dosage period. The initial dosage period or subsequent dosage period may be any of the periods of time described herein (e.g., weekly, every two weeks, semimonthly, every three weeks, monthly, etc., or every 7 days, every 10 days, every 14 days, every 21 days, every 30 days, etc.).

VII. DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS

In another aspect, the present disclosure provides bolus doses or dosage forms comprising an hGH-XTEN fusion protein described herein.

In one embodiment, the bolus dose or dosage of an hGH-XTEN fusion protein comprises a therapeutically effective bodyweight adjusted bolus dose for a human pediatric patient. In one other embodiment, the bolus dose or dosage comprises between about 0.8 mg/kg and about 6.3 mg/kg of hGH-XTEN fusion protein. Other bolus doses are described herein.

In other embodiments, the bolus dose or dosage is (i) for use in treating human PGHD in a pediatric subject in need; and/or (ii) formulated for subcutaneous administration. In one other embodiment, the hGH-XTEN fusion protein comprises the amino acid sequence shown as set forth in FIG. 1 (SEQ ID NO:1). In one embodiment, the bolus dose or dosage form is a pharmaceutical composition comprising the fusion protein having the sequence as set forth in FIG. 1 (SEQ ID NO:1) and a pharmaceutically acceptable carrier.

In another embodiment, the present disclosure provides kits, comprising packaging material and at least a first container comprising the pharmaceutical composition of the foregoing embodiment and a label identifying the pharmaceutical composition and storage and handling conditions, and a sheet of instructions for the preparation and/or administration of the pharmaceutical compositions to a pediatric subject.

In one additional aspect, the present disclosure provides compositions, pharmaceutical compositions, and dose amounts of an hGH-XTEN fusion protein. In one other embodiment, the pharmaceutical composition or dose amount comprises a fusion protein having the

sequence as set forth in FIG. 1 (SEQ ID NO:1), or a sequence having at least about 90%, at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99%, sequence identity to the sequence of SEQ ID NO:1. In another embodiment, the dose amount is for a human pediatric patient based upon the weight of the patient. The weight of the pediatric human patient can range from about 10 kg to about 50 kg. In one additional embodiment, the hGH-XTEN fusion protein is provided in the pharmaceutical composition, composition, or dose amount as a certain quantity. In one other embodiment, the pharmaceutical composition or dose amount further comprises a pharmaceutically acceptable carrier.

In one embodiment, the pharmaceutical composition is administered at a therapeutically effective dose. In another embodiment, the pharmaceutical composition is administered using multiple consecutive doses using a therapeutically effective dose regimen (as defined herein) for the length of the dosing period.

A therapeutically effective amount of the hGH-XTEN varies according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the fusion protein to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the hGH-XTEN are outweighed by the therapeutically beneficial effects.

It should be noted that where reference is made to a composition, pharmaceutical composition or dose amount comprising an amount of hGH-XTEN fusion protein between about a first mg and about a second mg, the “first mg” term may include the first mg value and the “second mg” term may include the second mg value.

In another aspect, the present disclosure provides hGH-XTEN fusion proteins for use in a pharmaceutical regimen or therapeutically effective dose regimen for the treatment of PGHD. In one embodiment, the hGH-XTEN fusion protein is for use in a regimen comprising a bolus dose of the fusion protein to treat a pediatric patient. In an additional embodiment, the regimen comprises the step of determining the amount of the hGH-XTEN fusion protein needed to achieve an IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 in the pediatric patient.

In one other embodiment, the regimen comprises a therapeutically effective bodyweight adjusted bolus dose. In another embodiment, the regimen comprises a bolus dose of the fusion protein that is between about 0.8 mg/kg and about 6.3 mg/kg. In one other embodiment, the regimen comprises the administration of consecutive bolus doses of fusion

protein. In one embodiment, the administration of consecutive bolus doses is about every week, about every two weeks, about every three weeks, or about every month. In one additional embodiment, the fusion protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1. In one embodiment, the regimen comprises subcutaneous administration of the bolus dose of the fusion protein. In another embodiment, the regimen is effective to treat PGHD in a pediatric patient.

VIII). ARTICLES OF MANUFACTURE

In one aspect, the present disclosure also provides kits and articles of manufacture containing materials useful for the treatment, prevention and/or diagnosis of disease (*e.g.*, PGHD) in pediatric patients. In another embodiment, the invention provides kits, comprising packaging material and at least a first container comprising a dosage form or pharmaceutical composition of the foregoing embodiment and a label identifying the dosage form or pharmaceutical composition and storage and handling conditions, and a sheet of instructions for the reconstitution and/or administration of the dosage form or pharmaceutical compositions to a pediatric subject. In one other embodiment, the kit includes a container and a label, which can be located on the container or associated with the container. The container may be a bottle, vial, syringe, cartridge (including autoinjector cartridges), or any other suitable container, and may be formed from various materials, such as glass or plastic. The container holds a composition having an hGH-XTEN fusion protein as described herein, and may have a sterile access port. Examples of containers include a vial with a stopper that can be pierced by a hypodermic injection needle. The kits may have additional containers that hold various reagents, *e.g.*, diluents, preservatives, and buffers. The label may provide a description of the composition as well as instructions for the intended use in pediatric patients.

In one other aspect, the container is a pre-filled syringe. In one embodiment, the syringe is pre-filled with a composition having an hGH-XTEN fusion protein as described herein. In one additional aspect, the present invention provides containers of the composition having a hGH-XTEN fusion protein as described herein, wherein the container is suitable for autoinjection of the composition. In one embodiment, the container is a cartridge. In another embodiment, the container is a cartridge in an autoinjection pen. Those of ordinary skill in the art will appreciate that other suitable autoinjection devices may be used for the present invention. In some embodiments, the autoinjection device comprises a spring-loaded syringe within a cylindrical housing that shields the needle tip prior to injection. In one embodiment,

the pediatric patient depresses a button on the device and the syringe needle is automatically inserted to deliver the contents.

In another embodiment, the device is a gas jet autoinjection device. In other embodiments, the gas jet device comprises a cylinder of pressurized gas but the needle is absent. Upon activation, the device propels a fine jet of liquid through the skin without the use of a needle. In one other embodiment, the device is an iontophoresis device or electromotive drug administration (EMDA) device (e.g., use of a small electric charge to deliver an agent through the skin without the use of a needle).

The kit has at least one container that includes a composition comprising an hGH-XTEN fusion protein described herein as the active agent. The container may comprise an hGH-XTEN fusion protein dosage form or a pharmaceutical composition. A label may be provided indicating that the dosage form or composition may be used to treat a disease in a pediatric patient. The label may also provide instructions for administration to a pediatric subject in need of treatment. The kit may further contain an additional container having a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. Finally, the kit may also contain any other suitable materials, including other buffers, diluents, filters, needles, and syringes.

In one aspect, the present disclosure provides a kit comprising a container which holds a pharmaceutical composition for administration to a human pediatric patient comprising a human growth hormone-XTEN (hGH-XTEN) fusion protein. In one embodiment, the hGH-XTEN fusion protein comprises an amino acid sequence having at least about 90% sequence identity to the sequence set forth in FIG. 1 (SEQ ID NO:1). In another embodiment, the kit further comprises a package insert associated with said container. In one other embodiment, the package insert indicates that said composition is for the treatment of growth hormone deficiency by administration of more than one dose of the composition. In one embodiment, the administration is an administration of an initial dose of between about 0.8 mg/kg and about 6.3 mg/kg of the hGH-XTEN and a plurality of subsequent doses of the hGH-XTEN in an amount of between about 0.8 mg/kg and about 6.3 mg/kg. In another embodiment, the doses are separated in time from each other by at least about 7 days. The package insert may further indicate different doses, dose ranges, and times between doses as described herein.

The following are examples of methods, treatment regimens, and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

EXAMPLES

5 **Phase 1b/2a Studies**

In a Phase 1b Study in pre-pubertal moderate GHD children, VRS-317 concentrations, IGF-I and IGFBP-3 responses were proportional to dose, with drug concentrations and increases in IGF-I and IGFBP-3 still present 30 days after a single subcutaneous injection at different concentrations (from about 0.80 to about 6.0 mg/kg) equivalent to about 4.8 to about 37 μ g rhGH/kg/day taken for 30 days. VRS-317 dosing did not come at the expense of overexposure to IGF-I. Only 2 patients at the 3.5 mg/kg semi-monthly dose had transient IGF-I SDS values above 2.0 and none above 3.0. In sum, single dose VRS-317 administration was found to be safe and well tolerated, with minimal injection site discomfort.

15 In a Phase 2a Study in pre-pubertal moderate GHD children, repeat dosing with VRS-317 was found to be safe and well tolerated. IGF-I increases over baseline were maintained without IGF-I overexposure when a total monthly dose of 5.0 mg/kg VRS-317 was given at weekly, semi-monthly, or monthly intervals. The mean annualized 6 month height velocities (a.k.a., growth velocities) from GHD children in the Phase 2a were found to be comparable to the historical age-matched controls administered at a comparable dose of daily rhGH (33 μ g rhGH/kg/day). Overall, data from the Phase 2a clinical trial of GHD children indicate that over a 6 month treatment period, VRS-317 has a comparable safety and efficacy profile to historical studies of daily rhGH administered at comparable doses.

Extension Study

25 An Extension Study was conducted to investigate the long term safety of extended treatment with somavaratan (VRS-317). Data is initially reported for an additional 6 months beyond the initial 6 month Phase 2a treatment window. Data is also reported from patients who had received an additional total of 12 months beyond the initial 6 month treatment period.

30 **Treatment with VRS-317 for 6-12 months**

Methods

An analysis of repeat dosing of VRS-317 was conducted to determine the safety, tolerability, and height velocity responses after 12 months of VRS-317 treatment. Patients

initially were selected for treatment with VRS-317 and monitored in a Phase 2a Study generally as described in WO/2014/164568 (U.S. Patent Application No. 14/771,445). Moderate GHD patients receiving VRS-317 at 5.0 mg/kg monthly, 2.5 mg/kg semi-monthly, or 1.15 mg/kg weekly in the Phase 2a Study (FIG. 2) were enrolled in an Extension Study for an additional 6 months of treatment (FIG. 3). Approximately 95% of patients from the Phase 2a Study elected to continue treatment and enroll in the Extension Study.

A PK/PD model for VRS-317 was built on results from the Phase 1b Study (FIG. 4) indicating that a change in VRS-317 treatment from 2.5 mg/kg semi-monthly to 3.5 mg/kg semi-monthly would increase average IGF-I SDS by nearly a full SD, bringing this measurement into the upper half of the normal range (FIG. 5 and FIG. 6). Daily growth hormone therapy dosed at 40 µg/kg/day in similar moderate GHD patients caused a comparable IGF-I response in a controlled U.S. study (FIG. 7). Therefore, patients dosed at 1.15 mg/kg weekly in the Phase 2a Study were switched on their next visit in the Extension Study to 3.5 mg/kg semi-monthly. The 3.5 mg/kg semi-monthly dose was selected based upon confirmation of the PK/PD model from the Phase 1b Study. Of these patients switched to 3.5 mg/kg semi-monthly, 5 switched on the day 1 visit of the Extension Study and 15 switched on the month 3 visit of the Extension Study. Throughout the 6 months in the Extension Study, dose administration was performed at home by the parent or caregiver with nearly complete compliance with the schedule of dosing (monthly or semi-monthly).

Results

The safety profile of VRS-317 in all patients over 12 months of continuous VRS-317 therapy was comparable to daily growth hormone therapy (FIG. 3). There were no unexpected or serious adverse events and the few events noted were mild and transient. The number of adverse events declined in the second 6 months of therapy and only a minority of patients reported any adverse events. There were no new adverse events or increases in adverse events for patients switching to the 3.5 mg/kg VRS-317 semi-monthly dose. There were only minimal transient excursions of IGF-I SDS above 2 and no excursions above 3.

As part of the Extension Study, the dosing for a subset of the patient population was increased such that 20 patients on the 1.15 mg/kg weekly dose in Phase 2a were switched to 3.5 mg/kg semi-monthly, the same dose that will also be used in the upcoming global Phase 3 trial. This dose change caused IGF-I levels to increase into the upper part of the therapeutic range moving the IGF-I SDS from -0.4 for the 2.5 mg/kg semi-monthly dose to +0.5 for the 3.5 mg/kg semi-monthly dose (FIG. 6). As seen in FIG. 9, this subset of patients (treated with 1.15 mg/kg weekly for 6 months and then switched to 3.5 mg/kg semi-monthly for 6

months) had a change in mean annualized height velocity from 7.5 cm/yr to 9.3 cm/yr, nearly a 2 cm/yr increase in height velocity. Typically, a decrease in height velocity in the second 6 months of treatment would have been expected as observed for daily rhGH therapy (FIG. 10).

The height velocities measured after 12 months of continuous VRS-317 therapy for the patients who remained on 5 mg/kg monthly and 2.5 mg/kg semi-monthly doses in the Extension Study were not significantly different from those observed in the same patients at 3, 6, and 9 months (FIG. 10). In particular, as shown in FIG. 10, the height velocity for patients completing 12 months of treatment at 2.5 mg/kg semi-monthly was 8.5 cm/yr, which is consistent with the first year growth rate for moderate GHD patients receiving the highest labeled dose of Genotropin[®] or Norditropin[®].

Conclusions

VRS-317 was safe, well tolerated, and effective after 12 months of treatment in pre-pubertal children with GHD. All regimens provided comparable IGF-I responses with minimal excursions ($>$ IGF-I SDS of 2). A PK/PD model confirmed the predicted change in average IGF-I SDS over dosing interval depending upon VRS-317 dose. Adjusting VRS-317 dose from 2.5 mg/kg semi-monthly to 3.5 mg/kg semi-monthly resulted in expected increase in IGF-I response without overexposure and increase in height velocity demonstrating dose response. Less waning of the growth response was observed over the first 12 months of VRS-317 treatment than typically observed with daily rhGH therapy. The lack of waning in the growth rates over 12 months suggests that VRS-317 may be providing a more consistent and measured growth response in GHD children compared to daily growth hormone therapy. Furthermore, these results clearly demonstrate a dose response in both IGF-I levels and height velocity, providing further confirmation of the selected Phase 3 VRS-317 dose of 3.5 mg/kg semi-monthly (FIG. 11).

Treatment with VRS-317 for 12-18 months

Methods

Patients in the aforementioned Extension Study continued treatment for an additional 12-18 plus months as illustrated in FIG. 12 to evaluate whether somavaratan at the Phase 3 dose (3.5 mg/kg) given twice-monthly between 12-18 months of treatment can continue to offset the decrease in height velocity (HVs) commonly seen during the second year of daily rhGH treatment.

Results

The vast majority (63 of 64) enrolled pre-pubertal GHD children completed the 6-month study of weekly, twice-monthly, or monthly dosing (5.0 mg/kg per month) and 56

subjects have completed 18 months of treatment. The mean age at Month 18 was 9.28 years; all but 2 subjects remained prepubertal. After increasing the dose in the twice-monthly dose group (n=17) from 2.5 to 3.5 mg/kg, somavaratan led to increased mean peak IGF-I SDS from -0.30 ± 1.2 to 0.32 ± 1.6 between 12-18 months ($P=0.007$, paired t-test; FIG. 13). At the 3.5 mg/kg dose, there were three IGF-I SDS > 2 and none > 3 .

The anticipated decline in 2nd year height velocity (HV) was not observed with the 3.5 mg/kg dose. In particular, as shown in FIG. 14, during the initial 12 months of treatment, mean HV was 7.9 ± 2.1 cm/year and 8.5 ± 2.1 cm/year for subjects in the 5 mg/kg monthly and 2.5 mg/kg twice-monthly dose groups, respectively. After 18 total months of treatment, the last 6 months at 3.5 mg/kg twice-monthly, the mean (annualized) 12-18 month HV was 8.1 ± 2.4 cm/year and 8.3 ± 1.8 cm/year for each dose group, respectively. Thus, FIG. 14 illustrates that the anticipated decline in height velocity in the second year of treatment seen with daily growth hormone therapy was not observed with 3.5 mg/kg of somavaratan dosed twice-monthly.

Treatment-related adverse events (AEs) between 12-18 months were reported in 7 patients (12.5%) with the 3.5 mg/kg dose. Only mild and transient treatment-related AEs were observed. Injection site pain or discomfort decreased with time on treatment, with only 4 subjects (7.1%) reporting pain or discomfort between 12-18 months. Safety profiles were similar pre- and post-dose increase. Anti-drug antibodies were detected but had no significant effect on PK, PD, safety or efficacy.

Conclusions

Transitioning patients to the Phase 3 somavaratan dose (3.5 mg/kg twice-monthly) at the start of the 2nd year of treatment led to an increase in mean peak IGF-I SDS, with similar safety profiles pre- and post-dose increase. After 18 months of continuous exposure to somavaratan and at least 6 months at the Phase 3 dose, the anticipated decline in 2nd-year HV was not observed.

WHAT IS CLAIMED IS:

1. A method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid
5 sequence having at least about 90% sequence identity to SEQ ID NO:1 when optimally aligned, as a bodyweight adjusted bolus dose between about 0.80 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.
- 10 2. The method of claim 1, wherein the treatment continues for at least about 6 months from first administration.
3. The method of claim 1, wherein the treatment continues for at least about 12 months from first administration.
4. The method of claim 1, wherein the treatment continues for at least about 18 months
15 from first administration.
5. The method of any one of claims 1 to 4, wherein the bolus dose of the hGH-XTEN fusion protein is administered once a month, two-times a month, three-times a month, or four-times a month.
6. The method of claim 5, wherein the bolus dose of the hGH-XTEN fusion protein is
20 administered once a month.
7. The method of claim 5, wherein the bolus dose of the hGH-XTEN fusion protein is administered every two weeks or semimonthly.
8. The method of any one of claims 1 to 7, wherein the bolus dose of the hGH-XTEN fusion protein is administered subcutaneously.
- 25 9. The method of any one of claims 1 to 8, wherein the treatment is effective to maintain the pediatric patient's height velocity within at least about 10%, at least about 20%, or at least about 30% of that compared to the height velocity achieved in pediatric patients administered daily injections of human growth hormone (hGH) alone of an equivalent amount, on a molar basis, over a comparable dose period.
- 30 10. The method of any one of claims 1 to 8, wherein the treatment is effective to achieve a height velocity equivalent to at least about 7 cm/yr to 12 cm/yr in a pediatric patient.

11. The method of any one of claims 1 to 8, wherein the treatment is effective to achieve a height velocity equivalent to at least about 8 cm/yr to 11 cm/yr in a pediatric patient.

12. The method of claims 10 or 11, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

13. The method of claims 10 or 11, wherein the height velocity achieved is a first year height velocity.

14. The method of any one of claims 1 to 8, wherein the treatment is effective to achieve at least the same height velocity as that achieved by administering daily injections of hGH alone over the same time period.

15. The method of claim 14, wherein the amount of hGH-XTEN fusion protein administered is comparable, on a molar basis, to an equivalent amount of an hGH alone and administered to a pediatric patient.

16. The method of any one of claims 10 to 15, wherein the bolus dose of the hGH-XTEN fusion protein is selected from about 0.8 mg/kg to about 1.5 mg/kg, about 1.8 mg/kg to about 3.2 mg/kg, or about 3.5 mg/kg to about 6.3 mg/kg.

17. The method of any one of claims 1 to 16, wherein the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration of the hGH-XTEN fusion protein.

18. The method of any one of claims 1 to 16, wherein the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

19. The method of any one of claims 1 to 16, wherein the pediatric patient maintains an increase from baseline serum IGF-I standard deviation score (SDS) of at least 1.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.
- 5 20. The method of any one of claims 1 to 16, wherein the pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the hGH-XTEN fusion protein.
21. The method of claim 20, wherein the IGF-I SDS is selected from the group consisting of greater than about -1.5 to about 2.0, greater than about -1.0 to about 2.0, greater than about
10 -0.5 to about 2.0, greater than about 0 to about 2.0, greater than about 0.5 to about 2.0, greater than about 1.0 to about 2.0, and greater than about 1.5 to about 2.0.
22. The method of claim 20, wherein the IGF-I SDS is selected from the group consisting of greater than about -1.0 to about 2.0, greater than about 0 to about 2.0, and greater than about 1.0 to about 2.0.
- 15 23. The method of claim 20, wherein the pediatric patient exhibits said serum IGF-I SDS following administration of the bolus dose, wherein the administration of the hGH-XTEN fusion protein is once a month, two-times a month, three-times a month, or four-times a month.
24. The method of claim 20, wherein the pediatric patient exhibits said serum IGF-I SDS
20 following administration of the bolus dose, wherein the administration of the hGH-XTEN fusion protein is two-times a month, or once a month.
25. The method of any one of claims 17 to 24, wherein the pediatric patient exhibits said serum IGF-I SDS following administration of at least a second, or a third, or a fourth bolus dose of the hGH-XTEN fusion protein.
- 25 26. The method of claim 20, wherein the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least
30 about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least

about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration of the hGH-XTEN fusion protein.

27. The method of claim 26, wherein the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

28. The method of claim 26, wherein the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

29. The method of any one of claims 26 to 28, wherein the IGF-I SDS is maintained between about -2.0 and about 2.0 following administration of a first, or a second, or a third, or a fourth bolus dose of the hGH-XTEN fusion protein.

30. The method of any one of claims 1 to 29, wherein the bolus dose of the hGH-XTEN fusion protein is selected from the group consisting of about 0.8 mg/kg, about 1.0 mg/kg, about 1.2 mg/kg, about 1.4 mg/kg, about 1.6 mg/kg, about 1.8 mg/kg, about 2.0 mg/kg, about 2.2 mg/kg, about 2.4 mg/kg, about 2.6 mg/kg, about 2.7 mg/kg, about 2.8 mg/kg, about 3 mg/kg, about 3.2 mg/kg, about 3.4 mg/kg, about 3.6 mg/kg, about 3.8 mg/kg, about 4.0 mg/kg, about 4.2 mg/kg, about 4.4 mg/kg, about 4.6 mg/kg, about 4.8 mg/kg, about 5.0 mg/kg, about 5.2 mg/kg, about 5.4 mg/kg, about 5.6 mg/kg, about 5.8 mg/kg, about 6.0 mg/kg, and about 6.3 mg/kg.

31. The method of any one of claims 1 to 29, wherein the bolus dose of the hGH-XTEN fusion protein is about 0.8 mg/kg to about 1.5 mg/kg.

32. The method of any one of claims 1 to 29, wherein the bolus dose of the hGH-XTEN fusion protein is about 1.8 mg/kg to about 3.2 mg/kg.

33. The method of any one of claims 1 to 29, wherein the bolus dose of the hGH-XTEN fusion protein is about 3.5 mg/kg to about 6.3 mg/kg.

34. The method of any one of claims 1 to 33, wherein the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1.

35. The method of any one of claims 1 to 33, wherein the hGH-XTEN fusion protein has at least about 91%, or at least about 92%, or at least about 93%, or at least about 94%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least

about 99% sequence identity to the amino acid sequence of SEQ ID NO:1 when optimally aligned.

36. A method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient, comprising administering to the patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 as a therapeutically effective bodyweight adjusted bolus dose that is effective to maintain the patient's serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 for at least 7 days after administration of the bolus dose, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

37. The method of claims 36, wherein the treatment continues at least about 6 months, at least about 12 months, or at least about 18 months from the first administration of the hGH-XTEN fusion protein.

38. The method of claims 36, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

39. The method of claim 36, wherein the bolus dose of the hGH-XTEN fusion protein is between about 0.8 mg/kg and about 6.3 mg/kg.

40. The method of claim 36 or 37, wherein said bolus dose is effective to maintain the patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, or at least about one month following administration.

41. The method of claim 40, wherein the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, at least about 21 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

42. The method of claim 40, wherein the bolus dose is effective to maintain the pediatric patient's serum IGF-I SDS between about -2.0 and about 2.0 for at least about 14 days, or at least about 30 days following administration of the hGH-XTEN fusion protein.

43. A pediatric bolus dose of an hGH-XTEN fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1, wherein the bolus dose is a therapeutically effective bodyweight adjusted bolus dose comprising between about 0.8 mg/kg and about 6.3 mg/kg of hGH-XTEN fusion protein.

44. The bolus dose of claim 43 for use in treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient in need, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

45. The bolus dose of claims 44, wherein the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein.

46. The bolus dose of claims 44, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

47. The bolus dose of claims 43 or 44, wherein the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1.

48. The bolus dose of any one of claims 43 to 47, which is formulated for subcutaneous administration.

49. An hGH-XTEN fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 for use in a method for the treatment of human pediatric growth hormone deficiency (PGHD) in a human pediatric patient, wherein the method comprises administering a bodyweight adjusted bolus dose of the hGH-XTEN fusion protein at a dose between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

50. The fusion protein of any claim 49, wherein the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein.

51. The fusion protein of claims 49, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing of the hGH-XTEN fusion protein in the pediatric patient.

52. Use of an hGH-XTEN fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:1 in the manufacture of a medicament for the treatment of PGHD in a pediatric patient, wherein the hGH-XTEN fusion protein is administered to the pediatric patient as a bodyweight adjusted bolus dose of the hGH-XTEN fusion protein at a dose between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

53. The use of claim 52, wherein the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein.

54. The use of claim 52, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

55. The hGH-XTEN fusion protein of claim 49 or the use of any one of claims 52 to 54, wherein the bolus dose is administered once a month, two-times a month, three-times a month, or four-times a month.

56. The hGH-XTEN fusion protein of claim 49 or the use of any one of claims 52 to 54, wherein the bolus dose is administered semimonthly, or monthly.

57. The hGH-XTEN fusion protein of claim 49 or the use of claim 52, wherein the hGH-XTEN fusion protein comprises the amino acid sequence of SEQ ID NO:1.

58. The hGH-XTEN fusion protein of claim or the use of claim 52, wherein the bolus dose is administered subcutaneously.

59. The hGH-XTEN fusion protein of claim 49 or the use of claim 52, wherein the human pediatric patient has a serum IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 following administration of the bolus dose.

60. The hGH-XTEN fusion protein of claims 49 or the use of claim 59, wherein the IGF-I SDS is selected from the group consisting of greater than about -1.5, greater than about -1.0, greater than about -0.5, greater than about 0, greater than about 0.5, greater than about 1.0, and greater than about 1.5.

61. The hGH-XTEN fusion protein of claim 49 or the use of claim 59, wherein the IGF-I SDS is selected from the group consisting of greater than about -1.0, greater than about 0, and greater than about 1.0.

62. The hGH-XTEN fusion protein of any claim 49 or the use of claim 52, wherein the administration is once a month, two-times a month, three-times a month, or four-times a month.

63. The hGH-XTEN fusion protein of 49 or the use of claim 52, wherein the administration is once a month, or two-times a month.

64. A kit for the treatment of pediatric growth hormone deficiency (PGHD) comprising (i) a container which holds a pharmaceutical composition comprising a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1 when optimally aligned, and

(ii) a package insert associated with said container, wherein the package insert indicates that said composition is for the treatment of pediatric growth hormone deficiency (PGHD) in a pediatric patient by administration of an initial dose of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg effective to increase the height of said pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and a plurality of subsequent doses of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg, wherein the doses are administered once a month, two-times a month, three-times a month, or four-times a month, and wherein the pediatric patient's height velocity does not decline during the treatment.

65. The kit of claims 64, wherein the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein.

66. The kit of claims 64, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

67. The kit of claim 64, wherein the container further comprises a pharmaceutically acceptable carrier.

68. A human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1 when optimally aligned for use in a pharmaceutical regimen for treatment of a pediatric growth hormone deficiency (PGHD) in a pediatric patient, said regimen comprising administering a bolus dose of the hGH-XTEN fusion protein to treat the pediatric patient, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

69. The fusion protein of claims 68, wherein the treatment continues for at least about 6 months, at least about 12 months, or at least about 18 months from first administration of the hGH-XTEN fusion protein.

70. The fusion protein of claims 68, wherein the height velocity is achieved after at least about 3 months, at least about 6 months, at least about 12 months, or at least about 18 months of dosing in the pediatric patient.

71. The hGH-XTEN fusion protein of any one of claims 68 to 70, wherein the pharmaceutical regimen further comprises the step of determining the amount of hGH-XTEN fusion protein needed to achieve an IGF-I standard deviation score (SDS) between about -2.0 and about 2.0 in the pediatric patient.

72. The hGH-XTEN fusion protein of any one of claims 68 to 71, wherein the pharmaceutical regimen for treating the pediatric patient comprises administering the hGH-XTEN fusion protein in an initial bolus dose between about 0.8 mg/kg and about 6.3 mg/kg and a plurality of subsequent bolus doses of the hGH-XTEN fusion protein between about 0.8 mg/kg and about 6.3 mg/kg.

73. The hGH-XTEN fusion protein of claim 72, wherein the bolus doses are administered once a month, two-times a month, three-times a month, or four-times a month.

74. The hGH-XTEN fusion protein of claim 72, wherein the bolus doses are administered once a month, or two-times a month.

FIG. 1

AEPAGSPTSTEEGTPGSGTASSPGSSTPSGATGSPGASPGTSSGTSPGSPAGSPTSTEEGTSESATPESGP
STEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGETPGSEPA
TSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSE
GSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGETPGTSTEPSEGS
APGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPA TSGETP
GTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGT
TEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPA TSGETPGTSESATPESGPGSEPA
SGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTS
TEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPA TSGETPGTSESATPESGPGSEPA TSGETP
GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPA TSGETPGTSESATPESGPGSP
AGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPA
TSGSETPGSEPA TSGETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPA TSGETPGTSESATP
ESGPGTSTEPSEGSAPGFPTPLSRLFDNAMLRAHRLHQLAFDTYOEFEAYIPKEOKYSFLQNPQTS
CFSESIPTPSNREETQOKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLLEGI
QTLMGRLLEDGSPRTGQIFKQTYSKFDTN SHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEG
SCGFGGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSE
SAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP
G (SEQ ID NO:1)

FIG. 2

	All Subjects	1.15 mg/kg Weekly	2.5 mg/kg Semimonthly	5.0 mg/kg Monthly
# Subjects	64	21	20	23
Demographics → Must Be Comparable for Evaluating Relative to Other Pediatric GHD Clinical Trials				
Age (Screening)	7.83 (2.4)	7.51 (2.3)	7.96 (2.4)	8.01 (2.5)
Height SDS	-2.51 (0.5)	-2.70 (0.7)	-2.53 (0.4)	-2.33 (0.5)
Bone Age	6.4 (2.4)	6.1 (2.5)	6.6 (2.2)	6.4 (2.6)
GH Stimulation Test	5.4 (2.6)	5.7 (2.0)	4.9 (2.8)	5.5 (2.8)
IGF-1 SDS	-1.72 (0.8)	-1.55 (0.9)	-2.00 (0.8)	-1.62 (0.7)

Moderate GHD, Pre-Pubertal Children Representative of
Typical US GHD Patient Population

FIG. 3

ADVERSE EVENT ¹	1.15 mg/kg Weekly to 3.5 mg/kg Semi-Monthly (6 Months)	1.15 mg/kg Weekly to 3.5 mg/kg Semi-Monthly (3 Months)	2.5 mg/kg Semi-Monthly	5.0 mg/kg Monthly
# Patients	5	15	18	22
# Patients with any AE	1	2	2	4
Musculoskeletal Pain	0	0	1	0
Injection Site Discomfort	0	2	1	3
Headache	0	0	1	0
Sinus Congestion	1	0	0	0


RESULTS

- * All Related AEs Are Mild (Grade 1) and Transient
- * No Related SAEs, no Unexpected AEs, No Lipoatrophy or Nodules
- * Number of AEs Decreased From First to Second 6 Months of Treatment
- * Few AEs Observed at 3.5 mg/kg Semi-Monthly Dose

Safety/Tolerability Profile Comparable to Daily rhGH

¹ - Reported in all patients in Extension Study.

FIG. 4



Data Used to Establish PK/PD Model

FIG. 5

Average IGF-I SDS Change from Baseline	MEDIAN AND INTERQUARTILE RANGES			
	# Patients	1.15 mg/kg Weekly	2.5 mg/kg Semi-monthly	5.0 mg/kg Monthly
	51 ¹	1.1 (0.7, 1.3)	1.1 (0.7, 1.5)	1.1 (0.7, 1.5)

RESULTS

- * Average Increase in IGF-I SDS Was Predicted from PK/PD Model (No Regimen Effects)
- * Increase in IGF-I SDS Led to Average IGF-I SDS in the Lower Therapeutic Range
- * Dose Adjusted from 2.5 mg/kg Semi-Monthly to 3.5 mg/kg Semi-Monthly to Increase Average IGF-I SDS into the Upper Therapeutic Range

Confirmation of PK/PD Model

¹ ~51 subjects with all available samples

FIG. 6






FIG. 7



3.5 mg/kg Dose Achieves Comparable IGF-I Response to Daily rhGH

FIG. 8




Established Dose Response Relationship Between
rhGH Dose and First Year Height Velocity

Adapted from "Developing Protein Delivery Systems for Commercial Success" presentation, January 2001


FIG. 9

COMPARISON IN SAME GHD CHILDREN DURING EXTENSION STUDY



Dose Increase to 3.5 mg/kg Resulted in Increased Height Velocity

FIG. 10




VRS-317 Provides More Consistent Rate of Growth
Over First Year Compared to Daily rhGH

* Daily rhGH source data: Summary Basis of Approval FDA 19-721 & FDA 21-246. Includes 340 patients comparable to VRS-317 study.

FIG. 11

**NAÏVE TO TREATMENT, PRE-PUBERTAL GHD
(Similar Inclusion / Exclusion to Phase 2a)**



- **Open Label, Randomized Non-Inferiority Design**
- **VRS-317** Dose Selection Validated by Extension Study Results for Subjects Switched to 3.5 mg/kg VRS-317 Semi-monthly; Single Injection Using 30 Gauge Needle in Majority of Patients
- **Daily rhGH** Dose Selection Is the Highest Approved Dose on the Label of Genotropin and Norditropin in All Regions (US, Western Europe, and Canada)

FIG. 12




FIG. 13





FIG. 14



The anticipated decline in 2nd year HV was not observed with 3.5 mg/kg somavaratan

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/68328

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 38/27, 38/16; C07K 14/615 (2016.01)

CPC - A61K 38/27, 38/16; C07K 14/615

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 38/27, 38/16; C07K 14/615 (2016.01)

CPC: C07K 14/61; A61K 38/27, 38/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); Google; Google Scholar; PubMed; EBSCO Discovery Service; 'Human growth hormone-XTEN', 'hGH-XTEN', 'fusion', 'human pediatric growth hormone deficiency', 'PGHD'

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/164568 A1 (AMUNIX OPERATING INC.) October 9, 2014; entire document	1-3, 5/1-3, 6/5/1-3, 7/5/1-3, 43-46, 47/43-44, 49-54, 55/49, 55/52-54, 56/49, 56/52-54, 57/49-59/49, 57/52-59/52, 62/49, 62/52, 63/49, 63/52, 64-71
---		-----
Y		4, 5/4, 6/5/4, 7/5/4
Y	(SIMON, CC) Big on HGH [online]. The Washington Post. 30 September 2003 [retrieved on 2016-04-06]. Retrieved from the Internet: <URL: https://www.washingtonpost.com/archive/lifestyle/wellness/2003/09/30/big-on-hgh/2783f33c-c037-4054-83f3-3ad499b7cc1a/ >; page 1.	4, 5/4, 6/5/4, 7/5/4
A	(COTTERILL, AM et al.) The Short-term Effects of Growth Hormone Therapy on Height Velocity and Cardiac Ventricular Wall Thickness in Children with Noonan's Syndrome. Journal of Clinical Endocrinology & Metabolism. June 1996, Vol. 81, No. 6; pages 2291-2297; DOI: 10.1210/jcem.81.6.8964866	1-4, 5/1-4, 6/5/1-4, 7/5/1-4, 43-46, 47/43-44, 49-54, 55/49, 55/52-54, 56/49, 56/52-54, 57/49-59/49, 57/52-59/52, 62/49, 62/52, 63/49, 63/52, 64-71

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 2016 (23.04.2016)

Date of mailing of the international search report

03 JUN 2016

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US15/68328

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 8-35, 48, 60, 61, 72-74
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Supplemental Page-

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Group I, Claims 1-7, 43-47, 49-59, 62-71

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US15/68328

-Continued from Box No. III: Observations where unity of invention is lacking-

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, Claims 1-7, 43-47, 49-59 and 62-71 are directed toward a method of treating human pediatric growth hormone deficiency (PGHD) in a pediatric patient, the treatment comprising administering to the pediatric patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to SEQ ID NO: 1 when optimally aligned, as a bodyweight adjusted bolus dose between about 0.80 mg/kg and about 6.3 mg/kg.

Group II, Claims 36-42 are directed toward a method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient, comprising administering to the patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 1 effective to maintain the patient's serum IGF-1 standard deviation score (SDS) between about -2.0 and about 2.0 for at least 7 days after administration.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical features of Group I include between about 0.8 mg/kg and about 6.3 mg/kg, not present in Group II; the special technical features of Group II include IGF-1 standard deviation score (SDS) between about -2.0 and about 2.0, not present in Group I.

Groups I and II share the technical features including: a method of treating human pediatric growth hormone deficiency (PGHD) in a human pediatric patient, comprising administering to the patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 1 as a therapeutically effective bodyweight adjusted bolus dose, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

However, these shared technical features are previously disclosed by US 2014/0162949 A1 to Harazin et al. (hereinafter 'Harazin') in view of the abstract of the article 'The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome' by Cotterill et al. (hereinafter 'Cotterill').

Harazin discloses a method of treating human pediatric growth hormone deficiency (PGHD) (a method of treating growth hormone deficiency in children (a method of treating human pediatric growth hormone deficiency (PGHD); paragraphs [0004], [0010]) in a human pediatric patient (in a child (a human pediatric patient); paragraph [0004]), comprising administering to the patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein (comprising administering to the patient with PGHD a human growth hormone-XTEN (hGH-XTEN) fusion protein; paragraphs [0004], [0010]) comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 1 (comprising an amino acid sequence having at least about 90% sequence identity to the amino acid sequence of SEQ ID NO: 1; paragraph [0011]; wherein SEQ ID NO: 1 is 100% identical to Applicants' SEQ ID NO: 1) as a therapeutically effective bodyweight adjusted bolus dose (as a therapeutically effective bodyweight adjusted bolus dose; paragraph [0011]). Harazin further discloses wherein the dose is effective to produce a serum IGF-I standard deviation score between about -2.0 and 2.0 following administration (wherein the dose is effective to produce a serum IGF-I standard deviation score between about -2.0 and 2.0 following administration; paragraph [0011]); wherein administration may be monthly (wherein administration may be monthly; paragraph [0011]); and wherein continuous infusion of rhGH with a pump produced comparable growth velocity to daily rhGH injection (wherein continuous infusion of rhGH with a pump produced comparable growth velocity to daily rhGH injection; paragraph [0004]) for 6 months (for 6 months; paragraph [0006]).

Harazin does not disclose wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment.

Cotterill discloses wherein Noonan's syndrome is associated with short stature (wherein Noonan's syndrome is associated with short stature; abstract), and wherein treatment of children with a standardized dose of rhGH (wherein treatment of children with 4 UI/m2/day (a standardized dose) of rhGH; abstract); wherein growth velocity significantly increased for the first 6 months of treatment (wherein growth velocity increased from 4.9 to 8.9 at 6 months (wherein growth velocity significantly increased for the first 6 months of treatment); abstract), and only slightly declined from 6 months to the end of the first year of treatment (and was 8.1 from months 6 to 12 of treatment (only slightly declined from 6 months to the end of the first year of treatment); abstract).

It would have been obvious to a person of ordinary skill in the art at the time of the invention was made to have modified the disclosure of Harazin to have provided an appropriate term of treatment, such as 6 months, 1 year, or more, as disclosed by Cotterill, in order to effect a desired outcome, such as increases in subject height, over said time period. It further would have been obvious to a person of ordinary skill in the art at the time of the invention was made to have controlled a treatment-related outcome, as disclosed by Harazin, such as height or growth velocity, as disclosed by Cotterill, by modulating the dose to the patient accordingly, in order to better produce a desired effect, such as a target increase in height, wherein the patient's height velocity does not decline during the treatment, in order to arrive at said target outcome within the treatment period.

Since none of the special technical features of the Groups I and II inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by a combination of the Harazin and Cotterill references, unity of invention is lacking.